{"PMC7108455": [["IntroductionScreening of most of the known respiratory viruses by PCR has allowed us to diagnose many viral infections in the majority of individuals with respiratory illnesses.", [["respiratory", "ANATOMY", 155, 166], ["viral infections", "DISEASE", 102, 118], ["respiratory illnesses", "DISEASE", 155, 176], ["the known respiratory viruses", "PROBLEM", 33, 62], ["PCR", "TEST", 66, 69], ["many viral infections", "PROBLEM", 97, 118], ["respiratory illnesses", "PROBLEM", 155, 176], ["respiratory", "ANATOMY", 43, 54], ["viruses", "OBSERVATION", 55, 62], ["viral", "OBSERVATION_MODIFIER", 102, 107], ["infections", "OBSERVATION", 108, 118], ["respiratory illnesses", "OBSERVATION", 155, 176]]], ["However, many respiratory infections still remain undiagnosed.", [["respiratory", "ANATOMY", 14, 25], ["respiratory infections", "DISEASE", 14, 36], ["many respiratory infections", "PROBLEM", 9, 36], ["undiagnosed", "PROBLEM", 50, 61], ["many", "OBSERVATION_MODIFIER", 9, 13], ["respiratory", "OBSERVATION_MODIFIER", 14, 25], ["infections", "OBSERVATION", 26, 36]]], ["A new parvovirus, the human bocavirus (HBoV), has recently been discovered by the application of random PCR/cloning technique on respiratory samples (Allender et al., 2005).", [["respiratory samples", "ANATOMY", 129, 148], ["parvovirus", "DISEASE", 6, 16], ["parvovirus", "ORGANISM", 6, 16], ["human", "ORGANISM", 22, 27], ["bocavirus", "GENE_OR_GENE_PRODUCT", 28, 37], ["HBoV", "ORGANISM", 39, 43], ["human", "SPECIES", 22, 27], ["human bocavirus", "SPECIES", 22, 37], ["HBoV", "SPECIES", 39, 43], ["A new parvovirus", "PROBLEM", 0, 16], ["the human bocavirus (HBoV", "PROBLEM", 18, 43], ["random PCR/cloning technique", "TREATMENT", 97, 125], ["new", "OBSERVATION_MODIFIER", 2, 5], ["parvovirus", "OBSERVATION", 6, 16]]], ["HBoV is suspected to be an etiologic agent of respiratory disease in humans (Manning et al., 2006, Maggi et al., 2007, Kesebir et al., 2007).", [["respiratory", "ANATOMY", 46, 57], ["HBoV", "DISEASE", 0, 4], ["respiratory disease", "DISEASE", 46, 65], ["HBoV", "ORGANISM", 0, 4], ["humans", "ORGANISM", 69, 75], ["humans", "SPECIES", 69, 75], ["HBoV", "SPECIES", 0, 4], ["humans", "SPECIES", 69, 75], ["HBoV", "PROBLEM", 0, 4], ["respiratory disease in humans", "PROBLEM", 46, 75], ["suspected to be", "UNCERTAINTY", 8, 23], ["etiologic", "OBSERVATION_MODIFIER", 27, 36], ["respiratory disease", "OBSERVATION", 46, 65]]], ["Respiratory distress and abnormal radiographic chest findings have frequently been associated with HBoV.", [["Respiratory", "ANATOMY", 0, 11], ["chest", "ANATOMY", 47, 52], ["Respiratory distress", "DISEASE", 0, 20], ["HBoV", "DISEASE", 99, 103], ["HBoV", "ORGANISM", 99, 103], ["HBoV", "SPECIES", 99, 103], ["Respiratory distress", "PROBLEM", 0, 20], ["abnormal radiographic chest findings", "PROBLEM", 25, 61], ["HBoV", "PROBLEM", 99, 103], ["distress", "OBSERVATION", 12, 20], ["abnormal", "OBSERVATION_MODIFIER", 25, 33], ["chest", "ANATOMY", 47, 52], ["HBoV", "OBSERVATION", 99, 103]]], ["Most viruses have been identified by animal experiments or virus replication in tissue culture, but this virus was discovered by molecular screening of respiratory tract samples and it has not yet been grown in cell culture.", [["tissue culture", "ANATOMY", 80, 94], ["respiratory tract samples", "ANATOMY", 152, 177], ["cell culture", "ANATOMY", 211, 223], ["tissue culture", "CELL", 80, 94], ["respiratory tract samples", "CANCER", 152, 177], ["cell culture", "CELL", 211, 223], ["Most viruses", "PROBLEM", 0, 12], ["virus replication", "PROBLEM", 59, 76], ["tissue culture", "TEST", 80, 94], ["this virus", "PROBLEM", 100, 110], ["respiratory tract samples", "PROBLEM", 152, 177], ["cell culture", "TEST", 211, 223], ["respiratory tract", "ANATOMY", 152, 169]]], ["Although, Koch's postulates have provided a standard for establishing a causal link between a pathogen and disease, in this case it was not possible to apply these rules.", [["a pathogen", "PROBLEM", 92, 102], ["disease", "PROBLEM", 107, 114]]], ["However, the frequent association of HBoV infection with respiratory tract disease (Anderson, 2007, Schenk et al., 2007, Simon et al., 2007) led us to consider this virus as a causative agent for respiratory tract diseases.", [["respiratory tract", "ANATOMY", 57, 74], ["respiratory tract", "ANATOMY", 196, 213], ["HBoV infection", "DISEASE", 37, 51], ["respiratory tract disease", "DISEASE", 57, 82], ["respiratory tract diseases", "DISEASE", 196, 222], ["HBoV", "ORGANISM", 37, 41], ["tract", "ORGANISM_SUBDIVISION", 69, 74], ["tract", "ORGANISM_SUBDIVISION", 208, 213], ["HBoV", "SPECIES", 37, 41], ["HBoV infection", "PROBLEM", 37, 51], ["respiratory tract disease", "PROBLEM", 57, 82], ["this virus", "PROBLEM", 160, 170], ["a causative agent", "TREATMENT", 174, 191], ["respiratory tract diseases", "PROBLEM", 196, 222], ["HBoV infection", "OBSERVATION", 37, 51], ["respiratory tract", "ANATOMY", 57, 74]]], ["Some studies have shown that HBoV is distributed all over the world (Manning et al., 2006, Maggi et al., 2007, Simon et al., 2007, Ma et al., 2006, Bastien et al., 2007) and recent data have shown that it can also be detected in stool samples from children with gastroenteritis (Vicente et al., 2007).", [["stool samples", "ANATOMY", 229, 242], ["gastroenteritis", "DISEASE", 262, 277], ["HBoV", "ORGANISM", 29, 33], ["stool samples", "ORGANISM_SUBSTANCE", 229, 242], ["children", "ORGANISM", 248, 256], ["children", "SPECIES", 248, 256], ["HBoV", "SPECIES", 29, 33], ["Some studies", "TEST", 0, 12], ["HBoV", "PROBLEM", 29, 33], ["gastroenteritis", "PROBLEM", 262, 277], ["HBoV", "OBSERVATION", 29, 33], ["distributed", "OBSERVATION_MODIFIER", 37, 48]]], ["Like other viruses, it is possible that HBoV could be involved in both respiratory and enteric diseases.ResultsIn this report, we describe a case of pneumonia and severe wheezing associated with HBoV DNA in the pharyngeal swab sample from a child.", [["respiratory", "ANATOMY", 71, 82], ["pharyngeal swab sample", "ANATOMY", 211, 233], ["respiratory and enteric diseases", "DISEASE", 71, 103], ["pneumonia", "DISEASE", 149, 158], ["wheezing", "DISEASE", 170, 178], ["HBoV", "ORGANISM", 40, 44], ["HBoV", "ORGANISM", 195, 199], ["DNA", "CELLULAR_COMPONENT", 200, 203], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 211, 226], ["child", "SPECIES", 241, 246], ["HBoV", "SPECIES", 40, 44], ["HBoV", "SPECIES", 195, 199], ["other viruses", "PROBLEM", 5, 18], ["HBoV", "PROBLEM", 40, 44], ["both respiratory and enteric diseases", "PROBLEM", 66, 103], ["pneumonia", "PROBLEM", 149, 158], ["severe wheezing", "PROBLEM", 163, 178], ["HBoV DNA", "PROBLEM", 195, 203], ["viruses", "OBSERVATION", 11, 18], ["HBoV", "OBSERVATION", 40, 44], ["both", "ANATOMY_MODIFIER", 66, 70], ["respiratory", "ANATOMY", 71, 82], ["enteric diseases", "OBSERVATION", 87, 103], ["pneumonia", "OBSERVATION", 149, 158], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["wheezing", "OBSERVATION", 170, 178], ["HBoV DNA", "OBSERVATION", 195, 203], ["pharyngeal swab", "ANATOMY", 211, 226]]], ["Informed consent was obtained from the parents of the child who provided specimens.ResultsThe child had been hospitalized at the age of 1 year due to rhinitis, airflow obstruction and acute wheezing.", [["specimens", "ANATOMY", 73, 82], ["rhinitis", "DISEASE", 150, 158], ["airflow obstruction", "DISEASE", 160, 179], ["wheezing", "DISEASE", 190, 198], ["child", "ORGANISM", 54, 59], ["child", "ORGANISM", 94, 99], ["child", "SPECIES", 54, 59], ["rhinitis", "PROBLEM", 150, 158], ["airflow obstruction", "PROBLEM", 160, 179], ["acute wheezing", "PROBLEM", 184, 198], ["rhinitis", "OBSERVATION", 150, 158], ["airflow obstruction", "OBSERVATION", 160, 179], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["wheezing", "OBSERVATION", 190, 198]]], ["He was treated with corticosteroids and inhalative bronchodilatators to control bronchocostriction.", [["bronchocostriction", "DISEASE", 80, 98], ["corticosteroids", "CHEMICAL", 20, 35], ["He", "ORGANISM", 0, 2], ["corticosteroids", "SIMPLE_CHEMICAL", 20, 35], ["corticosteroids", "TREATMENT", 20, 35], ["inhalative bronchodilatators", "TREATMENT", 40, 68], ["bronchocostriction", "PROBLEM", 80, 98]]], ["No antibiotics were administered.", [["antibiotics", "TREATMENT", 3, 14], ["antibiotics", "OBSERVATION", 3, 14]]], ["No causative agent was found in nasopharyngeal swab or serological tests and no sign of chronic lung disease was present when he was released.", [["nasopharyngeal swab", "ANATOMY", 32, 51], ["lung", "ANATOMY", 96, 100], ["chronic lung disease", "DISEASE", 88, 108], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 32, 51], ["lung", "ORGAN", 96, 100], ["causative agent", "PROBLEM", 3, 18], ["nasopharyngeal swab", "TEST", 32, 51], ["serological tests", "TEST", 55, 72], ["chronic lung disease", "PROBLEM", 88, 108], ["causative", "UNCERTAINTY", 3, 12], ["agent", "OBSERVATION", 13, 18], ["nasopharyngeal", "ANATOMY", 32, 46], ["no sign of", "UNCERTAINTY", 77, 87], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["lung", "ANATOMY", 96, 100], ["disease", "OBSERVATION", 101, 108]]], ["During the following year, he frequently suffered from respiratory tract infections associated with bronchoconstriction.", [["respiratory tract", "ANATOMY", 55, 72], ["respiratory tract infections", "DISEASE", 55, 83], ["tract", "ORGANISM_SUBDIVISION", 67, 72], ["respiratory tract infections", "PROBLEM", 55, 83], ["bronchoconstriction", "PROBLEM", 100, 119], ["respiratory tract", "ANATOMY", 55, 72], ["infections", "OBSERVATION", 73, 83], ["bronchoconstriction", "OBSERVATION", 100, 119]]], ["In order to understand the cause of bronchoconstriction, total and specific IgE were measured and high values were reported for egg proteins.ResultsHe was 3 years old when admitted for the most recent episode of respiratory distress.", [["egg", "ANATOMY", 128, 131], ["respiratory", "ANATOMY", 212, 223], ["respiratory distress", "DISEASE", 212, 232], ["IgE", "GENE_OR_GENE_PRODUCT", 76, 79], ["egg", "ORGANISM_SUBSTANCE", 128, 131], ["IgE", "PROTEIN", 76, 79], ["egg proteins", "PROTEIN", 128, 140], ["bronchoconstriction", "PROBLEM", 36, 55], ["total and specific IgE", "TEST", 57, 79], ["egg proteins", "PROBLEM", 128, 140], ["respiratory distress", "PROBLEM", 212, 232], ["bronchoconstriction", "OBSERVATION", 36, 55], ["respiratory", "ANATOMY", 212, 223], ["distress", "OBSERVATION", 224, 232]]], ["Clinical examination revealed a weakened general condition, a body temperature of 38 \u00b0C, tachycardia (pulse rate 140 per min), tachypnea (respiratory rate 52 per min), dyspnea, subcostal retractions, wheezing and left apical fine rales upon lung auscultation.", [["body", "ANATOMY", 62, 66], ["subcostal", "ANATOMY", 177, 186], ["lung", "ANATOMY", 241, 245], ["tachycardia", "DISEASE", 89, 100], ["tachypnea", "DISEASE", 127, 136], ["dyspnea", "DISEASE", 168, 175], ["wheezing", "DISEASE", 200, 208], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["lung", "ORGAN", 241, 245], ["Clinical examination", "TEST", 0, 20], ["a weakened general condition", "PROBLEM", 30, 58], ["a body temperature", "TEST", 60, 78], ["tachycardia", "PROBLEM", 89, 100], ["pulse rate", "TEST", 102, 112], ["tachypnea", "PROBLEM", 127, 136], ["respiratory rate", "TEST", 138, 154], ["dyspnea", "PROBLEM", 168, 175], ["subcostal retractions", "PROBLEM", 177, 198], ["wheezing", "PROBLEM", 200, 208], ["left apical fine rales", "PROBLEM", 213, 235], ["lung auscultation", "TEST", 241, 258], ["subcostal", "ANATOMY", 177, 186], ["retractions", "OBSERVATION", 187, 198], ["wheezing", "OBSERVATION", 200, 208], ["left", "ANATOMY_MODIFIER", 213, 217], ["apical", "ANATOMY_MODIFIER", 218, 224], ["fine", "OBSERVATION_MODIFIER", 225, 229], ["rales", "OBSERVATION", 230, 235], ["lung", "ANATOMY", 241, 245], ["auscultation", "OBSERVATION", 246, 258]]], ["Laboratory tests showed a leukocyte count of 22.0 \u00d7 109l\u22121, and C-reactive protein and erythrocyte sedimentation rate were normal.", [["leukocyte", "ANATOMY", 26, 35], ["erythrocyte", "ANATOMY", 87, 98], ["leukocyte", "CELL", 26, 35], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 64, 82], ["erythrocyte", "CELL", 87, 98], ["C-reactive protein", "PROTEIN", 64, 82], ["Laboratory tests", "TEST", 0, 16], ["a leukocyte count", "TEST", 24, 41], ["C", "TEST", 64, 65], ["reactive protein", "TEST", 66, 82], ["erythrocyte sedimentation rate", "TEST", 87, 117], ["reactive protein", "OBSERVATION", 66, 82], ["erythrocyte sedimentation", "OBSERVATION", 87, 112]]], ["Chest radiography, interpreted by a paediatric radiologist, revealed hyperinflation and pneumonic infiltrates of the upper left lobe.", [["upper left lobe", "ANATOMY", 117, 132], ["upper left lobe", "MULTI-TISSUE_STRUCTURE", 117, 132], ["Chest radiography", "TEST", 0, 17], ["hyperinflation", "PROBLEM", 69, 83], ["pneumonic infiltrates of the upper left lobe", "PROBLEM", 88, 132], ["hyperinflation", "OBSERVATION", 69, 83], ["pneumonic", "OBSERVATION_MODIFIER", 88, 97], ["infiltrates", "OBSERVATION", 98, 109], ["upper", "ANATOMY_MODIFIER", 117, 122], ["left lobe", "ANATOMY", 123, 132]]], ["Transcutaneously measured oxygen saturation was decreased to 82% while breathing ambient air and the patient required oxygen supplementation (8 l/min) and inhalative adrenaline.", [["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 118, 124], ["adrenaline", "CHEMICAL", 166, 176], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 118, 124], ["adrenaline", "CHEMICAL", 166, 176], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["patient", "ORGANISM", 101, 108], ["oxygen", "SIMPLE_CHEMICAL", 118, 124], ["adrenaline", "SIMPLE_CHEMICAL", 166, 176], ["patient", "SPECIES", 101, 108], ["Transcutaneously measured oxygen saturation", "TEST", 0, 43], ["breathing ambient air", "PROBLEM", 71, 92], ["oxygen supplementation", "TREATMENT", 118, 140], ["inhalative adrenaline", "TREATMENT", 155, 176]]], ["Oxygen was given for an additional 3 days along with intravenous corticosteroids and salbutamol by inhalation for persistent bronchoconstriction.", [["intravenous", "ANATOMY", 53, 64], ["Oxygen", "CHEMICAL", 0, 6], ["salbutamol", "CHEMICAL", 85, 95], ["Oxygen", "CHEMICAL", 0, 6], ["corticosteroids", "CHEMICAL", 65, 80], ["salbutamol", "CHEMICAL", 85, 95], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 64], ["salbutamol", "SIMPLE_CHEMICAL", 85, 95], ["Oxygen", "TREATMENT", 0, 6], ["intravenous corticosteroids", "TREATMENT", 53, 80], ["salbutamol", "TREATMENT", 85, 95], ["persistent bronchoconstriction", "PROBLEM", 114, 144], ["persistent", "OBSERVATION_MODIFIER", 114, 124], ["bronchoconstriction", "OBSERVATION", 125, 144]]], ["The child improved and was dismissed from hospital after 7 days.ResultsTo assess the aetiology of this respiratory disease, blood and nasopharyngeal swab were drawn from the patient upon admission and tested for the presence of viral, bacterial and fungal pathogens.", [["respiratory", "ANATOMY", 103, 114], ["blood", "ANATOMY", 124, 129], ["nasopharyngeal swab", "ANATOMY", 134, 153], ["respiratory disease", "DISEASE", 103, 122], ["child", "ORGANISM", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 134, 153], ["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["this respiratory disease", "PROBLEM", 98, 122], ["blood and nasopharyngeal swab", "TEST", 124, 153], ["viral, bacterial and fungal pathogens", "PROBLEM", 228, 265], ["improved", "OBSERVATION_MODIFIER", 10, 18], ["respiratory disease", "OBSERVATION", 103, 122], ["nasopharyngeal", "ANATOMY", 134, 148], ["viral", "OBSERVATION", 228, 233], ["fungal pathogens", "OBSERVATION", 249, 265]]], ["No infectious agent was detected by bacterial or fungal culture.", [["infectious agent", "PROBLEM", 3, 19], ["bacterial or fungal culture", "TEST", 36, 63], ["infectious", "OBSERVATION", 3, 13]]], ["The nasopharyngeal swab was also tested by PCR for Chamydia pneumoniae, Mycoplasma pneumoniae, Bordetella pertussis and Legionella pneumophila, respiratory syncytial virus (types A and B), metapneumovirus, influenza viruses (types A\u2013C), parainfluenza viruses (PIV-1, PIV-2, PIV-3 and PIV-4), rhinovirus, enterovirus, adenovirus, coronavirus (HcoV-OC43, HcoV-229E, NL63 and HKU11) and human bocavirus.", [["nasopharyngeal swab", "ANATOMY", 4, 23], ["Mycoplasma pneumoniae", "DISEASE", 72, 93], ["Bordetella pertussis", "DISEASE", 95, 115], ["Legionella pneumophila", "DISEASE", 120, 142], ["respiratory syncytial virus", "DISEASE", 144, 171], ["influenza viruses", "DISEASE", 206, 223], ["parainfluenza viruses", "DISEASE", 237, 258], ["rhinovirus, enterovirus, adenovirus, coronavirus", "DISEASE", 292, 340], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 4, 23], ["Chamydia pneumoniae", "ORGANISM", 51, 70], ["Mycoplasma pneumoniae", "ORGANISM", 72, 93], ["Bordetella pertussis", "ORGANISM", 95, 115], ["Legionella pneumophila", "ORGANISM", 120, 142], ["respiratory syncytial virus", "ORGANISM", 144, 171], ["metapneumovirus", "ORGANISM", 189, 204], ["influenza viruses", "ORGANISM", 206, 223], ["A\u2013C", "CANCER", 231, 234], ["parainfluenza viruses", "ORGANISM", 237, 258], ["PIV-1", "ORGANISM", 260, 265], ["PIV-2", "ORGANISM", 267, 272], ["PIV-3", "ORGANISM", 274, 279], ["PIV-4", "ORGANISM", 284, 289], ["rhinovirus", "ORGANISM", 292, 302], ["enterovirus", "ORGANISM", 304, 315], ["adenovirus", "ORGANISM", 317, 327], ["coronavirus", "ORGANISM", 329, 340], ["HcoV-OC43", "ORGANISM", 342, 351], ["HcoV-229E", "GENE_OR_GENE_PRODUCT", 353, 362], ["NL63", "GENE_OR_GENE_PRODUCT", 364, 368], ["HKU11", "GENE_OR_GENE_PRODUCT", 373, 378], ["human", "ORGANISM", 384, 389], ["Chamydia pneumoniae", "SPECIES", 51, 70], ["Mycoplasma pneumoniae", "SPECIES", 72, 93], ["Bordetella pertussis", "SPECIES", 95, 115], ["Legionella pneumophila", "SPECIES", 120, 142], ["respiratory syncytial virus", "SPECIES", 144, 171], ["parainfluenza", "SPECIES", 237, 250], ["rhinovirus", "SPECIES", 292, 302], ["coronavirus", "SPECIES", 329, 340], ["human", "SPECIES", 384, 389], ["Chamydia pneumoniae", "SPECIES", 51, 70], ["Mycoplasma pneumoniae", "SPECIES", 72, 93], ["Bordetella pertussis", "SPECIES", 95, 115], ["Legionella pneumophila", "SPECIES", 120, 142], ["respiratory syncytial virus", "SPECIES", 144, 171], ["PIV-1", "SPECIES", 260, 265], ["adenovirus", "SPECIES", 317, 327], ["human", "SPECIES", 384, 389], ["The nasopharyngeal swab", "TEST", 0, 23], ["PCR", "TEST", 43, 46], ["Chamydia pneumoniae", "PROBLEM", 51, 70], ["Mycoplasma pneumoniae", "PROBLEM", 72, 93], ["Bordetella pertussis", "PROBLEM", 95, 115], ["Legionella pneumophila", "PROBLEM", 120, 142], ["respiratory syncytial virus", "PROBLEM", 144, 171], ["metapneumovirus", "PROBLEM", 189, 204], ["influenza viruses", "PROBLEM", 206, 223], ["A\u2013C", "TEST", 231, 234], ["parainfluenza viruses", "PROBLEM", 237, 258], ["PIV", "TEST", 260, 263], ["PIV", "TEST", 267, 270], ["PIV", "TEST", 274, 277], ["PIV", "TEST", 284, 287], ["rhinovirus", "PROBLEM", 292, 302], ["enterovirus", "PROBLEM", 304, 315], ["adenovirus", "PROBLEM", 317, 327], ["coronavirus", "PROBLEM", 329, 340], ["HcoV", "TEST", 342, 346], ["HcoV", "TEST", 353, 357], ["NL63", "TEST", 364, 368], ["HKU11", "TEST", 373, 378], ["human bocavirus", "PROBLEM", 384, 399], ["nasopharyngeal", "ANATOMY", 4, 18], ["swab", "OBSERVATION", 19, 23], ["Mycoplasma pneumoniae", "OBSERVATION", 72, 93], ["respiratory", "ANATOMY", 144, 155], ["syncytial virus", "OBSERVATION", 156, 171], ["metapneumovirus", "ANATOMY", 189, 204], ["influenza viruses", "OBSERVATION", 206, 223], ["parainfluenza viruses", "OBSERVATION", 237, 258]]], ["The only positive result was obtained for HBoV, using the primers described by Simon et al. (2007).", [["HBoV", "ORGANISM", 42, 46], ["HBoV", "SPECIES", 42, 46], ["HBoV", "PROBLEM", 42, 46], ["the primers", "TREATMENT", 54, 65]]], ["Briefly, 5 \u03bcl of DNA (extracted from 200 \u03bcl of sample by using QIAamp mini kit; QIAGEN, Milan, Italy) was amplified using the forward primer 5\u2032 CCCAAGAAACGTCGTCTAAC 3\u2032 (HBoV nt 2301-2320) and the reverse primer 5\u2032 GTGTTGACTGAATACAGTGT 3\u2032 (HBoV nt 2681\u20132700), producing a fragment of 399 bp, partly overlapping the NP1 gene.", [["sample", "ANATOMY", 47, 53], ["HBoV nt 2301-2320", "CHEMICAL", 169, 186], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["NP1", "GENE_OR_GENE_PRODUCT", 314, 317], ["reverse primer 5", "DNA", 196, 212], ["NP1 gene", "DNA", 314, 322], ["DNA", "PROBLEM", 17, 20], ["QIAamp mini kit", "TREATMENT", 63, 78], ["CCCAAGAAACGTCGTCTAAC", "TEST", 144, 164], ["HBoV nt", "TEST", 169, 176], ["bp", "TEST", 287, 289], ["NP1 gene", "OBSERVATION", 314, 322]]], ["The cycling conditions were: an initial step at 94 \u00b0C for 5 min, followed by 40 cycles at 94 \u00b0C for 40 s, 48 \u00b0C for 40 s and 72 \u00b0C for 1 min; and a final incubation at 72 \u00b0C for 5 min.ResultsThe sensitivity of this PCR was very high, detecting up to 10 copies of HBoV genome (Fig. 1).", [["HBoV", "ORGANISM", 263, 267], ["HBoV genome", "DNA", 263, 274], ["HBoV", "SPECIES", 263, 267], ["this PCR", "TEST", 210, 218], ["HBoV genome", "PROBLEM", 263, 274], ["HBoV genome", "OBSERVATION", 263, 274]]], ["Virus detection was confirmed by sequence analysis of the PCR product.", [["Virus", "ORGANISM", 0, 5], ["Virus detection", "TEST", 0, 15], ["sequence analysis", "TEST", 33, 50], ["the PCR product", "TEST", 54, 69]]], ["Another specimen drawn from the child one month after he was discharged from the hospital was negative for HBoV by PCR.DiscussionThe detection of HBoV in the nasopharyngeal swab in a child with a clinical picture of pneumonia supports the assumption that this virus has a causative role in respiratory diseases.", [["specimen", "ANATOMY", 8, 16], ["nasopharyngeal swab", "ANATOMY", 158, 177], ["respiratory", "ANATOMY", 290, 301], ["pneumonia", "DISEASE", 216, 225], ["respiratory diseases", "DISEASE", 290, 310], ["child", "ORGANISM", 32, 37], ["HBoV", "ORGANISM", 107, 111], ["HBoV", "ORGANISM", 146, 150], ["nasopharyngeal swab", "ORGAN", 158, 177], ["HBoV", "SPECIES", 107, 111], ["HBoV", "SPECIES", 146, 150], ["Another specimen", "TEST", 0, 16], ["HBoV", "PROBLEM", 107, 111], ["PCR", "TEST", 115, 118], ["HBoV", "PROBLEM", 146, 150], ["the nasopharyngeal swab", "TEST", 154, 177], ["pneumonia", "PROBLEM", 216, 225], ["this virus", "PROBLEM", 255, 265], ["respiratory diseases", "PROBLEM", 290, 310], ["HBoV", "OBSERVATION", 146, 150], ["nasopharyngeal swab", "ANATOMY", 158, 177], ["pneumonia", "OBSERVATION", 216, 225], ["respiratory diseases", "OBSERVATION", 290, 310]]], ["The fact that it has been detected in children with or without respiratory symptoms could demonstrate that this virus might become more aggressive or overgrow, causing disease in particular hosts.", [["respiratory", "ANATOMY", 63, 74], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["respiratory symptoms", "PROBLEM", 63, 83], ["this virus", "PROBLEM", 107, 117], ["disease in particular hosts", "PROBLEM", 168, 195]]], ["Consequently, even the virus load could be an important parameter to be considered in the pathogenesis of the disease.", [["the virus load", "PROBLEM", 19, 33], ["the disease", "PROBLEM", 106, 117], ["disease", "OBSERVATION", 110, 117]]], ["We could not carry out a quantitative PCR due to the inadequacy of the sample and we did not have further samples from the child for a retrospective investigation.", [["a quantitative PCR", "TEST", 23, 41], ["a retrospective investigation", "TEST", 133, 162]]], ["However, by a semi-quantitative assay, the sample had more than 105 genome equivalents per millilitre (Fig. 1).DiscussionIn this case, it should be noted that the patient was suffering from wheezing and atopy characterized by a T cell driven airway inflammatory process, making the host an excellent substrate for viral growth.", [["T cell", "ANATOMY", 228, 234], ["airway", "ANATOMY", 242, 248], ["wheezing", "DISEASE", 190, 198], ["atopy", "DISEASE", 203, 208], ["patient", "ORGANISM", 163, 170], ["T cell", "CELL", 228, 234], ["airway", "MULTI-TISSUE_STRUCTURE", 242, 248], ["patient", "SPECIES", 163, 170], ["a semi-quantitative assay", "TEST", 12, 37], ["the sample", "TEST", 39, 49], ["wheezing", "PROBLEM", 190, 198], ["atopy", "PROBLEM", 203, 208], ["a T cell driven airway inflammatory process", "PROBLEM", 226, 269], ["viral growth", "PROBLEM", 314, 326], ["wheezing", "OBSERVATION", 190, 198], ["airway", "ANATOMY", 242, 248], ["inflammatory", "OBSERVATION", 249, 261]]], ["No coinfection was revealed, indicating that the presence of HBoV, the only agent in the sample, could not justify a pneumonia episode just as an innocent bystander.", [["coinfection", "DISEASE", 3, 14], ["HBoV", "DISEASE", 61, 65], ["pneumonia", "DISEASE", 117, 126], ["HBoV", "ORGANISM", 61, 65], ["HBoV", "SPECIES", 61, 65], ["coinfection", "PROBLEM", 3, 14], ["HBoV", "PROBLEM", 61, 65], ["a pneumonia episode", "PROBLEM", 115, 134], ["coinfection", "OBSERVATION", 3, 14], ["HBoV", "OBSERVATION", 61, 65], ["pneumonia", "OBSERVATION", 117, 126]]], ["It is also possible that this virus, frequently detected in subjects with asthma or wheezing, could be reactivated by inflammatory processes and that this reactivation could cause severe respiratory diseases, particularly in children.", [["respiratory", "ANATOMY", 187, 198], ["asthma", "DISEASE", 74, 80], ["wheezing", "DISEASE", 84, 92], ["respiratory diseases", "DISEASE", 187, 207], ["children", "ORGANISM", 225, 233], ["children", "SPECIES", 225, 233], ["this virus", "PROBLEM", 25, 35], ["asthma", "PROBLEM", 74, 80], ["wheezing", "PROBLEM", 84, 92], ["inflammatory processes", "PROBLEM", 118, 140], ["severe respiratory diseases", "PROBLEM", 180, 207], ["also possible", "UNCERTAINTY", 6, 19], ["virus", "OBSERVATION", 30, 35], ["wheezing", "OBSERVATION", 84, 92], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["respiratory diseases", "OBSERVATION", 187, 207]]], ["This report is a further confirmation of other published data showing that HBoV could be a causative agent of lower respiratory infections in young children.", [["respiratory", "ANATOMY", 116, 127], ["HBoV", "DISEASE", 75, 79], ["lower respiratory infections", "DISEASE", 110, 138], ["HBoV", "ORGANISM", 75, 79], ["lower respiratory", "ORGANISM_SUBDIVISION", 110, 127], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["HBoV", "SPECIES", 75, 79], ["HBoV", "PROBLEM", 75, 79], ["lower respiratory infections", "PROBLEM", 110, 138], ["HBoV", "OBSERVATION", 75, 79], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory", "ANATOMY", 116, 127], ["infections", "OBSERVATION", 128, 138]]], ["Nevertheless, future studies are necessary to establish the pathological role of this virus in respiratory diseases.", [["respiratory", "ANATOMY", 95, 106], ["respiratory diseases", "DISEASE", 95, 115], ["future studies", "TEST", 14, 28], ["this virus", "PROBLEM", 81, 91], ["respiratory diseases", "PROBLEM", 95, 115], ["respiratory diseases", "OBSERVATION", 95, 115]]]], "85931c154d726d61ef2ab2804a9c42e9d41108f5": [["IntroductionData volume and the multitude of sources have experienced exponential growth, creating new technical and application challenges; data generation has been estimated at 2.5 Exabytes (1 Exabyte = 1.000.000 Terabytes) of data per day [1] .", [["IntroductionData volume", "TREATMENT", 0, 23], ["exponential growth", "PROBLEM", 70, 88], ["Exabytes", "TEST", 183, 191], ["Exabyte", "TEST", 195, 202], ["new", "OBSERVATION_MODIFIER", 99, 102]]], ["These data come from everywhere: sensors used to gather climate, traffic and flight information, posts to social media sites (Twitter and Facebook are popular examples), digital pictures and videos (YouTube users upload 72 hours of new video content per minute [2] ), transaction records, and cell phone GPS signals, to name a few.", [["cell", "ANATOMY", 293, 297], ["cell", "CELL", 293, 297]]], ["The classic methods, algorithms, frameworks, and tools for data management have become both inadequate for processing this amount of data and unable to offer effective solutions for managing the data growth.", [["data management", "TREATMENT", 59, 74], ["effective solutions", "TREATMENT", 158, 177]]], ["The problem of managing and extracting useful knowledge from these data sources is currently one of the most popular topics in computing research [3, 4] .IntroductionIn this context, big data is a popular phenomenon that aims to provide an alternative to traditional solutions based on databases and data analysis.", [["a popular phenomenon", "PROBLEM", 195, 215], ["traditional solutions", "TREATMENT", 255, 276], ["databases and data analysis", "TEST", 286, 313]]], ["Big data is not just about storage or access to data; its solutions aim to analyse data in order to make sense of them and exploit their value.", [["analyse data", "TEST", 75, 87]]], ["Big data refers to datasets that are terabytes to of challenges in obtaining valuable knowledge for people and companies (see Value feature). \u2022 Velocity: refers to the speed of data transfers.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["Velocity", "TEST", 144, 152]]], ["The data's contents are constantly changing through the absorption of complementary data collections, the introduction of previous data or legacy collections, and the different forms of streamed data from multiple sources.", [["The data's contents", "TEST", 0, 19], ["complementary data collections", "PROBLEM", 70, 100], ["previous data", "TEST", 122, 135], ["legacy collections", "PROBLEM", 139, 157], ["streamed data", "PROBLEM", 186, 199]]], ["From this point of view, new algorithms and methods are needed to adequately process and analyse the online and streaming data. \u2022 Variety: refers to different types of data collected via sensors, smartphones or social networks, such as videos, images, text, audio, data logs, and so on.", [["new algorithms", "TEST", 25, 39], ["streaming data", "TEST", 112, 126], ["images", "TEST", 244, 250]]], ["Value is the most important characteristic of any big-data-based application, because it allows to generate useful business information. \u2022 Veracity: refers to the correctness and accuracy of information.IntroductionBehind any information management practice lie the core doctrines of data quality, data governance, and metadata management, along with considerations of privacy and legal concerns.IntroductionSome examples of potential big data sources are the Open Science Data Cloud [8] , the European Union Open Data Portal, open data from the U.S. government, healthcare data, public datasets on Amazon Web Services, etc. Social media [9] has become one of the most representative and relevant data sources for big data.", [["metadata management", "TREATMENT", 319, 338], ["most important", "OBSERVATION_MODIFIER", 13, 27], ["Veracity", "OBSERVATION", 139, 147], ["Portal", "ANATOMY", 519, 525]]], ["Social media data are generated from a wide number of Internet applications and Web sites, with some of the most popular being Facebook, Twitter, LinkedIn, YouTube, Instagram, Google, Tumblr, Flickr, and WordPress.", [["Internet applications", "TREATMENT", 54, 75]]], ["The fast growth of these Web sites allow users to be connected and has created a new generation of people (maybe a new kind of society [10] ) who are enthusiastic about interacting, sharing, and collaborating using these sites [11] .", [["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["fast", "OBSERVATION_MODIFIER", 4, 8], ["growth", "OBSERVATION_MODIFIER", 9, 15]]], ["Therefore, social big data will be based on the analysis of vast amounts of data that could come from multiple distributed sources but with a strong focus on social media.", [["the analysis", "TEST", 44, 56]]], ["Their applications can be extended to a wide number of domains such as health and political trending and forecasting, hobbies, e-business, cybercrime, counterterrorism, time-evolving opinion mining, social network analysis, and humanmachine interactions.", [["e-business", "DISEASE", 127, 137], ["counterterrorism", "DISEASE", 151, 167]]], ["The concept of social big data can be defined as follows:Introduction\"Those processes and methods that are designed to provide sensitive and relevant knowledge to any user or company from social media data sources when data sources can be characterised by their different formats and contents, their very large size, and the online or streamed generation of information.\"IntroductionThe gathering, fusion, processing and analysing of the big social media data from unstructured (or semi-structured) sources to extract value knowledge is an extremely difficult task which has not been completely solved.", [["fusion", "TREATMENT", 398, 404], ["an extremely difficult task", "PROBLEM", 537, 564], ["large", "OBSERVATION_MODIFIER", 305, 310], ["size", "OBSERVATION_MODIFIER", 311, 315]]], ["The classic methods, algorithms, frameworks and tools for data management have became inadequate for processing the vast amount of data.", [["data management", "TREATMENT", 58, 73]]], ["This issue has generated a large number of open problems and challenges on social big data domain related to different aspects as knowledge representation, data management, data processing, data analysis, and data visualisation [17] .", [["open problems", "PROBLEM", 43, 56], ["data analysis", "TEST", 190, 203], ["large", "OBSERVATION_MODIFIER", 27, 32]]], ["However, given the very large heterogeneous dataset from social media, one of the major challenges is to identify the valuable data and how analyse them to discover useful knowledge improving decision making of individual users and companies [18] .IntroductionIn order to analyse the social media data properly, the traditional analytic techniques and methods (data analysis) require adapting and integrating them to the new big data paradigms emerged for massive data processing.", [["social media", "TREATMENT", 57, 69], ["methods (data analysis", "TEST", 352, 374], ["massive data processing", "PROBLEM", 456, 479], ["large", "OBSERVATION_MODIFIER", 24, 29], ["heterogeneous", "OBSERVATION", 30, 43]]], ["Different big data frameworks such as Apache Hadoop [19] and Spark [20] have been arising to allow the efficient application of data mining methods and machine learning algorithms in different domains.", [["data mining methods", "TREATMENT", 128, 147]]], ["Based on these big data frameworks, several libraries such as Mahout [21] and SparkMLib [22] have been designed to develop new efficient versions of classical algorithms.", [["several libraries", "TREATMENT", 36, 53]]], ["This paper is focused on review those new methodologies, frameworks, and algorithms that are currently appearing under the big data paradigm, and their applications to a wide number of domains such as e-commerce, marketing, security, and healthcare.IntroductionFinally, summarising the concepts mentioned previously, Fig. 1 shows the conceptual representation of the three basic social big data areas: social media as a natural source for data analysis; big data as a parallel and massive processing paradigm; and data analysis as a set of algorithms and methods used to extract and analyse knowledge.", [["data analysis", "TEST", 439, 452], ["big data", "TEST", 454, 462], ["a parallel and massive processing paradigm", "PROBLEM", 466, 508], ["data analysis", "TEST", 514, 527]]], ["The intersections between these clusters reflect the concept of mixing those areas.", [["mixing", "OBSERVATION", 64, 70]]], ["For example, the intersection between big data and data analysis shows some machine learning frameworks that have been designed on top of big data technologies (Mahoot [21] , MLBase [23, 24] , or SparkMLib [22] ).", [["big data", "TEST", 38, 46], ["data analysis", "TEST", 51, 64], ["big data technologies", "TEST", 138, 159], ["MLBase", "TEST", 175, 181]]], ["The intersection between data analysis and social media represents the concept of current Web-based applications that intensively use social media information, such as applications related to marketing and e-health that are described in Section 4.", [["data analysis", "TEST", 25, 38], ["social media", "TREATMENT", 43, 55]]], ["The intersection between big data and social media is reflected in some social media applications such as LinkedIn, Facebook, and Youtube that are currently using big data technologies (Mon-goDB, Cassandra, Hadoop, and so on) to develop their Web systems.IntroductionFinally, the centre of this figure only represents the main goal of any social big data application: knowledge extraction and exploitation.IntroductionThe rest of the paper is structured as follows; Section 2 provides an introduction to the basics on the methodologies, frameworks, and software used to work with big data.", [["knowledge extraction", "TREATMENT", 368, 388]]], ["Section 4 describes a number of applications related to marketing, crime analysis, epidemic intelligence, and user experiences.", [["crime analysis", "TEST", 67, 81], ["epidemic intelligence", "PROBLEM", 83, 104]]], ["Finally, Section 5 describes some of the current problems and challenges in social big data; this section also provides some conclusions about the recent achievements and future trends in this interesting research area.Methodologies for social big dataCurrently, the exponential growth of social media has created serious problems for traditional data analysis algorithms and techniques (such as data mining, statistics, machine learning, and so on) due to their high computational complexity for large datasets.", [["the current problems", "PROBLEM", 37, 57], ["traditional data analysis algorithms", "TEST", 335, 371], ["large datasets", "PROBLEM", 497, 511]]], ["This type of methods does not properly scale as the data size increases.", [["size", "OBSERVATION_MODIFIER", 57, 61], ["increases", "OBSERVATION_MODIFIER", 62, 71]]], ["For this reason, the methodologies and frameworks behind the big data concept are becoming very popular in a wide number of research and industrial areas.Methodologies for social big dataThis section provides a short introduction to the methodology based on the MapReduce paradigm and a description of the most popular framework that implements this methodology, Apache Hadoop.", [["social big dataThis section", "TREATMENT", 172, 199], ["very", "OBSERVATION_MODIFIER", 91, 95], ["popular", "OBSERVATION", 96, 103], ["wide", "OBSERVATION_MODIFIER", 109, 113], ["number", "OBSERVATION_MODIFIER", 114, 120]]], ["Finally, some implementations and tools for big data domain related to distributed data file systems, data analytics, and machine learning techniques are presented.MapReduce and the big data processing problemMapReduce [25, 26] is presented as one of the most efficient big data solutions.", [["big data domain", "TEST", 44, 59], ["data analytics", "TEST", 102, 116], ["machine learning techniques", "TREATMENT", 122, 149], ["MapReduce", "TREATMENT", 164, 173]]], ["This programming paradigm and its related algorithms [27] , were developed to provide significant improvements in large-scale data-intensive applications in clusters [28] .", [["large", "OBSERVATION_MODIFIER", 114, 119]]], ["The programming model implemented by MapReduce is based on the definition of two basic elements: mappers and reducers.", [["mappers and reducers", "TREATMENT", 97, 117]]], ["The idea behind this programming model is to design map functions (or mappers) that are used to generate a set of intermediate key/value pairs, after which the reduce functions will merge (reduce can be used as a shuffling or combining function) all of the intermediate values that are associated with the same intermediate key.MapReduce and the big data processing problemThe key aspect of the MapReduce algorithm is that if every map and reduce is independent of all other ongoing maps and reduces, then the operations can be run in parallel on different keys and lists of data.MapReduce and the big data processing problemAlthough three functions, Map(), Combining()/Shuffling(), and Reduce(), are the basic processes in any MapReduce approach, usually they are decomposed as follows:MapReduce and the big data processing problem1.", [["the big data processing problem", "PROBLEM", 342, 373], ["the operations", "TREATMENT", 506, 520], ["the big data processing problem", "PROBLEM", 594, 625]]], ["Prepare the input: The MapReduce system designates map processors (or worker nodes), assigns the input key value K1 that each processor would work on, and provides each processor with all of the input data associated with that key value.", [["worker nodes", "MULTI-TISSUE_STRUCTURE", 70, 82], ["K1", "PROTEIN", 113, 115], ["the input data", "TEST", 191, 205]]], ["The Map() step: Each worker node applies the Map() function to the local data and writes the output to a temporary storage space.", [["the local data", "TEST", 63, 77], ["a temporary storage space", "TREATMENT", 103, 128], ["node", "OBSERVATION", 28, 32]]], ["The Map() code is run exactly once for each K1 key value, generating output that is organised by key values K2.", [["Map() code", "DNA", 4, 14], ["K1", "PROTEIN", 44, 46], ["K2", "PROTEIN", 108, 110]]], ["A master node arranges it so that for redundant copies of input data only one is processed.", [["node", "ANATOMY", 9, 13], ["node", "MULTI-TISSUE_STRUCTURE", 9, 13], ["A master node", "PROBLEM", 0, 13], ["node", "OBSERVATION", 9, 13]]], ["The Shuffle() step: The map output is sent to the reduce processors, which assign the K2 key value that each processor should work on, and provide that processor with all of the map-generated data associated with that key value, such that all data belonging to one key are located on the same worker node.", [["node", "ANATOMY", 300, 304], ["worker node", "MULTI-TISSUE_STRUCTURE", 293, 304], ["K2", "PROTEIN", 86, 88], ["The map output", "TEST", 20, 34], ["the map", "TEST", 174, 181], ["node", "OBSERVATION", 300, 304]]], ["The Reduce() step: Worker nodes process each group of output data (per key) in parallel, executing the user-provided Reduce() code; each function is run exactly once for each K2 key value produced by the map step.", [["Worker nodes", "MULTI-TISSUE_STRUCTURE", 19, 31], ["K2", "PROTEIN", 175, 177], ["output data", "TEST", 54, 65], ["nodes", "OBSERVATION", 26, 31]]], ["Produce the final output: The MapReduce system collects all of the reduce outputs and sorts them by K2 to produce the final outcome.", [["K2", "PROTEIN", 100, 102], ["The MapReduce system", "TREATMENT", 26, 46]]], ["Fig. 2 shows the classical \"word count problem\" using the MapReduce paradigm.", [["the classical \"word count problem", "PROBLEM", 13, 46]]], ["Once the key/values are generated by mappers, a shuffling process is used to mix (combine) these key values (combining the same keys in the same worker node).", [["worker node", "MULTI-TISSUE_STRUCTURE", 145, 156], ["the key/values", "TEST", 5, 19], ["a shuffling process", "TREATMENT", 46, 65], ["node", "OBSERVATION", 152, 156]]], ["Finally, the reduce functions are used to count the words that generate a common output as a result of the algorithm.", [["a common output", "PROBLEM", 72, 87], ["the algorithm", "TEST", 103, 116]]], ["As a result of the execution or wrappers/reducers, the output will generate a sorted list of word counts from the original text input.MapReduce and the big data processing problem(01, \"I thought I\") (02, \"thought of thinking\") (03, \"of thanking you\") Finally, and before the application of this paradigm, it is essential to understand if the algorithms can be translated to mappers and reducers or if the problem can be analysed using traditional strategies.", [["wrappers/reducers", "TREATMENT", 32, 49], ["the output", "PROBLEM", 51, 61], ["the big data processing problem", "PROBLEM", 148, 179], ["this paradigm", "TREATMENT", 290, 303], ["reducers", "TREATMENT", 386, 394], ["traditional strategies", "TREATMENT", 435, 457]]], ["MapReduce provides an excellent technique to work with large sets of data when the algorithm can work on small pieces of that dataset in parallel, but if the algorithm cannot be mapped into this methodology, it may be \"trying to use a sledgehammer to crack a nut\".Apache HadoopAny MapReduce system (or framework) is based on a MapReduce engine that allows for implementing the algorithms and distributing the parallel processes.", [["Apache", "TREATMENT", 264, 270], ["the algorithms", "TEST", 373, 387]]], ["Apache Hadoop [19] is an open-source software framework written in Java for the distributed storage and distributed processing of very large datasets using the MapReduce paradigm.", [["very large datasets", "PROBLEM", 130, 149], ["very", "OBSERVATION_MODIFIER", 130, 134], ["large", "OBSERVATION_MODIFIER", 135, 140]]], ["All of the modules in Hadoop have been designed taking into account the assumption that hardware failures (of individual machines or of racks of machines) are commonplace and thus should be automatically managed in the software by the framework.", [["hardware failures", "PROBLEM", 88, 105], ["modules", "OBSERVATION", 11, 18], ["hardware failures", "OBSERVATION", 88, 105]]], ["The core of Apache Hadoop comprises a storage area, the Hadoop Distributed File System (HDFS), and a processing area (MapReduce).Apache HadoopThe HDFS (see Section 2.4.1) spreads multiple copies of the data across different machines.", [["a storage area", "PROBLEM", 36, 50], ["a processing area", "TREATMENT", 99, 116], ["Apache Hadoop", "OBSERVATION", 12, 25]]], ["This not only offers reliability without the need for RAID-controlled disks but also allows for multiple locations to run the mapping.", [["RAID-controlled disks", "TREATMENT", 54, 75], ["the mapping", "TEST", 122, 133]]], ["If a machine with one copy of the data is busy or offline, another machine can be used.", [["another machine", "TREATMENT", 59, 74]]], ["However, Hadoop presents a number of limitations:Apache Hadoop1.", [["Hadoop1", "PROTEIN", 56, 63], ["Apache Hadoop1", "TREATMENT", 49, 63]]], ["For maximum parallelism, you need the maps and reduces to be stateless, to not depend on any data generated in the same MapReduce job.", [["the maps", "TEST", 34, 42]]], ["A database with an index will always be faster than running a MapReduce job over un-indexed data.", [["A database", "TEST", 0, 10], ["an index", "TEST", 16, 24]]], ["In the Hadoop implementation, reduce operations do not take place until all of the maps have been completed (or have failed and been skipped).", [["reduce operations", "TREATMENT", 30, 47], ["the maps", "TEST", 79, 87]]], ["As a result, you do not receive any data back until the entire mapping has finished.", [["the entire mapping", "TEST", 52, 70]]], ["There is a general assumption that the output of the reduce is smaller than the input to the map.", [["the output", "TEST", 35, 45], ["output", "OBSERVATION_MODIFIER", 39, 45], ["smaller", "OBSERVATION_MODIFIER", 63, 70]]], ["It provides high-level APIs in Java, Scala, Python, and R and an optimised engine that supports general execution graphs.", [["high", "OBSERVATION_MODIFIER", 12, 16], ["level APIs", "OBSERVATION", 17, 27], ["Scala", "ANATOMY", 37, 42]]], ["It also supports a rich set of high-level tools including Spark SQL for SQL and structured data processing, Spark MLlib for machine learning, GraphX for graph processing, and Spark Streaming.Apache SparkThe Spark framework allows for reusing a working set of data across multiple parallel operations.", [["graph processing", "TEST", 153, 169], ["multiple parallel operations", "TREATMENT", 271, 299]]], ["This includes many iterative machine learning algorithms as well as interactive data analysis tools.", [["many iterative machine learning algorithms", "TREATMENT", 14, 56]]], ["Therefore, this framework supports these applications while retaining the scalability and fault tolerance of MapReduce.", [["these applications", "TREATMENT", 35, 53], ["fault tolerance", "OBSERVATION", 90, 105]]], ["An RDD is a read-only collection of objects partitioned across a set of machines that can be rebuilt if a partition is lost.", [["collection of objects", "PROBLEM", 22, 43], ["objects", "OBSERVATION", 36, 43]]], ["In contrast to Hadoops two-stage disk-based MapReduce paradigm (mappers/reducers), Sparks in-memory primitives provide performance up to 100 times faster for certain applications by allowing user programs to load data into a clusters memory and to query it repeatedly.", [["Hadoops", "TEST", 15, 22]]], ["One of the multiple interesting features of Spark is that this framework is particularly well suited to machine learning algorithms [ [29] ].Apache SparkFrom a distributed computing perspective, Spark requires a cluster manager and a distributed storage system.", [["multiple", "OBSERVATION_MODIFIER", 11, 19]]], ["For cluster management, Spark supports stand-alone (native Spark cluster), Hadoop YARN, and Apache Mesos.", [["cluster management", "TREATMENT", 4, 22], ["Hadoop YARN", "TREATMENT", 75, 86]]], ["For distributed storage, Spark can interface with a wide variety, including the Hadoop Distributed File System, Apache Cassandra, OpenStack Swift, and Amazon S3.", [["a wide variety", "PROBLEM", 50, 64]]], ["Spark also supports a pseudo-distributed local mode that is usually used only for development or testing purposes, when distributed storage is not required and the local file system can be used instead; in this scenario, Spark is running on a single machine with one executor per CPU core.Other MapReduce implementations and softwareA list related to big data implementations and MapReduce-based applications was generated by Mostosi [30] .", [["testing purposes", "TEST", 97, 113], ["big data implementations", "TEST", 351, 375], ["MapReduce-based applications", "TREATMENT", 380, 408]]], ["This list comprises 33 different topics related to big data, and a selection of those technologies and applications were chosen.", [["big data", "TEST", 51, 59], ["those technologies", "TREATMENT", 80, 98]]], ["Those topics are related to: distributed programming, distributed files systems, a document data model, a key-value data model, a graph data model, machine learning, applications, business intelligence, and data analysis.", [["data analysis", "TEST", 207, 220]]], ["This selection attempts to reflect some of the recent popular frameworks and software implementations that are commonly used to develop efficient MapReduce-based systems and applications.Distributed programming & distributed filesystems\u2022 Apache Pig.", [["Apache Pig", "TREATMENT", 238, 248]]], ["Pig provides an engine for executing data flows in parallel on Hadoop.", [["executing data flows", "TEST", 27, 47]]], ["Pig Latin includes operators for many of the traditional data operations (join, sort, filter, etc.), as well as the ability for users to develop their own functions for reading, processing, and writing data. \u2022 Apache Storm.", [["Pig", "SPECIES", 0, 3], ["the traditional data operations", "TREATMENT", 41, 72], ["filter", "TREATMENT", 86, 92]]], ["It is a distributed real-time computation system for rapidly processing large streams of data.", [["large", "OBSERVATION_MODIFIER", 72, 77], ["streams", "OBSERVATION_MODIFIER", 78, 85]]], ["Storm is an architecture based on a master-workers paradigm, so that a Storm cluster mainly consists of master and worker nodes, with coordination done by Zookeeper [33] . \u2022 Stratosphere [34] .", [["worker nodes", "MULTI-TISSUE_STRUCTURE", 115, 127], ["nodes", "OBSERVATION", 122, 127]]], ["It is compatible with the Hadoop ecosystem:, accessing data stored in the HDFS and running with Hadoops new cluster manager YARN.", [["compatible with", "UNCERTAINTY", 6, 21]]], ["The new runtime allows for defining more advanced operations that include more transformations than only map and reduce.", [["more advanced operations", "TREATMENT", 36, 60]]], ["Additionally, Stratosphere allows for expressing analysis jobs using advanced data flow graphs, which are able to resemble common data analysis task more naturally. \u2022 Apache HDFS.", [["advanced data flow graphs", "TEST", 69, 94], ["Apache HDFS", "PROBLEM", 167, 178]]], ["The most extended and popular distributed file system for MapReduce frameworks and applications is the Hadoop Distributed File System.", [["MapReduce frameworks", "TREATMENT", 58, 78], ["most extended", "OBSERVATION_MODIFIER", 4, 17]]], ["Hadoop and HDFS were derived from the Google File System (GFS) [35] .Document data model & graph data modelCassandra is a recent open source fork of a stand-alone distributed non-SQL DBMS system that was initially coded by Facebook, derived from what was known of the original Google BigTable [36] and Google File System designs [35] .", [["HDFS", "PROBLEM", 11, 15]]], ["Cassandra uses a system inspired by Amazons Dynamo for storing data, and MapReduce can retrieve data from Cassandra.", [["Cassandra", "TREATMENT", 106, 115]]], ["Cassandra can run without the HDFS or on top of it (the DataStax fork of Cassandra). \u2022 Apache Giraph.", [["the HDFS", "PROBLEM", 26, 34]]], ["Giraph is an iterative graph processing system built for high scalability.", [["high scalability", "OBSERVATION", 57, 73]]], ["Giraph was originated as the open-source counterpart to Pregel [37] , the graph processing framework developed at Google (see Section 3.1 for a further description). \u2022 MongoDB.Document data model & graph data modelMongoDB is an open-source document-oriented database system and is part of the NoSQL family of database systems [38] .", [["MongoDB", "PROTEIN", 168, 175], ["NoSQL family", "PROTEIN", 293, 305], ["Giraph", "TEST", 0, 6]]], ["It provides high performance, high availability, and automatic scaling.", [["automatic scaling", "PROBLEM", 53, 70]]], ["Instead of storing data in tables as is done in a classical relational database, MongoDB stores structured data as JSON-like documents, which are data structures composed of fields and value pairs.", [["MongoDB", "PROTEIN", 81, 88]]], ["The Mahout(TM) Machine Learning (ML) library is an Apache(TM) project whose main goal is to build scalable libraries that contain the implementation of a number of the conventional ML algorithms (dimensionality reduction, classification, clustering, and topic models, among others).", [["Mahout(TM) Machine Learning (ML) library", "DNA", 4, 44], ["The Mahout(TM) Machine Learning (ML) library", "TREATMENT", 0, 44], ["an Apache(TM)", "TREATMENT", 48, 61], ["the conventional ML algorithms", "TREATMENT", 164, 194], ["dimensionality reduction", "TREATMENT", 196, 220]]], ["In addition, this library includes implementations for a set of recommender systems (user-based and item-based strategies).", [["a set of recommender systems", "TREATMENT", 55, 83]]], ["The first versions of Mahout implemented the algorithms built on the Hadoop framework, but recent versions include many new implementations built on the Mahout-Samsara environment, which runs on Spark and H2O.", [["H2O", "CHEMICAL", 205, 208], ["H2O", "CHEMICAL", 205, 208], ["new", "OBSERVATION_MODIFIER", 120, 123]]], ["MLlib is Sparks scalable machine learning library, which consists of common learning algorithms and utilities, including classification, regression, clustering, collaborative filtering, and dimensionality reduction, as well as underlying optimization primitives.", [["MLlib", "DNA", 0, 5], ["collaborative filtering", "TREATMENT", 161, 184], ["dimensionality reduction", "TREATMENT", 190, 214], ["optimization primitives", "OBSERVATION", 238, 261]]], ["It supports writing applications in Java, Scala, or Python and can run on any Hadoop2/YARN cluster with no preinstallation.", [["Hadoop2/YARN cluster", "DNA", 78, 98], ["Python", "PROBLEM", 52, 58], ["any Hadoop2/YARN cluster", "TREATMENT", 74, 98], ["Scala", "ANATOMY", 42, 47]]], ["The first version of MLlib was developed at UC Berkeley by 11 contributors, and it provided a limited set of standard machine learning methods.", [["standard machine learning methods", "TREATMENT", 109, 142]]], ["However, MLlib is currently experiencing dramatic growth, and it has over 140 contributors from over 50 organisations. \u2022 MLBase [23] .", [["MLlib", "PROTEIN", 9, 14], ["dramatic growth", "PROBLEM", 41, 56], ["dramatic", "OBSERVATION_MODIFIER", 41, 49], ["growth", "OBSERVATION_MODIFIER", 50, 56]]], ["The MLbase platform consists of three layers: ML Optimizer, MLlib, and MLI.", [["MLbase", "PROTEIN", 4, 10], ["MLI", "PROTEIN", 71, 74], ["The MLbase platform", "TEST", 0, 19], ["MLI", "ANATOMY", 71, 74]]], ["ML Optimizer (currently under development) aims to automate the task of ML pipeline construction.", [["ML pipeline construction", "TREATMENT", 72, 96]]], ["The optimizer solves a search problem over the feature extractors and ML algorithms included in MLI and MLlib.", [["MLI", "PROTEIN", 96, 99], ["MLlib", "PROTEIN", 104, 109]]], ["MLI [24] is an experimental API for feature extraction and algorithm development that introduces high-level ML programming abstractions.", [["MLI", "CHEMICAL", 0, 3], ["an experimental API", "TREATMENT", 12, 31], ["feature extraction", "TREATMENT", 36, 54], ["algorithm development", "TEST", 59, 80], ["high-level ML programming abstractions", "TREATMENT", 97, 135]]], ["A prototype of MLI has been implemented against Spark and serves as a test bed for MLlib.", [["MLI", "CHEMICAL", 15, 18], ["MLI", "DNA", 15, 18], ["MLlib", "PROTEIN", 83, 88], ["A prototype of MLI", "TREATMENT", 0, 18]]], ["Finally, MLlib is Apache Sparks distributed ML library.", [["MLlib", "DNA", 9, 14], ["Apache Sparks distributed ML library", "DNA", 18, 54]]], ["MLlib was initially developed as part of the MLbase project, and the library is currently supported by the Spark community.", [["MLlib", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Pentaho is an open source data integration (Kettle) tool that delivers powerful extraction, transformation, and loading capabilities using a groundbreaking, metadata-driven approach.Applications & business intelligence & data analysisIt also provides analytics, reporting, visualisation, and a predictive analytics framework that is directly designed to work with Hadoop nodes.", [["Pentaho", "CHEMICAL", 0, 7], ["Hadoop nodes", "MULTI-TISSUE_STRUCTURE", 364, 376], ["Pentaho", "TREATMENT", 0, 7], ["powerful extraction", "TREATMENT", 71, 90], ["data analysis", "TEST", 221, 234], ["visualisation", "TEST", 273, 286], ["Hadoop nodes", "PROBLEM", 364, 376], ["nodes", "OBSERVATION", 371, 376]]], ["It provides data integration and analytic platforms based on Hadoop in which datasets can be streamed, blended, and then automatically published into one of the popular analytic databases. \u2022 SparkR.", [["SparkR", "GENE_OR_GENE_PRODUCT", 191, 197], ["SparkR", "PROTEIN", 191, 197], ["analytic platforms", "TEST", 33, 51], ["Hadoop", "TREATMENT", 61, 67]]], ["There is an important number of R-based applications for MapReduce and other big data applications.", [["R-based applications", "TREATMENT", 32, 52], ["MapReduce", "TREATMENT", 57, 66]]], ["R [39] is a popular and extremely powerful programming language for statistics and data analysis.", [["statistics and data analysis", "TEST", 68, 96]]], ["SparkR provides an R frontend for Spark.", [["SparkR", "PROTEIN", 0, 6]]], ["It allows users to interactively run jobs from the R shell on a cluster, automatically serializes the necessary variables to execute a function on the cluster, and also allows for easy use of existing R packages.Social data analytic methods and algorithmsSocial big data analytic can be seen as the set of algorithms and methods used to extract relevant knowledge from social media data sources that could provide heterogeneous contents, with very large size, and constantly changing (stream or online data).", [["existing R packages", "TREATMENT", 192, 211], ["heterogeneous contents", "PROBLEM", 414, 436], ["heterogeneous", "OBSERVATION_MODIFIER", 414, 427], ["contents", "OBSERVATION", 428, 436], ["very", "OBSERVATION_MODIFIER", 443, 447], ["large", "OBSERVATION_MODIFIER", 448, 453], ["size", "OBSERVATION_MODIFIER", 454, 458]]], ["This is inherently interdisciplinary and spans areas such as data mining, machine learning, statistics, graph mining, information retrieval, and natural language among others.", [["inherently", "OBSERVATION_MODIFIER", 8, 18], ["interdisciplinary", "OBSERVATION_MODIFIER", 19, 36]]], ["This section provides a description of the basic methods and algorithms related to network analytics, community detection, text analysis, information diffusion, and information fusion, which are the areas currently used to analyse and process information from social-based sources.Network analyticsToday, society lives in a connected world in which communication networks are intertwined with daily life.", [["the basic methods", "TEST", 39, 56], ["network analytics", "TEST", 83, 100], ["community detection", "TEST", 102, 121], ["text analysis", "TEST", 123, 136], ["information diffusion", "TEST", 138, 159]]], ["In social networks, individuals interact with one another and provide information on their preferences and relationships, and these networks have become important tools for collective intelligence extraction.", [["social networks", "MULTI-TISSUE_STRUCTURE", 3, 18], ["collective intelligence extraction", "TREATMENT", 173, 207]]], ["These connected networks can be represented using graphs, and network analytic methods [41] can be applied to them for extracting useful knowledge.Network analyticsGraphs are structures formed by a set of vertices (also called nodes) and a set of edges, which are connections between pairs of vertices.", [["networks", "MULTI-TISSUE_STRUCTURE", 16, 24], ["nodes", "OBSERVATION", 227, 232], ["edges", "OBSERVATION_MODIFIER", 247, 252], ["vertices", "ANATOMY_MODIFIER", 293, 301]]], ["The information extracted from a social network can be easily represented as a graph in which the vertices or nodes represent the users and the edges represent the relationships among them (e.g., a re-tweet of a message or a favourite mark in Twitter).", [["nodes", "MULTI-TISSUE_STRUCTURE", 110, 115], ["a graph", "TEST", 77, 84], ["nodes", "OBSERVATION", 110, 115]]], ["These measures have high computational complexity in large-scale networks.", [["high", "OBSERVATION_MODIFIER", 20, 24], ["computational", "OBSERVATION_MODIFIER", 25, 38], ["complexity", "OBSERVATION_MODIFIER", 39, 49], ["large", "OBSERVATION_MODIFIER", 53, 58], ["-scale", "OBSERVATION_MODIFIER", 58, 64]]], ["To solve this problem, focusing on a large-scale graph analysis, a second generation of frameworks based on the MapReduce paradigm has appeared, including Hama, Giraph (based on Pregel), and GraphLab among others [42] .Network analyticsPregel [37] is a graph-parallel system based on the Bulk Synchronous Parallel model (BSP) [43] .", [["a graph-parallel system", "TREATMENT", 251, 274]]], ["A BSP abstract computer can be interpreted as a set of processors that can follow different threads of computation in which each processor is equipped with fast local memory and interconnected by a communication network.", [["BSP", "GENE_OR_GENE_PRODUCT", 2, 5]]], ["According to this, the platform based on this model comprises three major components:Network analytics\u2022 Components capable of processing and/or local memory transactions (i.e., processors). \u2022 A network that routes messages between pairs of these components. \u2022 A hardware facility that allows for the synchronisation of all or a subset of components.Network analyticsTaking into account this model, a BSP algorithm is a sequence of global supersteps that consists of three components:Network analytics1.", [["BSP", "GENE_OR_GENE_PRODUCT", 400, 403], ["BSP", "PROTEIN", 400, 403], ["local memory transactions", "TREATMENT", 144, 169], ["A hardware facility", "TREATMENT", 260, 279], ["a BSP algorithm", "TEST", 398, 413], ["hardware", "OBSERVATION", 262, 270]]], ["Concurrent computation: Every participating processor may perform local asynchronous computations.", [["local asynchronous computations", "TREATMENT", 66, 97]]], ["Barrier synchronisation: When a process reaches this point (the barrier), it waits until all other processes have reached the same barrier.Network analyticsHama [44] and Giraph are two distributed graph processing frameworks on Hadoop that implement Pregel.", [["Pregel", "PROTEIN", 250, 256]]], ["The main difference between the two frameworks is the matrix computation using the MapReduce paradigm.", [["matrix", "CELLULAR_COMPONENT", 54, 60], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["two", "OBSERVATION_MODIFIER", 32, 35], ["frameworks", "OBSERVATION_MODIFIER", 36, 46], ["matrix", "OBSERVATION_MODIFIER", 54, 60]]], ["Apache Giraph is an iterative graph processing system in which the input is a graph composed of vertices and directed edges.", [["Apache", "TREATMENT", 0, 6], ["an iterative graph processing system", "TREATMENT", 17, 53], ["edges", "OBSERVATION_MODIFIER", 118, 123]]], ["Initially, every vertex is active, and for each superstep, every active vertex invokes the \"Compute Method\" that will implement the graph algorithm that will be executed.", [["the graph algorithm", "TEST", 128, 147], ["active", "OBSERVATION", 27, 33]]], ["This means that the algorithms implemented using Giraph are vertex oriented.", [["the algorithms", "TEST", 16, 30]]], ["Apache Hama does not only allow users to work with Pregel-like graph applications.", [["Pregel", "TREATMENT", 51, 57]]], ["This computing engine can also be used to perform computeintensive general scientific applications and machine learning algorithms.", [["machine learning algorithms", "TREATMENT", 103, 130]]], ["Moreover, it currently supports YARN, which is the resource management technology that lets multiple computing frameworks run on the same Hadoop cluster using the same underlying storage.", [["Hadoop cluster", "DNA", 138, 152]]], ["Therefore, the same data could be analysed using MapReduce or Spark.Network analyticsIn contrast, GraphLab is based on a different concept.", [["GraphLab", "TREATMENT", 98, 106]]], ["Whereas Pregel is a one-vertex-centric model, this framework uses vertexto-node mapping in which each vertex can access the state of adjacent vertices.", [["vertexto-node", "ANATOMY", 66, 79], ["Pregel", "PROTEIN", 8, 14], ["vertexto-node mapping", "TREATMENT", 66, 87], ["node", "OBSERVATION", 75, 79]]], ["In Pregel, the interval between two supersteps is defined by the run time of the vertex with the largest neighbourhood.", [["vertex", "ANATOMY_MODIFIER", 81, 87], ["largest", "OBSERVATION_MODIFIER", 97, 104]]], ["The GraphLab approach improves this splitting of vertices with large neighbourhoods across different machines and synchronises them.Network analyticsFinally, Elser and Montresor [42] present a study of these data frameworks and their application to graph algorithms.", [["The GraphLab approach", "TREATMENT", 0, 21], ["a study", "TEST", 191, 198], ["these data frameworks", "TEST", 202, 223], ["graph algorithms", "TEST", 249, 265], ["large", "OBSERVATION_MODIFIER", 63, 68], ["neighbourhoods", "OBSERVATION_MODIFIER", 69, 83]]], ["The k-core decomposition algorithm is adapted to each framework.", [["The k-core decomposition algorithm", "TREATMENT", 0, 34]]], ["The goal of this algorithm is to compute the centrality of each node in a given graph.", [["node", "ANATOMY", 64, 68], ["node", "MULTI-TISSUE_STRUCTURE", 64, 68], ["this algorithm", "TEST", 12, 26], ["node", "OBSERVATION", 64, 68]]], ["The results obtained confirm the improvement achieved in terms of execution time for these frameworks based on Hadoop.", [["these frameworks", "TREATMENT", 85, 101]]], ["However, from a programming paradigm point of view, the authors recommend Pregel-inspired frameworks (a vertex-centric framework), which is the better fit for graph-related problems.Community detection algorithmsThe community detection problem in complex networks has been the subject of many studies in the field of data mining and social network analysis.", [["related problems", "PROBLEM", 165, 181], ["Community detection algorithms", "TEST", 182, 212], ["many studies", "TEST", 288, 300], ["social network analysis", "TEST", 333, 356]]], ["The goal of the community detection problem is similar to the idea of graph partitioning in graph theory [45, 46] .", [["the community detection problem", "PROBLEM", 12, 43]]], ["A cluster in a graph can be easily mapped into a community.", [["cluster", "OBSERVATION_MODIFIER", 2, 9]]], ["Random walks, spectral clustering, modularity maximization, and statistical mechanics have all been applied to detecting communities [46] .", [["spectral clustering", "PROBLEM", 14, 33], ["modularity maximization", "TREATMENT", 35, 58]]], ["It is generally accepted that a subset of vertices forms a good cluster if the induced sub-graph is dense and there are few connections from the included vertices to the rest of the graph [47] .", [["good", "OBSERVATION_MODIFIER", 59, 63], ["dense", "OBSERVATION_MODIFIER", 100, 105], ["few", "OBSERVATION_MODIFIER", 120, 123]]], ["Considering both connectivity and density, a possible definition of a graph cluster could be a connected component or a maximal clique [48] .", [["a graph cluster", "PROBLEM", 68, 83], ["a connected component", "PROBLEM", 93, 114], ["density", "OBSERVATION", 34, 41]]], ["This is a sub-graph into which no vertex can be added without losing the clique property.Community detection algorithmsOne of the most well-known algorithms for community detection was proposed by Girvan and Newman [49] .", [["a sub-graph", "TREATMENT", 8, 19], ["Community detection algorithms", "TEST", 89, 119], ["community detection", "TEST", 161, 180], ["sub", "OBSERVATION_MODIFIER", 10, 13]]], ["The proposed algorithm is based on identifying the edges that lie between communities and their successive removal, achieving the isolation of the communities.", [["their successive removal", "TREATMENT", 90, 114], ["successive", "OBSERVATION_MODIFIER", 96, 106], ["removal", "OBSERVATION_MODIFIER", 107, 114]]], ["The main disadvantage of this algorithm is its high computational complexity with very large networks.Community detection algorithmsModularity is the most used and best known quality measure for graph clustering techniques, but its computation is an NP-complete problem.", [["Community detection algorithms", "TEST", 102, 132], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21], ["high", "OBSERVATION_MODIFIER", 47, 51], ["very", "OBSERVATION_MODIFIER", 82, 86], ["large", "OBSERVATION_MODIFIER", 87, 92], ["networks", "OBSERVATION", 93, 101]]], ["However, there are currently a number of algorithms based on good approximations of modularity that are able to detect communities in a reasonable time.", [["modularity", "OBSERVATION", 84, 94]]], ["The first greedy technique to maximize modularity was a method proposed by Newman [50] .", [["The first greedy technique", "TREATMENT", 0, 26], ["a method", "TREATMENT", 54, 62]]], ["This was an agglomerative hierarchical clustering algorithm in which groups of vertices were successively joined to form larger communities such that modularity increased after the merging.", [["an agglomerative hierarchical clustering algorithm", "TREATMENT", 9, 59], ["larger", "OBSERVATION_MODIFIER", 121, 127], ["modularity", "OBSERVATION_MODIFIER", 150, 160], ["increased", "OBSERVATION_MODIFIER", 161, 170]]], ["The update of the matrix in the Newman algorithm involved a large number of useless operations owing to the sparseness of the adjacency matrix.", [["matrix", "CELLULAR_COMPONENT", 18, 24], ["matrix", "CELLULAR_COMPONENT", 136, 142], ["useless operations", "TREATMENT", 76, 94], ["large", "OBSERVATION_MODIFIER", 60, 65], ["adjacency matrix", "OBSERVATION", 126, 142]]], ["However, the algorithm was improved by Clauset et al. [51] , who used the matrix of modularity variations to arrange for the algorithm to perform more efficiently.Community detection algorithmsDespite the improvements to and modifications of the accuracy of these greedy algorithms, they have poor performance when they are compared against other techniques.", [["the algorithm", "TREATMENT", 121, 134], ["Community detection algorithms", "TEST", 163, 193], ["these greedy algorithms", "TEST", 258, 281]]], ["For this reason, Newman reformulated the modularity measure in terms of eigenvectors by replacing the Laplacian matrix with the modularity matrix [52] , called the spectral optimization of modularity.", [["the Laplacian matrix", "TREATMENT", 98, 118], ["modularity", "OBSERVATION", 189, 199]]], ["This improvement must also be applied in order to improve the results of other optimization techniques [53, 54] .Community detection algorithmsRandom walks can also be useful for finding communities.", [["Community detection algorithms", "TEST", 113, 143]]], ["If a graph has a strong community structure, a random walker spends a long time inside a community because of the high density of internal edges and the consequent number of paths that could be followed.", [["a random walker", "TREATMENT", 45, 60], ["the high density of internal edges", "PROBLEM", 110, 144], ["high", "OBSERVATION_MODIFIER", 114, 118], ["density", "OBSERVATION", 119, 126], ["internal edges", "OBSERVATION_MODIFIER", 130, 144]]], ["Zhou and Lipowsky [55] , based on the fact that walkers move preferentially towards vertices that share a large number of neighbours, defined a proximity index that indicates how close a pair of vertices is to all other vertices.", [["large", "OBSERVATION_MODIFIER", 106, 111]]], ["Communities are detected with a procedure called NetWalk, which is an agglomerative hierarchical clustering method by which the similarity between vertices is expressed by their proximity.Community detection algorithmsA number of these techniques are focused on finding disjointed communities.", [["a procedure", "TREATMENT", 30, 41], ["Community detection algorithms", "TEST", 188, 218]]], ["The network is partitioned into dense regions in which nodes have more connections to each other than to the rest of the network, but it is interesting that in some domains, a vertex could belong to several clusters.", [["nodes", "ANATOMY", 55, 60], ["dense", "OBSERVATION_MODIFIER", 32, 37], ["nodes", "OBSERVATION", 55, 60]]], ["For instance, it is well-known that people in a social network for natural memberships in multiple communities.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["Therefore, the overlap is a significant feature of many realworld networks.", [["realworld networks", "MULTI-TISSUE_STRUCTURE", 56, 74]]], ["To solve this problem, fuzzy clustering algorithms applied to graphs [56] and overlapping approaches [57] have been proposed.Community detection algorithmsXie et al. [58] reviewed the state of the art in overlapping community detection algorithms.", [["this problem", "PROBLEM", 9, 21], ["fuzzy clustering algorithms", "PROBLEM", 23, 50]]], ["This work noticed that for low overlapping density networks, SLPA, OSLOM, Game, and COPRA offer better performance.", [["SLPA", "PROTEIN", 61, 65], ["OSLOM", "PROTEIN", 67, 72], ["Game", "PROTEIN", 74, 78], ["COPRA", "PROTEIN", 84, 89], ["low overlapping density networks", "PROBLEM", 27, 59], ["density", "OBSERVATION", 43, 50]]], ["For networks with high overlapping density and high overlapping diversity, both SLPA and Game provide relatively stable performance.", [["high overlapping density", "PROBLEM", 18, 42], ["high overlapping diversity", "PROBLEM", 47, 73], ["high overlapping", "OBSERVATION_MODIFIER", 18, 34], ["density", "OBSERVATION", 35, 42], ["high overlapping", "OBSERVATION_MODIFIER", 47, 63], ["diversity", "OBSERVATION_MODIFIER", 64, 73], ["stable", "OBSERVATION_MODIFIER", 113, 119]]], ["However, test results also suggested that the detection in such networks is still not yet fully resolved .", [["the detection", "TEST", 42, 55]]], ["A common feature that is observed by various algorithms in real-world networks is the relatively small fraction of overlapping nodes (typically less than 30%), each of which belongs to only 2 or 3 communities.Text analyticsA significant portion of the unstructured content collected from social media is text.", [["nodes", "ANATOMY", 127, 132], ["overlapping nodes", "PROBLEM", 115, 132], ["relatively", "OBSERVATION_MODIFIER", 86, 96], ["small", "OBSERVATION_MODIFIER", 97, 102], ["fraction", "OBSERVATION_MODIFIER", 103, 111], ["overlapping", "OBSERVATION_MODIFIER", 115, 126], ["nodes", "OBSERVATION", 127, 132], ["significant", "OBSERVATION_MODIFIER", 225, 236], ["portion", "OBSERVATION_MODIFIER", 237, 244], ["content", "OBSERVATION", 265, 272]]], ["Text mining techniques can be applied for automatic organization, navigation, retrieval, and summary of huge volumes of text documents [59] [60] [61] .", [["Text mining techniques", "TREATMENT", 0, 22]]], ["This concept covers a number of topics and algorithms for text analysis including natural language processing (NLP), information retrieval, data mining, and machine learning [62] .Text analyticsInformation extraction techniques attempt to extract entities and their relationships from texts, allowing for the inference of new meaningful knowledge.", [["algorithms", "TEST", 43, 53], ["text analysis", "TEST", 58, 71], ["extraction techniques", "TREATMENT", 206, 227]]], ["Another function that is currently used is the inverse document frequency (IDF); typically, documents are represented as TF-IDF feature vectors.", [["TF-IDF feature vectors", "DNA", 121, 143]]], ["Using this data representation, a document represents a data point in n-dimensional space where n is the size of the corpus vocabulary.Text analyticsText data tend to be sparse and high dimensional.", [["corpus", "ANATOMY", 117, 123], ["corpus", "ORGANISM_SUBDIVISION", 117, 123], ["Text analytics", "TEST", 135, 149], ["Text data", "TEST", 149, 158], ["size", "OBSERVATION_MODIFIER", 105, 109], ["corpus vocabulary", "OBSERVATION", 117, 134], ["high dimensional", "OBSERVATION_MODIFIER", 181, 197]]], ["A text document corpus can be represented as a large sparse TF-IDF matrix, and applying dimensionality reduction methods to represent the data in compressed format [63] can be very useful.", [["TF", "PROTEIN", 60, 62], ["a large sparse TF-IDF matrix", "TREATMENT", 45, 73], ["dimensionality reduction methods", "TREATMENT", 88, 120], ["large", "OBSERVATION_MODIFIER", 47, 52], ["sparse", "OBSERVATION_MODIFIER", 53, 59], ["IDF matrix", "OBSERVATION", 63, 73]]], ["Latent semantic indexing [64] is an automatic indexing method that projects both documents and terms into a low-dimensional space that attempts to represent the semantic concepts in the document.", [["an automatic indexing method", "PROBLEM", 33, 61]]], ["This method is based on the singular value decomposition of the term-document matrix, which constructs a low-ranking approximation of the original matrix while preserving the similarity between the documents.", [["matrix", "CELLULAR_COMPONENT", 147, 153], ["low", "OBSERVATION_MODIFIER", 105, 108]]], ["Another family of dimension reduction techniques is based on probabilistic topic mod-els such as latent Dirichlet allocation (LDA) [65] .", [["dimension reduction techniques", "TREATMENT", 18, 48]]], ["This technique provides the mechanism for identifying patterns of term co-occurrence and using those patterns to identify coherent topics.", [["This technique", "TREATMENT", 0, 14]]], ["Standard LDA implementations of the algorithm read the documents of the training corpus numerous times and in a serial way.", [["the algorithm", "TEST", 32, 45]]], ["However, new, efficient, parallel implementations of this algorithm have appeared [66] in attempts to improve its efficiency.Text analyticsUnsupervised machine learning methods can be applied to any text data without the need for a previous manual process.", [["this algorithm", "TEST", 53, 67], ["learning methods", "TREATMENT", 160, 176], ["a previous manual process", "TREATMENT", 230, 255], ["new", "OBSERVATION_MODIFIER", 9, 12], ["efficient", "OBSERVATION_MODIFIER", 14, 23]]], ["These techniques can automatically organise a document corpus into clusters or similar groups based on a blind search in an unlabelled data collection, grouping the data with similar properties into clusters without human supervision.", [["human", "ORGANISM", 216, 221], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221]]], ["Generally, document clustering methods can be mainly categorized into two types [67] : partitioning algorithms that divide a document corpus into a given number of disjoint clusters that are optimal in terms of some predefined criteria functions [68] and hierarchical algorithms that group the data points into a hierarchical tree structure or a dendrogram [69] .", [["partitioning algorithms", "TREATMENT", 87, 110], ["disjoint clusters", "PROBLEM", 164, 181], ["hierarchical algorithms", "PROBLEM", 255, 278]]], ["Both types of clustering algorithms have strengths and weaknesses depending on the structure and characteristics of the dataset used.", [["clustering algorithms", "OBSERVATION", 14, 35]]], ["In Zhao and Karypis [70] , a comparative assessment of different clustering algorithms (partitioning and hierarchical) was performed using different similarity measures on high-dimensional text data.", [["a comparative assessment", "TEST", 27, 51]]], ["The study showed that partitioning algorithms perform better and can also be used to produce hierarchies of higher quality than those returned by the hierarchical ones.Text analyticsIn contrast, the classification problem is one of the main topics in the supervised machine learning literature.", [["The study", "TEST", 0, 9], ["Text analytics", "TEST", 168, 182]]], ["Nearly all of the wellknown techniques for classification, such as decision trees, association rules, Bayes methods, nearest neighbour classifiers, SVM classifiers, and neural networks, have been extended for automated text categorisation [71] .", [["neural networks", "ANATOMY", 169, 184], ["neural networks", "MULTI-TISSUE_STRUCTURE", 169, 184]]], ["Therefore, most of the existing techniques designed for this purpose are based on classifiers [72] .Text analyticsHowever, the emergence of social networks has created massive and continuous streams of text data.", [["social networks", "MULTI-TISSUE_STRUCTURE", 140, 155], ["Text analytics", "TEST", 100, 114], ["text data", "TEST", 202, 211], ["massive", "OBSERVATION_MODIFIER", 168, 175]]], ["For example, the online spherical k-means algorithm [74] is a segment-wise approach that was proposed for streaming text clustering.", [["streaming text clustering", "PROBLEM", 106, 131]]], ["This technique splits the incoming text stream into small segments that can be processed effectively in memory.", [["This technique", "TREATMENT", 0, 14], ["small segments", "OBSERVATION_MODIFIER", 52, 66]]], ["Then, a set of k-means iterations is applied to each segment in order to cluster them.", [["a set of k-means iterations", "TREATMENT", 6, 33]]], ["Moreover, in order to consider less important old documents during the clustering process, a decay factor is included.Information diffusion models and methodsOne of the most important roles of social media is to spread information to social links.", [["decay factor", "PROTEIN", 93, 105], ["Information diffusion models", "TEST", 118, 146]]], ["With the large amount of data and the complex structures of social networks, it has been even more difficult to understand how (and why) information is spread by social reactions (e.g., retweeting in Twitter and like in Facebook).", [["social networks", "MULTI-TISSUE_STRUCTURE", 60, 75], ["large", "OBSERVATION_MODIFIER", 9, 14], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["complex", "OBSERVATION_MODIFIER", 38, 45], ["social networks", "OBSERVATION", 60, 75]]], ["It can be applied to various applications, e.g., viral marketing, popular topic detection, and virus prevention [75] .Information diffusion models and methodsAs a result, many studies have been proposed for modelling the information diffusion patterns on social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 255, 270], ["viral marketing", "TREATMENT", 49, 64], ["popular topic detection", "TEST", 66, 89], ["virus prevention", "TREATMENT", 95, 111], ["Information diffusion models", "TEST", 118, 146], ["many studies", "TEST", 171, 183]]], ["The characteristics of the diffusion models are (i) the topological structure of the network (a sub-graph composed of a set of users to whom the information has been spread) and (ii) temporal dynamics (the evolution of the number of users whom the information has reached over time) [76] .Information diffusion models and methodsAccording to the analytics, these diffusion models can be categorized into explanatory and predictive approaches [77] .Information diffusion models and methods\u2022 Explanatory models: The aim of these models is to discover the hidden spreading cascades once the activation sequences are collected.", [["Information diffusion models", "TEST", 289, 317], ["Information diffusion models", "TEST", 448, 476], ["the hidden spreading cascades", "PROBLEM", 549, 578], ["the activation sequences", "TEST", 584, 608]]], ["The NETINT method [78] has applied sub-modular, function-based iterative optimisation to discover the spreading cascade (path) that maximises the likelihood of the collected dataset.", [["The NETINT method", "TEST", 0, 17], ["sub-modular", "TREATMENT", 35, 46], ["based iterative optimisation", "TREATMENT", 57, 85]]], ["Depending on the previous diffusion patterns, there are two main categories of predictive models: (i) structure-based models (graph-based approaches) and (ii) content-analysis-based models (non-graph-based approaches).Information diffusion models and methodsMoreover, there are more existing approaches to understanding information diffusion patterns.", [["the previous diffusion patterns", "TEST", 13, 44], ["based models", "TEST", 176, 188], ["Information diffusion models", "TEST", 218, 246], ["main", "OBSERVATION_MODIFIER", 60, 64]]], ["The projected greedy approach for non-sub-modular problems [80] was recently proposed to populate the useful seeds in social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 118, 133], ["The projected greedy approach", "TREATMENT", 0, 29]]], ["Additionally, an evolutionary dynamics model was presented in [ [81] , [82] ] that attempted to understand the temporal dynamics of information diffusion over time.Information diffusion models and methodsOne of the relevant topics for analysing information diffusion patterns and models is the concept of time and how it can be represented and managed.", [["Information diffusion models", "TEST", 164, 192]]], ["Any time series can be defined as a chronological collection of observations or events.", [["events", "PROBLEM", 80, 86]]], ["The main characteristics of this type of data are large size, high dimensionality, and continuous change.", [["large size", "PROBLEM", 50, 60], ["high dimensionality", "PROBLEM", 62, 81], ["main", "OBSERVATION_MODIFIER", 4, 8], ["large", "OBSERVATION_MODIFIER", 50, 55], ["size", "OBSERVATION_MODIFIER", 56, 60], ["high", "OBSERVATION_MODIFIER", 62, 66], ["dimensionality", "OBSERVATION_MODIFIER", 67, 81], ["continuous", "OBSERVATION_MODIFIER", 87, 97], ["change", "OBSERVATION_MODIFIER", 98, 104]]], ["In the context of data mining, the main problem is how to represent the data.", [["main", "OBSERVATION_MODIFIER", 35, 39]]], ["An effective mechanism for compressing the vast amount of time series data is needed in the context of information diffusion.", [["An effective mechanism", "TREATMENT", 0, 22]]], ["In Lin et al. [84] , a new symbolic representation of time series is proposed that allows for a dimensionality/numerosity reduction.", [["a dimensionality/numerosity reduction", "TREATMENT", 94, 131]]], ["This representation is tested using different classic data mining tasks such as clustering, classification, query by content, and anomaly detection.Information diffusion models and methodsBased on the mathematical models mentioned above, we need to compare a number of various applications that can support users in many different domains.", [["Information diffusion models", "TEST", 148, 176], ["various applications", "TREATMENT", 269, 289]]], ["Such meaningful events and topics can be discovered by well-known text processing schemes (e.g., TF-IDF) and simple statistical approaches (e.g., LDA, Gibbs sampling, and the TSTE method [85] ).", [["TF", "PROTEIN", 97, 99], ["Gibbs sampling", "TEST", 151, 165]]], ["These fusion can be done in different ways and affect to different technologies, methods and even research areas.", [["These fusion", "TREATMENT", 0, 12], ["methods", "TREATMENT", 81, 88], ["fusion", "OBSERVATION", 6, 12]]], ["Two of these possible areas are Ontologies and Social Networks, next how previous areas could benefit from information fusion in social big data are briefly described:Information fusion for social big data\u2022 Ontology-based fusion.", [["Ontology-based fusion", "TREATMENT", 207, 228], ["possible", "UNCERTAINTY", 13, 21], ["areas", "OBSERVATION_MODIFIER", 22, 27], ["fusion", "OBSERVATION", 222, 228]]], ["Semantic heterogeneity is an important issue on information fusion.", [["Semantic heterogeneity", "PROBLEM", 0, 22], ["information fusion", "TREATMENT", 48, 66], ["heterogeneity", "OBSERVATION", 9, 22]]], ["Social networks have inherently different semantics from other types of network.", [["network", "MULTI-TISSUE_STRUCTURE", 72, 79]]], ["Such semantic heterogeneity includes not only linguistic differences (e.g., between 'reference' and 'bibliography') but also mismatching between conceptual structures.", [["Such semantic heterogeneity", "PROBLEM", 0, 27], ["mismatching between conceptual structures", "PROBLEM", 125, 166], ["semantic heterogeneity", "OBSERVATION", 5, 27], ["mismatching", "OBSERVATION", 125, 136]]], ["To deal with these problems, in [87] ontologies are exploited from multiple social networks, and more importantly, semantic correspondences obtained by ontology matching methods.", [["social networks", "MULTI-TISSUE_STRUCTURE", 76, 91], ["these problems", "PROBLEM", 13, 27]]], ["More practically, semantic meshup applications have been illustrated.", [["semantic meshup applications", "TREATMENT", 18, 46]]], ["To remedy the data integration issues of the traditional web mashups, the semantic technologies uses the linked open data (LOD) based on RDF data model, as the unified data model for combining, aggregating, and transforming data from heterogeneous data resources to build linked data mashups [88] . \u2022 Social network integration.", [["Social network", "MULTI-TISSUE_STRUCTURE", 301, 315], ["RDF data model", "TEST", 137, 151]]], ["Next issue is how to integrate the distributed social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 47, 62]]], ["This field includes methodologies that can be applied to different areas such as e-commerce, marketing, security, and healthcare [18] ; more recent methodologies have been applied to treat social big data.", [["methodologies", "TREATMENT", 20, 33]]], ["This section provides short descriptions of some applications of these methodologies in domains that intensively use social big data sources for business intelligence.MarketingMarketing researchers believe that big social media analytics and cloud computing offer a unique opportunity for businesses to obtain opinions from a vast number of customers, improving traditional strategies.", [["these methodologies", "TREATMENT", 65, 84]]], ["A significant market transformation has been accomplished by leading e-commerce enterprises such Amazon and eBay through their innovative and highly scalable e-commerce platforms and recommender systems.MarketingSocial network analysis extracts user intelligence and can provide firms with the opportunity for generating more targeted advertising and marketing campaigns.", [["A significant market transformation", "PROBLEM", 0, 35], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["market transformation", "OBSERVATION", 14, 35]]], ["Maurer and Wiegmann [92] show an analysis of advertising effectiveness on social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 74, 89], ["an analysis", "TEST", 30, 41]]], ["In particular, they carried out a case study using Facebook to determine users perceptions regarding Facebook ads.", [["a case study", "TEST", 32, 44]]], ["The authors found that most of the participants perceived the ads on Facebook as annoying or not helpful for their purchase decisions.", [["participants", "ORGANISM", 35, 47], ["participants", "SPECIES", 35, 47]]], ["However, Trattner and Kappe [93] show how ads placed on users social streams that have been generated by the Facebook tools and applications can increase the number of visitors and the profit and ROI of a Web-based platform.", [["Kappe", "TEST", 22, 27]]], ["In addition, the authors present an analysis of real-time measures to detect the most valuable users on Facebook.MarketingA study of microblogging (Twitter) utilization as an eWOM (electronic word-of-mouth) advertising mechanism is carried out in Jansen et al. [94] .", [["mouth", "ORGANISM_SUBDIVISION", 200, 205], ["MarketingA study", "TEST", 113, 129]]], ["Summary MethodsTrattner and Kappe [93] Targeted advertising on Facebook Real-time measures to detect the most valuable users Jansen et al. [94] Twitter as eWOM advertising mechanism Sentiment analysis Asur et al. [95] Using Twitter to forecast box-office revenues for movies Topics detection, sentiment analysis Ma et al. [96] Viral marketing in social networks Social network analysis, information diffusion models content of tweets in various corporate accounts.", [["[94] Twitter", "CHEMICAL", 139, 151], ["Kappe", "TEST", 28, 33]]], ["Of the branding microblogs, nearly 20% contained some expression of brand sentiments.", [["brand sentiments", "OBSERVATION", 68, 84]]], ["Moreover, the sentiment extraction from Twitter is used to improve the forecasting power of social media.Ref. num.", [["the sentiment extraction", "TREATMENT", 10, 34]]], ["Summary MethodsBecause of the exponential growth use of social networks, researchers are actively attempting to model the dynamics of viral marketing based on the information diffusion process.", [["viral marketing", "TREATMENT", 134, 149]]], ["Ma et al. [96] proposed modelling social network marketing using heat diffusion processes.", [["social network", "MULTI-TISSUE_STRUCTURE", 34, 48], ["heat diffusion processes", "TREATMENT", 65, 89]]], ["Heat diffusion is a physical phenomenon related to heat, which always flows from a position with higher temperature to a position with lower temperature.", [["Heat diffusion", "PROBLEM", 0, 14], ["a physical phenomenon", "PROBLEM", 18, 39]]], ["The authors present three diffusion models along with three algorithms for selecting the best individuals to receive marketing samples.", [["marketing samples", "TEST", 117, 134]]], ["These models can diffuse both positive and negative comments on products or brands in order to simulate the real opinions within social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 129, 144], ["diffuse", "OBSERVATION_MODIFIER", 17, 24], ["positive", "OBSERVATION_MODIFIER", 30, 38]]], ["Moreover, the authors complexity analysis shows that the model is also scalable to large social networks.", [["social networks", "MULTI-TISSUE_STRUCTURE", 89, 104], ["the authors complexity analysis", "TEST", 10, 41], ["large", "OBSERVATION_MODIFIER", 83, 88], ["social networks", "OBSERVATION", 89, 104]]], ["Table 1 shows a brief summary of the previously described applications, including the basic functionalities for each and their basic methods.Crime analysisCriminals tend to have repetitive pattern behaviours, and these behaviours are dependent upon situational factors.", [["the basic functionalities", "TREATMENT", 82, 107], ["Crime analysisCriminals", "TEST", 141, 164], ["repetitive pattern behaviours", "PROBLEM", 178, 207]]], ["The purpose of crime data analysis is to identify these crime patterns, allowing for detecting and discovering crimes and their relationships with criminals.", [["crime data analysis", "TEST", 15, 34]]], ["Most of these communications are saved or transformed into written text and then archived in a digital format, which has led to opportunities for automatic text analysis using NLP techniques to improve the effectiveness of law enforcement [98] .", [["automatic text analysis", "TEST", 146, 169], ["NLP techniques", "TREATMENT", 176, 190]]], ["A decision support system that combines the use of NLP techniques, similarity measures, and classification approaches is proposed by Ku and Leroy [99] to automate and facilitate crime analysis.", [["Ku", "GENE_OR_GENE_PRODUCT", 133, 135], ["Ku", "PROTEIN", 133, 135], ["NLP techniques", "TREATMENT", 51, 65], ["crime analysis", "TEST", 178, 192]]], ["Based on this concept, Phillips and lee [100] present a crime data analysis technique that allows for discovering co-distribution patterns between large, aggregated and heterogeneous datasets.", [["discovering co-distribution patterns between large, aggregated and heterogeneous datasets", "PROBLEM", 102, 191], ["large", "OBSERVATION_MODIFIER", 147, 152], ["heterogeneous", "OBSERVATION_MODIFIER", 169, 182], ["datasets", "OBSERVATION", 183, 191]]], ["In this approach, aggregated datasets are modelled as graphs that store the geospatial distribution of crime within given regions, and then these graphs are used to discover datasets that show similar geospatial distribution characteristics.", [["these graphs", "TEST", 140, 152], ["similar", "OBSERVATION_MODIFIER", 193, 200], ["geospatial distribution", "OBSERVATION", 201, 224]]], ["The experimental results obtained in this work show that it is possible to discover geospatial co-distribution relationships among crime incidents and socio-economic, socio-demographic and spatial features.Crime analysisAnother analytical technique that is now in high use by law enforcement agencies to visually identify where crime tends to be highest is the hotspot mapping.", [["Crime analysis", "TEST", 206, 220], ["Another analytical technique", "TREATMENT", 220, 248]]], ["This technique is used to predict where crime may happen, using data from the past to inform future actions.", [["This technique", "TREATMENT", 0, 14]]], ["Each crime event is represented as a point, allowing for the geographic distribution analysis of these points.", [["the geographic distribution analysis", "TEST", 57, 93]]], ["A number of mapping techniques can be used to identify crime hotspots, such as: point mapping, thematic mapping of geographic areas, spatial ellipses, grid thematic mapping, and kernel density estimation (KDE), among others.", [["mapping techniques", "TREATMENT", 12, 30], ["point mapping", "TEST", 80, 93], ["thematic mapping", "TEST", 95, 111], ["geographic areas", "PROBLEM", 115, 131], ["spatial ellipses", "PROBLEM", 133, 149], ["grid thematic mapping", "TEST", 151, 172], ["kernel density estimation", "TEST", 178, 203], ["spatial ellipses", "OBSERVATION", 133, 149]]], ["Chainey et al. [101] conducted a comparative assessment of these techniques, and the results obtained showed that KDE was the technique that consistently outperformed the others.", [["a comparative assessment", "TEST", 31, 55], ["these techniques", "TEST", 59, 75]]], ["Moreover, the authors offered a benchmark to compare with the results of other techniques and other crime types, including comparisons between advanced spatial analysis techniques and prediction mapping methods.", [["advanced spatial analysis techniques", "TEST", 143, 179], ["prediction mapping methods", "TEST", 184, 210]]], ["This work shows the use of Twitter, applying a linguistic analysis and statistical topic modelling to automatically identify discussion topics across a city in the United States.", [["a linguistic analysis", "TEST", 45, 66]]], ["The experimental results showed that adding Twitter data improved crime prediction performance versus a standard approach based on KDE.Crime analysisFinally, the use of data mining in fraud detection is very popular, and there are numerous studies on this area.", [["a standard approach", "TREATMENT", 102, 121], ["Crime analysis", "TEST", 135, 149], ["fraud detection", "TEST", 184, 199], ["numerous studies", "TEST", 231, 247], ["very", "OBSERVATION_MODIFIER", 203, 207], ["popular", "OBSERVATION", 208, 215]]], ["Kirkos et al. [103] analysed the effectiveness of data mining classification techniques (decision trees, neural networks and Bayesian belief networks) for identifying fraudulent financial statements, and the experimental results concluded that Bayesian belief networks provided higher accuracy for fraud classification.", [["neural networks", "ANATOMY", 105, 120], ["neural networks", "MULTI-TISSUE_STRUCTURE", 105, 120]]], ["The system these authors proposed uses a self-organization map to filter and analyse customer behaviour to detect fraud.", [["a self-organization map", "TREATMENT", 39, 62]]], ["The main idea is to detect the patterns of the legal cardholder and of the fraudulent transactions through neural network learning and then to develop rules for these two different behaviours.", [["neural network", "ANATOMY", 107, 121], ["neural network", "MULTI-TISSUE_STRUCTURE", 107, 121], ["these two different behaviours", "PROBLEM", 161, 191], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["One typical fraud in this area is the ATM phone scams that attempts to transfer a victims money into fraudulent accounts.", [["typical", "OBSERVATION_MODIFIER", 4, 11], ["fraud", "OBSERVATION", 12, 17]]], ["In order to identify the signs of fraudulent accounts and the patterns of fraudulent transactions, Li et al. [105] applied Bayesian classification and association rules.", [["Li", "CHEMICAL", 99, 101], ["Bayesian classification", "TEST", 123, 146], ["fraudulent", "OBSERVATION", 34, 44]]], ["Table 2 shows a brief summary of all of the applications that were previously mentioned, providing a description of the basic functionalities of each and their main methods.", [["the applications", "TREATMENT", 40, 56]]], ["[99] Technique to discover geospatial co-distribution relations among crime incidents Network analysis Chainey et al. [101] Comparative assessment of mapping techniques to predict where crimes may happen Spatial analysis, mapping methods Gerber [102] Identify discussion topics across a city in the United States to predict crimes Linguistic analysis, statistical topic modelling Kirkos et al. [103] Identification of fraudulent financial statements Classification (decision trees, neural networks and Bayesian belief networks) Quah and Sriganesh [104] Detect fraud detection in real-time credit card transactions Neural network learning, association rules Li et al. [105] Identify the signs of fraudulent accounts and the patterns of fraudulent transactions Bayesian classification, association rulesEpidemic intelligenceEpidemic intelligence can be defined as the early identification, assessment, and verification of potential public health risks [106] and the timely dissemination of the appropriate alerts.", [["neural", "ANATOMY", 482, 488], ["Neural network", "MULTI-TISSUE_STRUCTURE", 614, 628], ["Comparative assessment", "TEST", 124, 146], ["mapping techniques", "TREATMENT", 150, 168], ["Linguistic analysis", "TEST", 331, 350], ["fraud detection", "TEST", 560, 575], ["Epidemic intelligence", "PROBLEM", 822, 843], ["assessment", "TEST", 888, 898]]], ["This discipline includes surveillance techniques for the automated and continuous analysis of unstructured free text or media information available on the Web from social networks, blogs, digital news media, and official sources.Epidemic intelligenceText mining techniques have been applied to biomedical text corpora for named entity recognition, text classification, terminology extraction, and relationship extraction [107] .", [["surveillance techniques", "TEST", 25, 48], ["continuous analysis", "TEST", 71, 90], ["Epidemic intelligence", "PROBLEM", 229, 250], ["Text mining techniques", "TREATMENT", 250, 272], ["terminology extraction", "TREATMENT", 369, 391]]], ["These methods are human language processing algorithms that aim to convert unstructured textual data from large-scale collections to a specific format, filtering them according to need.", [["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["unstructured textual data", "TEST", 75, 100], ["large-scale collections", "PROBLEM", 106, 129]]], ["They can be used to detect words related to diseases or their symptoms in published texts [108] .", [["diseases", "PROBLEM", 44, 52], ["their symptoms", "PROBLEM", 56, 70]]], ["Furthermore, a specific disease can have multiple associated names and symptoms, which increases the complexity of the problem.", [["a specific disease", "PROBLEM", 13, 31], ["symptoms", "PROBLEM", 71, 79]]], ["Ontologies can help to automate human understanding of key concepts and the relationships between them, and they allow for achieving a certain level of filtering accuracy.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37]]], ["In the health domain, it is necessary to identify and link term classes such as diseases, symptoms, and species in order to detect the potential focus of disease outbreaks.", [["diseases", "PROBLEM", 80, 88], ["symptoms", "PROBLEM", 90, 98], ["species", "PROBLEM", 104, 111], ["disease outbreaks", "PROBLEM", 154, 171], ["disease", "OBSERVATION", 154, 161]]], ["For example, the BioCaster ontology [109] is based on the OWL Semantic Web language, and it was designed to support automated reasoning across terms in 12 languages.Epidemic intelligenceThe increasing popularity and use of microblogging services such as Twitter are recently a new valuable data source for Web-based surveillance because of their message volume and frequency.", [["the BioCaster ontology", "TEST", 13, 35], ["Epidemic intelligence", "PROBLEM", 165, 186], ["microblogging services", "TREATMENT", 223, 245], ["increasing", "OBSERVATION_MODIFIER", 190, 200], ["popularity", "OBSERVATION_MODIFIER", 201, 211]]], ["Furthermore, user posts retrieved from the public Twitter API can come with GPS-based location tags, which can be used to locate the potential centre of disease outbreaks.", [["disease outbreaks", "PROBLEM", 153, 170], ["disease", "OBSERVATION", 153, 160]]], ["In this work, Twitter messages related to the flu were gathered, and then a number of classification systems based on different regression models to correlate these messages with CDC statistics were compared; the study found that the best model had a correlation of 0.78 (simple model regression).", [["CDC statistics", "TEST", 179, 193], ["the study", "TEST", 209, 218]]], ["Aramaki [111] presented a comparative study of various machinelearning methods to classify tweets related to influenza into two categories: positive and negative.", [["influenza", "DISEASE", 109, 118], ["a comparative study", "TEST", 24, 43], ["influenza", "PROBLEM", 109, 118], ["negative", "OBSERVATION", 153, 161]]], ["Their experimental results showed that the SVM model that used polynomial kernels achieved the highest accuracy (FMeasure of 0.756) and the lowest training time.Epidemic intelligenceWell-known regression models were evaluated on their ability to assess disease outbreaks from tweets in Bodnar and Salath\u00e9 [112] .", [["the SVM model", "PROBLEM", 39, 52], ["polynomial kernels", "TREATMENT", 63, 81], ["Epidemic intelligenceWell", "PROBLEM", 161, 186], ["known regression models", "PROBLEM", 187, 210], ["disease outbreaks", "PROBLEM", 253, 270]]], ["Regression methods such as linear, multivariable, and SVM were applied to the raw count of tweets that contained at least one of the keywords related to a specific disease, in this case \"flu\".", [["flu", "DISEASE", 187, 190], ["Regression methods", "PROBLEM", 0, 18], ["linear, multivariable, and SVM", "PROBLEM", 27, 57], ["a specific disease", "PROBLEM", 153, 171], ["linear", "OBSERVATION_MODIFIER", 27, 33], ["specific", "OBSERVATION_MODIFIER", 155, 163], ["disease", "OBSERVATION", 164, 171]]], ["The models also validated that even using irrelevant tweets and randomly generated datasets, regression methods were able to assess disease levels comparatively well.Epidemic intelligenceA new unsupervised machine learning approach to detect public health events was proposed in Fisichella et al. [113] that can complement existing systems because it allows for identifying public health events even if no matching keywords or linguistic patterns can be found.", [["regression methods", "TEST", 93, 111], ["Epidemic intelligence", "PROBLEM", 166, 187], ["A new unsupervised machine learning approach", "TREATMENT", 187, 231], ["matching keywords", "PROBLEM", 406, 423]]], ["This new approach defined a generative model for predictive event detection from documents by modelling the features based on trajectory distributions.Epidemic intelligenceHowever, in recent years, a number of surveillance systems have appeared that apply these social mining techniques and that have been widely used by public health organizations such as the World Health Organization (WHO) and the European Centre for Disease Prevention and Control [114] .", [["Epidemic intelligenceHowever", "PROBLEM", 151, 179], ["surveillance systems", "TEST", 210, 230], ["Disease Prevention", "TREATMENT", 421, 439]]], ["Tracking and monitoring mechanisms for early detection are critical in reducing the impact of epidemics through rapid responses.Epidemic intelligenceOne of the earliest surveillance systems is the Global Public Health Intelligence Network (GPHIN) [115] developed by the Public Health Agency of Canada in collaboration with the WHO.", [["Tracking and monitoring mechanisms", "TEST", 0, 34], ["early detection", "TEST", 39, 54]]], ["It is a secure, Web-based, multilingual warning tool that continuously monitors and analyses global media data sources to identify information about disease outbreaks and other events related to public healthcare.", [["disease outbreaks", "PROBLEM", 149, 166], ["other events", "PROBLEM", 171, 183]]], ["From 2002 to 2003, this surveillance system was able to detect the outbreak of SARS (severe acute respiratory syndrome).Epidemic intelligenceFrom the BioCaster ontology in 2006 arose the BioCaster system [116] for monitoring online media data.", [["SARS", "DISEASE", 79, 83], ["acute respiratory syndrome", "DISEASE", 92, 118], ["SARS", "PROBLEM", 79, 83], ["severe acute respiratory syndrome", "PROBLEM", 85, 118], ["monitoring online media data", "TEST", 214, 242], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118]]], ["The extracted text is classified based on its topical relevance and plotted onto a Google map using geo-information.", [["Google map", "DNA", 83, 93]]], ["The system has four main stages: topic classification, named entity recognition, disease/location detection, and event recognition.", [["disease", "PROBLEM", 81, 88], ["location detection", "TEST", 89, 107], ["main", "OBSERVATION_MODIFIER", 20, 24], ["stages", "OBSERVATION_MODIFIER", 25, 31]]], ["Then, for the relevant document corpora, entities of interest from 18 concept types based on the ontology related to diseases, viruses, bacteria, locations, and symptoms are searched.Epidemic intelligenceHealthMap project [117] is a global disease alert map that uses data from different sources such as Google News, expert-curated discussions such as ProMED-mail, and official organization reports such as those from the WHO or Euro Surveillance, an automated real-time system that monitors, organises, integrates, filters, visualises, and disseminates online information about emerging diseases.Epidemic intelligenceAnother system that collects news from the Web related to human and animal health and that plots the data on Google Maps is EpiSpider [118] .", [["human", "ORGANISM", 676, 681], ["human", "SPECIES", 676, 681], ["human", "SPECIES", 676, 681], ["diseases", "PROBLEM", 117, 125], ["viruses", "PROBLEM", 127, 134], ["bacteria", "PROBLEM", 136, 144], ["symptoms", "PROBLEM", 161, 169], ["Epidemic intelligence", "PROBLEM", 183, 204], ["a global disease alert map", "PROBLEM", 231, 257], ["emerging diseases", "PROBLEM", 579, 596], ["Epidemic intelligence", "PROBLEM", 597, 618]]], ["This tool automatically extracts information on infectious disease outbreaks from multiple sources including ProMedmail and medical Web sites, and it is used as a surveillance system by Table 3 Basic features related to social big data applications in health care area.AuthorsRef. num.", [["infectious disease", "DISEASE", 48, 66], ["infectious disease outbreaks", "PROBLEM", 48, 76], ["ProMedmail", "TREATMENT", 109, 119], ["medical Web sites", "TREATMENT", 124, 141], ["infectious", "OBSERVATION_MODIFIER", 48, 58]]], ["Summary Methods Culotta [110] Track and predict outbreak detection using Twitter Classification (regression models) Aramaki et al. [111] Classify tweets related to influenza Classification Bodnar and Salath\u00e9 [112] Assess disease outbreaks from tweets Regression methods Fisichella et al. [113] Detect public health events Modelling trajectory distributions GPHIN [115] Identify information about disease outbreaks and other events related to public healthcareAuthorsClassification documents for relevance BioCaster [116] Monitoring online media data related to diseases, viruses, bacteria, locations and symptomsAuthorsTopic classification, named entity recognition, event recognition HealthMap [117] Global disease alert map Mapping techniques EpiSpider [118] Human and animal disease alert map Topic and location detection [126] Collecting user experiences into a continually growing and adapting multimedia diary.AuthorsClassification of patterns in sensor readings from a camera, microphone, and accelerometers Many Eyes [127] Creating visualisations in collaborative environment from upload data sets Visualisation layout algorithms TweetPulse [128] Building social pulse by aggregating identical user experiences Visualising temporal dynamics of the thematic events public healthcare organizations, a number of universities, and health research organizations.", [["influenza", "DISEASE", 164, 173], ["Human", "ORGANISM", 761, 766], ["Human", "SPECIES", 761, 766], ["influenza", "PROBLEM", 164, 173], ["disease outbreaks", "PROBLEM", 221, 238], ["disease outbreaks", "PROBLEM", 396, 413], ["other events", "PROBLEM", 418, 430], ["Monitoring online media data", "TEST", 521, 549], ["diseases", "PROBLEM", 561, 569], ["viruses", "PROBLEM", 571, 578], ["bacteria", "PROBLEM", 580, 588], ["symptoms", "PROBLEM", 604, 612], ["HealthMap", "TEST", 685, 694], ["Global disease", "PROBLEM", 701, 715], ["EpiSpider", "TEST", 745, 754], ["animal disease", "PROBLEM", 771, 785], ["location detection", "TEST", 806, 824], ["a camera", "TREATMENT", 974, 982], ["microphone", "TREATMENT", 984, 994], ["diseases", "OBSERVATION", 561, 569]]], ["Additionally, this system automatically converts the topic and location information from the reports into RSS feeds.", [["RSS feeds", "TREATMENT", 106, 115]]], ["Finally, Lyon et al. [119] conducted a comparative assessment of these three systems (BioCaster, EpiSpider, and HealthMap) related to their ability to gather and analyse information that is relevant to public health.", [["a comparative assessment", "TEST", 37, 61]]], ["EpiSpider obtained more relevant documents in this study.", [["this study", "TEST", 46, 56]]], ["For instance, Biocaster gives special priority to languages from the Asia-Pacific region, and EpiSpider only considers documents written in English.", [["Biocaster", "CHEMICAL", 14, 23]]], ["Table 3 shows a summary of the previous applications and their related functionalities and methods.User experiences-based visualisationBig data from social media needs to be visualised for better user experiences and services.", [["the previous applications", "TREATMENT", 27, 52]]], ["For example, the large volume of numerical data (usually in tabular form) can be transformed into different formats.", [["numerical data", "TEST", 33, 47], ["large", "OBSERVATION_MODIFIER", 17, 22], ["volume", "OBSERVATION_MODIFIER", 23, 29]]], ["The capability of supporting timely decisions based on visualising such big data is essential to various domains, e.g., business success, clinical treatments, cyber and national security, and disaster management [120] .", [["clinical treatments", "TREATMENT", 138, 157], ["disaster management", "TREATMENT", 192, 211]]], ["It is important for understanding users needs in social networking services.User experiences-based visualisationThere have been many visualisation approaches to collecting (and improving) user experiences.", [["many", "OBSERVATION_MODIFIER", 128, 132], ["visualisation", "OBSERVATION", 133, 146]]], ["Such systems are R-based software packages [122] and GGobi [123] .", [["GGobi", "TEST", 53, 58]]], ["A Bayesian inference scheme-based multi-input/multi-output (MIMO) system [124] has been developed for better visualisation.User experiences-based visualisationWe can also consider life-logging services that record all user experiences [125] , which is also known as quantify-self.", [["A Bayesian inference scheme", "TREATMENT", 0, 27]]], ["Various sensors can capture continuous physiological data (e.g., mood, arousal, and blood oxygen levels) together with user activities.", [["blood", "ANATOMY", 84, 89], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 90, 96], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["oxygen", "SIMPLE_CHEMICAL", 90, 96], ["Various sensors", "TEST", 0, 15], ["continuous physiological data", "TEST", 28, 57], ["mood", "TEST", 65, 69], ["arousal", "TEST", 71, 78], ["blood oxygen levels", "TEST", 84, 103]]], ["Systems such as Insense [126] are based on wearable devices and can collect users experiences into a continually growing and adapting multimedia diary.", [["wearable devices", "TREATMENT", 43, 59]]], ["The inSense system uses the patterns in sensor readings from a camera, a microphone, and accelerometers to classify the users activities and automatically collect multimedia clips when the user is in an interesting situation.User experiences-based visualisationMoreover, visualisation systems such as Many Eyes [127] have been designed to upload datasets and create visualisations in collaborative environments, allowing users to upload data, create visualisation of that data, and leave comments on both the visualisation and the data, providing a medium to foment discussion among users.", [["a microphone", "TREATMENT", 71, 83], ["multimedia clips", "TREATMENT", 163, 179], ["clips", "OBSERVATION", 174, 179]]], ["Many Eyes is designed for ordinary people and does not require any extensive training or prior knowledge to take full advantage of its functionalities.User experiences-based visualisationOther visual analytics tools have shown some graphical visualisations for supporting efficient analytics of the given big data.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["any extensive training", "TREATMENT", 63, 85]]], ["Particularly, TweetPulse [128] has built social pulses by aggregating identical user experiences in social networks (e.g., Twitter), and visualised temporal dynamics of the thematic events.", [["social networks", "MULTI-TISSUE_STRUCTURE", 100, 115]]], ["Finally, Table 4 provides a summary of those applications related to the methods used for visualisation based on user experiences.Conclusions and open problemsWith the large number and rapid growth of social media systems and applications, social big data has become an important topic in a broad array of research areas.", [["those applications", "TREATMENT", 39, 57], ["the methods", "TREATMENT", 69, 80], ["social media systems", "TREATMENT", 201, 221], ["large", "OBSERVATION_MODIFIER", 168, 173], ["rapid", "OBSERVATION_MODIFIER", 185, 190], ["growth", "OBSERVATION_MODIFIER", 191, 197]]], ["The aim of this study has been to provide a holistic view and insights for potentially helping to find the most relevant solutions that are currently available for managing knowledge in social media.Conclusions and open problemsAs such, we have investigated the state-of-the-art technologies and applications for processing the big data from social media.", [["this study", "TEST", 11, 21], ["open problems", "PROBLEM", 215, 228]]], ["These technologies and applications were discussed in the following aspects: (i) What are the main methodologies and technologies that are available for gathering, storing, processing, and analysing big data from social media? (ii) How does one analyse social big data to discover meaningful patterns? and (iii) How can these patterns be exploited as smart, useful user services through the currently deployed examples in social-based applications?Conclusions and open problemsMore practically, this survey paper shows and describes a number of existing systems (e.g., frameworks, libraries, software applications) that have been developed and that are currently being used in various domains and applications based on social media.", [["open problems", "PROBLEM", 464, 477], ["software applications", "TREATMENT", 592, 613]]], ["The paper has avoided describing or analysing those straightforward applications such as Facebook and Twitter that currently intensively use big data technologies, instead focusing on other applications (such as those related to marketing, crime analysis, or epidemic intelligence) that could be of interest to potential readers.Conclusions and open problemsAlthough it is extremely difficult to predict which of the different issues studied in this work will be the next \"trending topic\" in social big data research, from among all of the problems and topics that are currently under study in different areas, we selected some \"open topics\" related to privacy issues, streaming and online algorithms, and data fusion visualisation, providing some insights and possible future trends.Privacy issuesIn the era of online big data and social media, protecting the privacy of the users on social media has been regarded as an important issue.", [["crime analysis", "TEST", 240, 254], ["open problems", "PROBLEM", 345, 358], ["the different issues", "PROBLEM", 413, 433], ["online algorithms", "TEST", 683, 700], ["data fusion visualisation", "TEST", 706, 731], ["Privacy issues", "PROBLEM", 784, 798], ["social media", "TREATMENT", 832, 844], ["social media", "TREATMENT", 885, 897]]], ["Ironically, as the analytics introduced in this paper become more advanced, the risk of privacy leakage is growing.Privacy issuesAs such, many privacy-preserving studies have been proposed to address privacy-related issues.", [["privacy leakage", "PROBLEM", 88, 103], ["privacy leakage", "OBSERVATION", 88, 103]]], ["The second approach is \"differential privacy\", which can provide an efficient way to maximise the accuracy of queries from statistical databases while minimising the chances of identifying its records [130] .Privacy issuesHowever, there are still open issues related to privacy.", [["statistical databases", "TEST", 123, 144], ["Privacy issues", "PROBLEM", 208, 222]]], ["The second issue is evaluation.", [["evaluation", "TEST", 20, 30]]], ["Therefore, it would be particularly interesting in the future to consider how to build useful benchmark datasets for evaluation.Privacy issuesMoreover, we have to consider this data privacy issues in many other research areas.", [["evaluation", "TEST", 117, 127]]], ["It is still open issue on how (and what) to design the curriculum for the data privacy.Streaming and online algorithmsOne of the current main challenges in data mining related to big data problems is to find adequate approaches to analysing massive amounts of online data (or data streams).", [["big data problems", "PROBLEM", 179, 196], ["online data", "TEST", 260, 271]]], ["Because classification methods require previous labelling, these methods also require great effort for real-time analysis.", [["previous labelling", "TREATMENT", 39, 57], ["real-time analysis", "TEST", 103, 121]]], ["However, because unsupervised techniques do not need this previous process, clustering has become a promising field for real-time analysis, especially when these data come from social media sources.", [["real-time analysis", "TEST", 120, 138]]], ["When data streams are analysed, it is important to consider the analysis goal in order to determine the best type of algorithm to be used.", [["the analysis goal", "TEST", 60, 77]]], ["We were able to divide data stream analysis into two main categories:Streaming and online algorithms\u2022 Offline analysis: We consider a portion of data (usually large data) and apply an offline clustering algorithm to analyse the data.Streaming and online algorithms\u2022 Online analysis: The data are analysed in real time.", [["an offline clustering algorithm", "TREATMENT", 181, 212]]], ["These kinds of algorithms are constantly receiving new data and are not usually able to keep past information.Streaming and online algorithmsA new generation of online [132, 133] and streaming [134, 135] algorithms is currently being developed in order to manage social big data challenges, and these algorithms require high scalability in both memory consumption [136] and time computation.", [["new", "OBSERVATION_MODIFIER", 143, 146]]], ["Some new developments related to traditional clustering algorithms, such as the K-mean [137] , EM [138] , which has been modified to work with the MapReduce paradigm, and more sophisticated approaches based on graph computing (such as spectral clustering), are currently being developed [139] [140] [141] into more efficient versions from the state-of-theart algorithms [142, 143] .Methods for data fusion & data visualisationFinally, data fusion and data visualisation are two clear challenges in social big data.", [["traditional clustering algorithms", "PROBLEM", 33, 66], ["the K-mean", "TEST", 76, 86], ["data fusion & data visualisation", "TEST", 394, 426], ["data fusion and data visualisation", "TEST", 435, 469], ["new", "OBSERVATION_MODIFIER", 5, 8]]], ["Although both areas have been intensively studied with regard to large, distributed, heterogeneous, and streaming data fusion [144] and data visualisation and analysis [145] , the current, rapid evolution of social media sources jointly with big data technologies creates some particularly interesting challenges related to:Methods for data fusion & data visualisation\u2022 Obtaining more reliable methods for fusing the multiple features of multimedia objects for social media applications [146] . \u2022 Studying the dynamics of individual and group behaviour, characterising patterns of information diffusion, and identifying influential individuals in social networks and other social media-based applications [147] . \u2022 Identifying events [148] in social media documents via clustering and using similarity metric learning approaches to produce highquality clustering results [149] . \u2022 The open problems and challenges related to visual analytics [145] , especially related to the capacity to collect and store new data, are rapidly increasing in number, including the ability to analyse these data volumes [150] , to record data about the movement of people and objects at a large scale [151] , and to analyse spatio-temporal data and solve spatio-temporal problems in social media [152] , among others.", [["people", "ORGANISM", 1147, 1153], ["people", "SPECIES", 1147, 1153], ["large, distributed, heterogeneous, and streaming data fusion", "PROBLEM", 65, 125], ["data visualisation", "TEST", 136, 154], ["analysis", "TEST", 159, 167], ["big data technologies", "TREATMENT", 242, 263], ["data fusion", "TREATMENT", 336, 347], ["data visualisation", "TEST", 350, 368], ["information diffusion", "TEST", 581, 602], ["The open problems", "PROBLEM", 881, 898], ["visual analytics", "TEST", 925, 941], ["temporal problems", "PROBLEM", 1244, 1261], ["large", "OBSERVATION_MODIFIER", 65, 70], ["distributed", "OBSERVATION_MODIFIER", 72, 83], ["heterogeneous", "OBSERVATION_MODIFIER", 85, 98], ["rapidly", "OBSERVATION_MODIFIER", 1020, 1027], ["increasing", "OBSERVATION_MODIFIER", 1028, 1038]]]], "a2fce0b31118c4df6ba6f629af6e53883fd0fe43": [["WHAT THIS PAPER ADDS?What is already known on this subject -The use of Hydroxychloroquine (HCQ) or HCQ with azithromycin (AZI) has been associated with viral load reduction at 6 days in COVID-19 infected patients -No difference between HCQ and no-HCQ groups in terms of risk of death or need for mechanical ventilation was found in two large cohorts of hospitalized COVID-19 infected patientsWhat this study adds-Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found no evidence for efficacy of HCQ on 28-day mortality -Our results suggest an excess risk of mortality in patients treated by a combination of HCQ and AZI, but not with HCQ alone -Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies .", [["Hydroxychloroquine", "CHEMICAL", 71, 89], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 99, 102], ["azithromycin", "CHEMICAL", 108, 120], ["AZI", "CHEMICAL", 122, 125], ["HCQ", "CHEMICAL", 236, 239], ["HCQ", "CHEMICAL", 247, 250], ["death", "DISEASE", 278, 283], ["COVID-19 infected", "DISEASE", 366, 383], ["COVID-19", "CHEMICAL", 482, 490], ["infection", "DISEASE", 491, 500], ["HCQ", "CHEMICAL", 602, 605], ["HCQ", "CHEMICAL", 715, 718], ["AZI", "CHEMICAL", 723, 726], ["HCQ", "CHEMICAL", 741, 744], ["HCQ", "CHEMICAL", 834, 837], ["Hydroxychloroquine", "CHEMICAL", 71, 89], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 99, 102], ["azithromycin", "CHEMICAL", 108, 120], ["AZI", "CHEMICAL", 122, 125], ["HCQ", "CHEMICAL", 236, 239], ["HCQ", "CHEMICAL", 247, 250], ["HCQ", "CHEMICAL", 602, 605], ["HCQ", "CHEMICAL", 715, 718], ["AZI", "CHEMICAL", 723, 726], ["HCQ", "CHEMICAL", 741, 744], ["HCQ", "CHEMICAL", 834, 837], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 71, 89], ["HCQ", "SIMPLE_CHEMICAL", 91, 94], ["HCQ", "SIMPLE_CHEMICAL", 99, 102], ["azithromycin", "SIMPLE_CHEMICAL", 108, 120], ["AZI", "SIMPLE_CHEMICAL", 122, 125], ["COVID-19", "ORGANISM", 186, 194], ["patients", "ORGANISM", 204, 212], ["HCQ", "SIMPLE_CHEMICAL", 236, 239], ["no-HCQ", "SIMPLE_CHEMICAL", 244, 250], ["patients", "ORGANISM", 384, 392], ["inpatients", "ORGANISM", 454, 464], ["HCQ", "SIMPLE_CHEMICAL", 602, 605], ["patients", "ORGANISM", 678, 686], ["HCQ", "SIMPLE_CHEMICAL", 715, 718], ["AZI", "SIMPLE_CHEMICAL", 723, 726], ["HCQ", "SIMPLE_CHEMICAL", 741, 744], ["patients", "ORGANISM", 814, 822], ["HCQ", "SIMPLE_CHEMICAL", 834, 837], ["patients", "SPECIES", 204, 212], ["patients", "SPECIES", 384, 392], ["patients", "SPECIES", 678, 686], ["patients", "SPECIES", 814, 822], ["Hydroxychloroquine (HCQ)", "TREATMENT", 71, 95], ["HCQ", "TREATMENT", 99, 102], ["azithromycin (AZI", "TREATMENT", 108, 125], ["viral load reduction", "TREATMENT", 152, 172], ["COVID", "TEST", 186, 191], ["HCQ", "TEST", 236, 239], ["death", "PROBLEM", 278, 283], ["mechanical ventilation", "TREATMENT", 296, 318], ["hospitalized COVID", "TREATMENT", 353, 371], ["this study", "TEST", 397, 407], ["COVID-19 infection", "PROBLEM", 482, 500], ["HCQ", "TREATMENT", 602, 605], ["HCQ", "TREATMENT", 715, 718], ["AZI", "TREATMENT", 723, 726], ["HCQ", "TREATMENT", 741, 744], ["further confirmation", "TEST", 866, 886], ["replicative studies", "TEST", 890, 909], ["viral load", "OBSERVATION", 152, 162], ["no evidence for", "UNCERTAINTY", 574, 589]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["16.20132597 doi: medRxiv preprintIntroductionThe COVID-19 pandemic due to the SARS-CoV-2 coronavirus started in Wuhan, China last December, 2019.", [["SARS-CoV-2 coronavirus", "ORGANISM", 78, 100], ["CoV-2 coronavirus", "SPECIES", 83, 100], ["SARS-CoV-2 coronavirus", "SPECIES", 78, 100], ["The COVID", "TEST", 45, 54], ["pandemic", "PROBLEM", 58, 66], ["the SARS", "PROBLEM", 74, 82], ["CoV", "TEST", 83, 86], ["coronavirus", "PROBLEM", 89, 100]]], ["1 The COVID-19 epidemic is a worldwide pandemic with more than 5.4 million cases reported up to May 27, 2020 , of whom nearly 350,000 have died.", [["The COVID", "TEST", 2, 11]]], ["Because effective treatments are urgently needed, more than 600 clinical trials are currently ongoing in a worldwide effort to fight the coronavirus.IntroductionThe 4-aminoquinolines chloroquine (CQ) and hydroxychloroquine (HCQ) are synthetic antimalarials drugs (AMD).", [["coronavirus", "DISEASE", 137, 148], ["4-aminoquinolines", "CHEMICAL", 165, 182], ["chloroquine", "CHEMICAL", 183, 194], ["CQ", "CHEMICAL", 196, 198], ["hydroxychloroquine", "CHEMICAL", 204, 222], ["HCQ", "CHEMICAL", 224, 227], ["AMD", "DISEASE", 264, 267], ["4-aminoquinolines", "CHEMICAL", 165, 182], ["chloroquine", "CHEMICAL", 183, 194], ["CQ", "CHEMICAL", 196, 198], ["hydroxychloroquine", "CHEMICAL", 204, 222], ["HCQ", "CHEMICAL", 224, 227], ["coronavirus", "ORGANISM", 137, 148], ["4-aminoquinolines chloroquine", "SIMPLE_CHEMICAL", 165, 194], ["CQ", "SIMPLE_CHEMICAL", 196, 198], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 204, 222], ["HCQ", "SIMPLE_CHEMICAL", 224, 227], ["effective treatments", "TREATMENT", 8, 28], ["the coronavirus", "PROBLEM", 133, 148], ["Introduction", "TREATMENT", 149, 161], ["The 4-aminoquinolines chloroquine (CQ)", "TREATMENT", 161, 199], ["hydroxychloroquine (HCQ)", "TREATMENT", 204, 228], ["synthetic antimalarials drugs", "TREATMENT", 233, 262]]], ["Due to their anti-inflammatory and immunomodulatory properties, synthetic AMDs are the standard treatment in autoimmune diseases such as lupus.", [["AMDs", "CHEMICAL", 74, 78], ["autoimmune diseases", "DISEASE", 109, 128], ["lupus", "DISEASE", 137, 142], ["AMDs", "SIMPLE_CHEMICAL", 74, 78], ["immunomodulatory properties", "TREATMENT", 35, 62], ["synthetic AMDs", "TREATMENT", 64, 78], ["the standard treatment", "TREATMENT", 83, 105], ["autoimmune diseases", "PROBLEM", 109, 128], ["lupus", "PROBLEM", 137, 142], ["anti-inflammatory", "OBSERVATION_MODIFIER", 13, 30], ["autoimmune diseases", "OBSERVATION", 109, 128], ["lupus", "OBSERVATION", 137, 142]]], ["In vitro data schowed a non-specific antiviral action of synthetic AMDs against emerging viruses such as HIV, dengue, hepatitis C, chikungunya, influenza, Ebola, severe acute respiratory syndrome, and middle east respiratory syndrome and human immunodeficiency viruses.", [["AMDs", "CHEMICAL", 67, 71], ["HIV, dengue, hepatitis C", "DISEASE", 105, 129], ["chikungunya", "DISEASE", 131, 142], ["influenza", "DISEASE", 144, 153], ["Ebola", "DISEASE", 155, 160], ["acute respiratory syndrome", "DISEASE", 169, 195], ["middle east respiratory syndrome", "DISEASE", 201, 233], ["human immunodeficiency viruses", "DISEASE", 238, 268], ["AMDs", "SIMPLE_CHEMICAL", 67, 71], ["HIV", "ORGANISM", 105, 108], ["hepatitis C", "ORGANISM", 118, 129], ["Ebola", "ORGANISM", 155, 160], ["human immunodeficiency viruses", "ORGANISM", 238, 268], ["HIV", "SPECIES", 105, 108], ["Ebola", "SPECIES", 155, 160], ["human", "SPECIES", 238, 243], ["HIV", "SPECIES", 105, 108], ["dengue", "SPECIES", 110, 116], ["hepatitis C", "SPECIES", 118, 129], ["human immunodeficiency viruses", "SPECIES", 238, 268], ["a non-specific antiviral action", "TREATMENT", 22, 53], ["synthetic AMDs", "PROBLEM", 57, 71], ["emerging viruses", "PROBLEM", 80, 96], ["HIV", "PROBLEM", 105, 108], ["dengue", "PROBLEM", 110, 116], ["hepatitis C", "PROBLEM", 118, 129], ["chikungunya", "PROBLEM", 131, 142], ["influenza", "PROBLEM", 144, 153], ["Ebola", "PROBLEM", 155, 160], ["severe acute respiratory syndrome", "PROBLEM", 162, 195], ["middle east respiratory syndrome", "PROBLEM", 201, 233], ["human immunodeficiency viruses", "PROBLEM", 238, 268], ["hepatitis", "OBSERVATION", 118, 127], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["respiratory syndrome", "OBSERVATION", 175, 195], ["middle", "ANATOMY_MODIFIER", 201, 207], ["respiratory syndrome", "OBSERVATION", 213, 233], ["immunodeficiency viruses", "OBSERVATION", 244, 268]]], ["2 The use of HCQ or HCQ with azithromycin (AZI) has arisen as a promising treatment or combination of treatment for COVID-19 infection.", [["HCQ", "CHEMICAL", 13, 16], ["HCQ", "CHEMICAL", 20, 23], ["azithromycin", "CHEMICAL", 29, 41], ["AZI", "CHEMICAL", 43, 46], ["COVID-19", "CHEMICAL", 116, 124], ["infection", "DISEASE", 125, 134], ["HCQ", "CHEMICAL", 13, 16], ["HCQ", "CHEMICAL", 20, 23], ["azithromycin", "CHEMICAL", 29, 41], ["AZI", "CHEMICAL", 43, 46], ["HCQ", "SIMPLE_CHEMICAL", 13, 16], ["HCQ", "SIMPLE_CHEMICAL", 20, 23], ["azithromycin", "SIMPLE_CHEMICAL", 29, 41], ["AZI", "SIMPLE_CHEMICAL", 43, 46], ["COVID-19", "ORGANISM", 116, 124], ["COVID-19", "SPECIES", 116, 124], ["HCQ", "TREATMENT", 13, 16], ["HCQ", "TREATMENT", 20, 23], ["azithromycin (AZI)", "TREATMENT", 29, 47], ["a promising treatment", "TREATMENT", 62, 83], ["treatment", "TREATMENT", 102, 111], ["COVID-19 infection", "PROBLEM", 116, 134], ["infection", "OBSERVATION", 125, 134]]], ["First, in vitro data have shown the effectiveness of HCQ (and to a lesser extent CQ) in reducing the viral load of cells infected with SARS-CoV-2.", [["cells", "ANATOMY", 115, 120], ["HCQ", "CHEMICAL", 53, 56], ["CQ", "CHEMICAL", 81, 83], ["HCQ", "CHEMICAL", 53, 56], ["HCQ", "SIMPLE_CHEMICAL", 53, 56], ["CQ", "SIMPLE_CHEMICAL", 81, 83], ["cells", "CELL", 115, 120], ["SARS-CoV-2", "ORGANISM", 135, 145], ["SARS-CoV", "SPECIES", 135, 143], ["HCQ", "TREATMENT", 53, 56], ["the viral load of cells", "PROBLEM", 97, 120], ["CoV", "TEST", 140, 143], ["viral load", "OBSERVATION", 101, 111]]], ["3 Then, a Chinese clinical trial showed that CQ had a significant effect, including a better clinical outcome, when compared to control groups.", [["CQ", "CHEMICAL", 45, 47], ["CQ", "SIMPLE_CHEMICAL", 45, 47], ["a Chinese clinical trial", "TEST", 8, 32], ["CQ", "PROBLEM", 45, 47]]], ["4 A French research team suggested that HCQ, at a dose of 600 mg/day, was associated with viral load reduction in twenty COVID-19 patients and its effect was strengthened by AZI.", [["HCQ", "CHEMICAL", 40, 43], ["AZI", "CHEMICAL", 174, 177], ["HCQ", "CHEMICAL", 40, 43], ["HCQ", "SIMPLE_CHEMICAL", 40, 43], ["patients", "ORGANISM", 130, 138], ["AZI", "SIMPLE_CHEMICAL", 174, 177], ["patients", "SPECIES", 130, 138], ["HCQ", "TREATMENT", 40, 43], ["viral load reduction", "TREATMENT", 90, 110]]], ["5 These preliminary results were further backed up by two prospective cohorts from the same team of 80 and 1,061 participants, suggesting good clinical outcomes in 65 (81%) and 973 (92%) patients, respectively, with lower frequency of aggressive clinical course requiring oxygen therapy, fewer transfers to the intensive care unit (ICU), or death after at least 3 days of treatment and a viral load reduction at day 6.", [["oxygen", "CHEMICAL", 272, 278], ["death", "DISEASE", 341, 346], ["oxygen", "CHEMICAL", 272, 278], ["patients", "ORGANISM", 187, 195], ["oxygen", "SIMPLE_CHEMICAL", 272, 278], ["participants", "SPECIES", 113, 125], ["patients", "SPECIES", 187, 195], ["oxygen therapy", "TREATMENT", 272, 286], ["treatment", "TREATMENT", 372, 381], ["a viral load reduction", "TREATMENT", 386, 408], ["good", "OBSERVATION_MODIFIER", 138, 142], ["oxygen therapy", "OBSERVATION", 272, 286], ["viral load", "OBSERVATION", 388, 398]]], ["6, 7 More recently, several published or preprint publications have raised the question of HCQ efficacy for COVID-19 infection.", [["HCQ", "CHEMICAL", 91, 94], ["COVID-19", "CHEMICAL", 108, 116], ["infection", "DISEASE", 117, 126], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "SIMPLE_CHEMICAL", 91, 94], ["COVID-19", "ORGANISM", 108, 116], ["COVID-19", "SPECIES", 108, 116], ["HCQ efficacy", "PROBLEM", 91, 103], ["COVID-19 infection", "PROBLEM", 108, 126], ["infection", "OBSERVATION", 117, 126]]], ["Four observational studies with diverse cohort sizes (81, 368, 1,376, and 1,438 participants) failed to find a difference between HCQ and no-HCQ groups in terms of risk of death or need for mechanical ventilation.", [["HCQ", "CHEMICAL", 130, 133], ["HCQ", "CHEMICAL", 141, 144], ["death", "DISEASE", 172, 177], ["HCQ", "CHEMICAL", 130, 133], ["HCQ", "CHEMICAL", 141, 144], ["HCQ", "SIMPLE_CHEMICAL", 130, 133], ["no-HCQ", "SIMPLE_CHEMICAL", 138, 144], ["participants", "SPECIES", 80, 92], ["Four observational studies", "TEST", 0, 26], ["HCQ", "TEST", 130, 133], ["HCQ groups", "TREATMENT", 141, 151], ["death", "PROBLEM", 172, 177], ["mechanical ventilation", "TREATMENT", 190, 212], ["mechanical ventilation", "OBSERVATION", 190, 212]]], ["[8] [9] [10] [11] Preliminary results from the UK RECOVERY randomized trial have been communicated, but not yet published, concluding that there was no beneficial effect of HCQ on 28-day mortality in hospitalized patients with COVID- 19.", [["HCQ", "CHEMICAL", 173, 176], ["HCQ", "CHEMICAL", 173, 176], ["COVID- 19", "CHEMICAL", 227, 236], ["[8] [9] [10", "SIMPLE_CHEMICAL", 0, 11], ["HCQ", "SIMPLE_CHEMICAL", 173, 176], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["HCQ", "TREATMENT", 173, 176], ["COVID", "TEST", 227, 232]]], ["12 Data from large health care databases provide a unique opportunity to assess the potential effectiveness and harm of HCQ in a real-world setting, including unselected population.", [["HCQ", "CHEMICAL", 120, 123], ["HCQ", "CHEMICAL", 120, 123], ["HCQ", "SIMPLE_CHEMICAL", 120, 123], ["HCQ", "TREATMENT", 120, 123]]], ["Because some variation has been reported between studies, replicated analyses minimizing selection and confounding biases are crucially needed to disentangle current evidence on the actual risks and benefits of HCQ-based treatments.", [["HCQ", "CHEMICAL", 211, 214], ["HCQ", "CHEMICAL", 211, 214], ["HCQ", "SIMPLE_CHEMICAL", 211, 214], ["confounding biases", "PROBLEM", 103, 121], ["HCQ-based treatments", "TREATMENT", 211, 231]]], ["We consequently aimed to assess the clinical effectiveness of oral HCQ in preventing death or allowing to hospital discharge using a large, exhaustive, nonselected population of in-patients hospitalized for COVID-19 infection in 39 hospitals in France, accounting in detail for patients characteristics.Introduction.", [["oral", "ANATOMY", 62, 66], ["HCQ", "CHEMICAL", 67, 70], ["death", "DISEASE", 85, 90], ["COVID-19", "CHEMICAL", 207, 215], ["infection", "DISEASE", 216, 225], ["HCQ", "CHEMICAL", 67, 70], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["HCQ", "SIMPLE_CHEMICAL", 67, 70], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 278, 286], ["oral HCQ", "TREATMENT", 62, 70], ["death", "PROBLEM", 85, 90], ["COVID-19 infection", "PROBLEM", 207, 225], ["infection", "OBSERVATION", 216, 225]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprintStudy DesignWe performed a retrospective cohort study using the Corona OMOP database, which combines electronic medical records and administrative claim data from the Greater Paris Public Hospitals (Assistance Publique -H\u00f4pitaux de Paris (AP-HP) data warehouse, called 'Entrep\u00f4t de Donn\u00e9es de Sant\u00e9' (EDS).", [["CC", "CHEMICAL", 0, 2], ["EDS", "DISEASE", 656, 659], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["a retrospective cohort study", "TEST", 380, 408], ["med", "ANATOMY", 105, 108]]], ["This study was approved by the French data protection agency Commission Nationale de l'Informatique et des Libert\u00e9s (regulatory decision DE-2017-013), IRB00011591.", [["This study", "TEST", 0, 10]]], ["Patients and the public were not involved in the present study.Data sourcesThe EDS currently collects data on more than 11 million patients treated in the 39 hospitals of the AP-HP, Ile-de-France, France.", [["EDS", "DISEASE", 79, 82], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 131, 139], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 131, 139], ["the present study", "TEST", 45, 62]]], ["The warehouse contains medico-administrative data from the Medical Information System Program (PMSI), the French national hospital database which gathers information from standardized discharge reports on diagnoses and procedures performed in all medical units involved in patient management during his/her hospital stay.", [["patient", "ORGANISM", 273, 280], ["patient", "SPECIES", 273, 280], ["procedures", "TREATMENT", 219, 229], ["patient management", "TREATMENT", 273, 291]]], ["Primary and associated diagnoses are recorded using the International Classification of Diseases, 10 th edition (ICD-10) and therapeutic procedures using a national standardized classification system (Classification Commune des Actes M\u00e9dicaux, CCAM, 11 th edition).", [["ICD", "TREATMENT", 113, 116], ["therapeutic procedures", "TREATMENT", 125, 147]]], ["Since discharge reports are mandatory and used for hospital fund allocation, the PMSI database contains exhaustive information on all admissions to hospitals in France, including proprietary and public hospitals.Data sourcesIn addition to PMSI data, the EDS gathers information from multiple electronic health record databases, including biology and imaging results, drug prescriptions (stored within the ORBIS medication database and coded according to the international Anatomical Therapeutic Chemical (ATC) classification system) and medical text reports associated with hospital visits, including emergency department data and outpatient visits.Data acquisitionBecause PMSI coding requires human-based and time-consuming processing, complete PMSI information was not available for a number of patients being still hospitalized or for whom discharge reports were not yet processed at the time of analysis.", [["human", "ORGANISM", 694, 699], ["patients", "ORGANISM", 797, 805], ["PMSI coding", "DNA", 673, 684], ["PMSI", "DNA", 746, 750], ["human", "SPECIES", 694, 699], ["patients", "SPECIES", 797, 805], ["human", "SPECIES", 694, 699], ["imaging", "TEST", 350, 357], ["Data acquisition", "TEST", 649, 665], ["analysis", "TEST", 899, 907]]], ["Likewise, information on drugs prescriptions were not directly available in some ICU not using the ORBIS medication system.", [["drugs prescriptions", "TREATMENT", 25, 44], ["the ORBIS medication system", "TREATMENT", 95, 122]]], ["Consequently, data acquisition for the present study relied on both structured data (i.e. PMSI pertaining to past hospitalizations, if any, biological results, ORBIS medication system) and unstructured data (i.e. medical text records).", [["data acquisition", "TEST", 14, 30], ["the present study", "TEST", 35, 52]]], ["For the latter, we used artificial intelligence algorithms based on Natural Language Processing (NLP), to extract information on patients diagnoses (including comorbidities, see below) and drugs prescriptions (including HCQ+/-AZI), considering contexts where mentions of drugs by name do not correspond to actual prescriptions (i.e. when the drug is mentioned in a negative context), 13 and considering both International non-proprietary name (INN) and trade-marks.Study population.", [["HCQ", "CHEMICAL", 220, 223], ["INN", "CHEMICAL", 444, 447], ["HCQ", "CHEMICAL", 220, 223], ["patients", "ORGANISM", 129, 137], ["HCQ", "SIMPLE_CHEMICAL", 220, 223], ["patients", "SPECIES", 129, 137], ["artificial intelligence algorithms", "TREATMENT", 24, 58], ["comorbidities", "PROBLEM", 159, 172], ["drugs prescriptions", "TREATMENT", 189, 208], ["HCQ", "TREATMENT", 220, 223], ["drugs", "TREATMENT", 271, 276], ["Study population", "TEST", 465, 481]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Study populationThe copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprint All adult (\u2265 18 years of age) inpatients with at least one polymerase chain reaction-documented SARS-CoV-2 RNA from a nasopharyngeal sample between February 1 st , 2020 and April 6 th , 2020 were eligible for the present analysis.", [["nasopharyngeal sample", "ANATOMY", 478, 499], ["CC", "CHEMICAL", 0, 2], ["inpatients", "ORGANISM", 390, 400], ["SARS-CoV-2 RNA", "RNA", 456, 470], ["ND", "PROBLEM", 9, 11], ["Study population", "TEST", 202, 218], ["one polymerase chain reaction", "PROBLEM", 415, 444], ["SARS", "TEST", 456, 460], ["CoV", "TEST", 461, 464], ["the present analysis", "TEST", 569, 589], ["med", "ANATOMY", 105, 108], ["nasopharyngeal", "ANATOMY", 478, 492]]], ["The date of inclusion in the study cohort (index date) was defined as the date of admission.", [["the study", "TEST", 25, 34]]], ["We restricted the study population to previously hydroxychloroquine-and azithromycin-naive inpatients, defined as those who had not received a prescription before the index date, and excluded those having received specific COVID-19 treatments, i.e. treatments assessed in ongoing trials: remdesivir, lopinavir-ritonavir (ATC J05AR10), favipiravir (J05AX27), anti-interleukin 1 -i.e., anakinra (ATC L04AC03), canakinumab (ATC L04AC038) -anti-interleukin 6 -i.e., tocilizumab (ATC L04AC037), sarilumab (ATC L04AC14).", [["hydroxychloroquine", "CHEMICAL", 49, 67], ["azithromycin", "CHEMICAL", 72, 84], ["remdesivir", "CHEMICAL", 288, 298], ["lopinavir-ritonavir", "CHEMICAL", 300, 319], ["ATC J05AR10", "CHEMICAL", 321, 332], ["favipiravir", "CHEMICAL", 335, 346], ["J05AX27", "CHEMICAL", 348, 355], ["anakinra", "CHEMICAL", 384, 392], ["ATC L04AC03", "CHEMICAL", 394, 405], ["canakinumab", "CHEMICAL", 408, 419], ["ATC L04AC038", "CHEMICAL", 421, 433], ["tocilizumab", "CHEMICAL", 462, 473], ["ATC L04AC037", "CHEMICAL", 475, 487], ["sarilumab", "CHEMICAL", 490, 499], ["hydroxychloroquine", "CHEMICAL", 49, 67], ["azithromycin", "CHEMICAL", 72, 84], ["remdesivir", "CHEMICAL", 288, 298], ["lopinavir", "CHEMICAL", 300, 309], ["ritonavir", "CHEMICAL", 310, 319], ["ATC J05AR10", "CHEMICAL", 321, 332], ["favipiravir", "CHEMICAL", 335, 346], ["J05AX27", "CHEMICAL", 348, 355], ["anakinra", "CHEMICAL", 384, 392], ["canakinumab", "CHEMICAL", 408, 419], ["sarilumab", "CHEMICAL", 490, 499], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 49, 67], ["azithromycin", "SIMPLE_CHEMICAL", 72, 84], ["inpatients", "ORGANISM", 91, 101], ["remdesivir", "SIMPLE_CHEMICAL", 288, 298], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 300, 319], ["ATC", "SIMPLE_CHEMICAL", 321, 324], ["J05AR10", "SIMPLE_CHEMICAL", 325, 332], ["favipiravir", "SIMPLE_CHEMICAL", 335, 346], ["J05AX27", "SIMPLE_CHEMICAL", 348, 355], ["anti-interleukin 1", "GENE_OR_GENE_PRODUCT", 358, 376], ["anakinra", "SIMPLE_CHEMICAL", 384, 392], ["ATC L04AC03", "SIMPLE_CHEMICAL", 394, 405], ["canakinumab", "SIMPLE_CHEMICAL", 408, 419], ["ATC", "SIMPLE_CHEMICAL", 421, 424], ["L04AC038", "SIMPLE_CHEMICAL", 425, 433], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 441, 454], ["tocilizumab", "SIMPLE_CHEMICAL", 462, 473], ["ATC L04AC037", "SIMPLE_CHEMICAL", 475, 487], ["sarilumab", "SIMPLE_CHEMICAL", 490, 499], ["ATC L04AC14", "SIMPLE_CHEMICAL", 501, 512], ["interleukin 6", "PROTEIN", 441, 454], ["hydroxychloroquine", "TREATMENT", 49, 67], ["azithromycin", "TREATMENT", 72, 84], ["specific COVID-19 treatments", "TREATMENT", 214, 242], ["treatments", "TREATMENT", 249, 259], ["remdesivir", "TREATMENT", 288, 298], ["lopinavir", "TREATMENT", 300, 309], ["ritonavir (ATC J05AR10)", "TREATMENT", 310, 333], ["favipiravir (J05AX27)", "TREATMENT", 335, 356], ["anti-interleukin", "TREATMENT", 358, 374], ["anakinra (ATC L04AC03)", "TREATMENT", 384, 406], ["canakinumab (ATC L04AC038", "TREATMENT", 408, 433], ["anti-interleukin", "TREATMENT", 436, 452], ["tocilizumab (ATC L04AC037)", "TREATMENT", 462, 488], ["sarilumab (ATC L04AC14", "TREATMENT", 490, 512]]], ["When patients were transferred between hospitals for the same stay, several discharge reports were available which were analyzed as a single hospital stay until first discharge home.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Patients who died or were discharged within 24 hours following their admission were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The end of follow-up was defined by the time of death, discharge home, day 28 (D28) after admission, whichever occurred first, or administrative censoring on May 4, 2020.", [["death", "DISEASE", 48, 53]]], ["Patients transferred to hospitals outside AP-HP or to follow-up care and rehabilitation services before day 28 were considered as censored.OutcomesThe study's primary outcome was all-cause 28-day mortality, assessed as a time-to-event endpoint under a competing risks survival analysis framework.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["The study", "TEST", 147, 156]]], ["For patients discharged home before day 28, we looked at subsequent re-admissions to determine vital status on day 28.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The secondary outcome was 28-day discharge home, also assessed as a time-to-event endpoint.Drug exposuresWhile there was no overarching recommendation regarding HCQ+/-AZI prescription at the AP-HP level, guidelines were nonetheless proposed at local level in several individual hospitals, suggesting hydroxychloroquine to physicians as a therapeutic option for patients with moderateto-severe COVID-19 infection, i.e. requiring oxygen.", [["HCQ", "CHEMICAL", 161, 164], ["hydroxychloroquine", "CHEMICAL", 300, 318], ["COVID", "DISEASE", 393, 398], ["infection", "DISEASE", 402, 411], ["oxygen", "CHEMICAL", 428, 434], ["HCQ", "CHEMICAL", 161, 164], ["hydroxychloroquine", "CHEMICAL", 300, 318], ["oxygen", "CHEMICAL", 428, 434], ["HCQ", "SIMPLE_CHEMICAL", 161, 164], ["-AZI", "SIMPLE_CHEMICAL", 166, 170], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 300, 318], ["patients", "ORGANISM", 361, 369], ["oxygen", "SIMPLE_CHEMICAL", 428, 434], ["patients", "SPECIES", 361, 369], ["Drug exposures", "PROBLEM", 91, 105], ["HCQ", "TEST", 161, 164], ["AZI prescription", "TREATMENT", 167, 183], ["hydroxychloroquine", "TREATMENT", 300, 318], ["moderateto-severe COVID-19 infection", "PROBLEM", 375, 411], ["oxygen", "TREATMENT", 428, 434], ["severe", "OBSERVATION_MODIFIER", 386, 392], ["infection", "OBSERVATION", 402, 411]]], ["The suggested HCQ regimen was a loading dose of 600 mg on day 1, followed by 400 mg daily for 9 additional days.", [["HCQ", "CHEMICAL", 14, 17], ["HCQ", "CHEMICAL", 14, 17], ["HCQ", "SIMPLE_CHEMICAL", 14, 17], ["HCQ regimen", "TREATMENT", 14, 25], ["a loading dose", "TREATMENT", 30, 44]]], ["AZI at a dose of 500 mg on day 1 and then 250 mg daily for 4 more days in combination with HCQ was an additional suggested therapeutic option.", [["AZI", "CHEMICAL", 0, 3], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 91, 94], ["AZI", "SIMPLE_CHEMICAL", 0, 3], ["HCQ", "SIMPLE_CHEMICAL", 91, 94], ["AZI", "TREATMENT", 0, 3], ["HCQ", "TREATMENT", 91, 94], ["therapeutic option", "TREATMENT", 123, 141]]], ["Prescription of HCQ or HCQ together with AZI was at the discretion of the physicians.Drug exposuresUsing data acquisition procedures previously detailed, we identified patients with a prescription of HCQ (ATC P01BA02), AZI (ATC J01FA10), steroids (ATC H02AB), and antithrombotic agents (heparin group, ATC B01AB) usually used for acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 336, 347], ["HCQ", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 23, 26], ["AZI", "CHEMICAL", 41, 44], ["HCQ", "CHEMICAL", 200, 203], ["AZI", "CHEMICAL", 219, 222], ["steroids", "CHEMICAL", 238, 246], ["ATC H02AB", "CHEMICAL", 248, 257], ["heparin", "CHEMICAL", 287, 294], ["ATC B01AB", "CHEMICAL", 302, 311], ["acute respiratory distress syndrome", "DISEASE", 330, 365], ["HCQ", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 23, 26], ["HCQ", "CHEMICAL", 200, 203], ["P01BA02", "CHEMICAL", 209, 216], ["AZI", "CHEMICAL", 219, 222], ["steroids", "CHEMICAL", 238, 246], ["HCQ", "SIMPLE_CHEMICAL", 16, 19], ["HCQ", "SIMPLE_CHEMICAL", 23, 26], ["AZI", "SIMPLE_CHEMICAL", 41, 44], ["patients", "ORGANISM", 168, 176], ["HCQ", "SIMPLE_CHEMICAL", 200, 203], ["ATC P01BA02", "SIMPLE_CHEMICAL", 205, 216], ["AZI", "SIMPLE_CHEMICAL", 219, 222], ["steroids", "SIMPLE_CHEMICAL", 238, 246], ["ATC H02AB", "SIMPLE_CHEMICAL", 248, 257], ["antithrombotic agents", "SIMPLE_CHEMICAL", 264, 285], ["heparin", "SIMPLE_CHEMICAL", 287, 294], ["patients", "SPECIES", 168, 176], ["HCQ", "TREATMENT", 16, 19], ["HCQ", "TREATMENT", 23, 26], ["HCQ (ATC P01BA02)", "TREATMENT", 200, 217], ["AZI (ATC J01FA10)", "TREATMENT", 219, 236], ["steroids (ATC H02AB)", "TREATMENT", 238, 258], ["antithrombotic agents", "TREATMENT", 264, 285], ["heparin group", "TREATMENT", 287, 300], ["ATC B01AB)", "TREATMENT", 302, 312], ["acute respiratory distress syndrome", "PROBLEM", 330, 365], ["acute", "OBSERVATION_MODIFIER", 330, 335], ["respiratory distress", "OBSERVATION", 336, 356]]], ["14,15 Exposure to a HCQ/AZI combination was defined as a simultaneous prescription of the two treatments (within one day).", [["HCQ", "CHEMICAL", 20, 23], ["AZI", "CHEMICAL", 24, 27], ["HCQ", "CHEMICAL", 20, 23], ["AZI", "CHEMICAL", 24, 27], ["HCQ", "SIMPLE_CHEMICAL", 20, 23], ["AZI", "SIMPLE_CHEMICAL", 24, 27], ["a HCQ/AZI combination", "TREATMENT", 18, 39]]], ["Based on previous possible combinations, patients were further classified into three groups: (i) receiving HCQ alone, (ii) receiving HCQ together with AZI, and (iii) receiving neither HCQ nor AZI.", [["HCQ", "CHEMICAL", 107, 110], ["HCQ", "CHEMICAL", 133, 136], ["AZI", "CHEMICAL", 151, 154], ["HCQ", "CHEMICAL", 184, 187], ["AZI", "CHEMICAL", 192, 195], ["HCQ", "CHEMICAL", 107, 110], ["HCQ", "CHEMICAL", 133, 136], ["AZI", "CHEMICAL", 151, 154], ["HCQ", "CHEMICAL", 184, 187], ["AZI", "CHEMICAL", 192, 195], ["patients", "ORGANISM", 41, 49], ["HCQ", "SIMPLE_CHEMICAL", 107, 110], ["HCQ", "SIMPLE_CHEMICAL", 133, 136], ["HCQ", "SIMPLE_CHEMICAL", 184, 187], ["AZI", "SIMPLE_CHEMICAL", 192, 195], ["patients", "SPECIES", 41, 49], ["HCQ", "TREATMENT", 107, 110], ["HCQ", "TREATMENT", 133, 136], ["AZI", "TREATMENT", 151, 154], ["AZI", "PROBLEM", 192, 195]]], ["Patients receiving AZI alone were excluded, in accordance with our objective to assess clinical effectiveness of HCQ with or without AZI vs. neither specific treatment.Covariates.", [["AZI", "CHEMICAL", 19, 22], ["HCQ", "CHEMICAL", 113, 116], ["AZI", "CHEMICAL", 133, 136], ["AZI", "CHEMICAL", 19, 22], ["HCQ", "CHEMICAL", 113, 116], ["AZI", "CHEMICAL", 133, 136], ["Patients", "ORGANISM", 0, 8], ["AZI", "SIMPLE_CHEMICAL", 19, 22], ["HCQ", "SIMPLE_CHEMICAL", 113, 116], ["AZI", "SIMPLE_CHEMICAL", 133, 136], ["Patients", "SPECIES", 0, 8], ["AZI alone", "TREATMENT", 19, 28], ["HCQ", "TREATMENT", 113, 116]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprint For each patient, age, sex, hospital-admission location, ICU admission, ICU stay length and hospital stay length were recorded.", [["CC", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 352, 359], ["patient", "SPECIES", 352, 359], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Co-morbidities and risk factors (smoker status, obesity, hypertension, diabetes, dyslipidemia, ischaemic or rhythmic heart diseases, heart failure, renal disease, presence of chronic respiratory insufficiency or asthma or cystic fibrosis, and cancer) were recorded for the two-year period before the index date.", [["heart", "ANATOMY", 117, 122], ["heart", "ANATOMY", 133, 138], ["renal", "ANATOMY", 148, 153], ["respiratory", "ANATOMY", 183, 194], ["cystic", "ANATOMY", 222, 228], ["cancer", "ANATOMY", 243, 249], ["Co-morbidities", "DISEASE", 0, 14], ["obesity", "DISEASE", 48, 55], ["hypertension", "DISEASE", 57, 69], ["diabetes", "DISEASE", 71, 79], ["dyslipidemia", "DISEASE", 81, 93], ["ischaemic or rhythmic heart diseases", "DISEASE", 95, 131], ["heart failure", "DISEASE", 133, 146], ["renal disease", "DISEASE", 148, 161], ["chronic respiratory insufficiency", "DISEASE", 175, 208], ["asthma", "DISEASE", 212, 218], ["cystic fibrosis", "DISEASE", 222, 237], ["cancer", "DISEASE", 243, 249], ["heart", "ORGAN", 117, 122], ["heart", "ORGAN", 133, 138], ["renal", "ORGAN", 148, 153], ["cystic", "ORGAN", 222, 228], ["cancer", "CANCER", 243, 249], ["obesity", "PROBLEM", 48, 55], ["hypertension", "PROBLEM", 57, 69], ["diabetes", "PROBLEM", 71, 79], ["dyslipidemia", "PROBLEM", 81, 93], ["ischaemic", "PROBLEM", 95, 104], ["rhythmic heart diseases", "PROBLEM", 108, 131], ["heart failure", "PROBLEM", 133, 146], ["renal disease", "PROBLEM", 148, 161], ["chronic respiratory insufficiency", "PROBLEM", 175, 208], ["asthma", "PROBLEM", 212, 218], ["cystic fibrosis", "PROBLEM", 222, 237], ["cancer", "PROBLEM", 243, 249], ["hypertension", "OBSERVATION", 57, 69], ["dyslipidemia", "OBSERVATION", 81, 93], ["ischaemic", "OBSERVATION_MODIFIER", 95, 104], ["rhythmic", "OBSERVATION_MODIFIER", 108, 116], ["heart", "ANATOMY", 117, 122], ["diseases", "OBSERVATION", 123, 131], ["heart", "ANATOMY", 133, 138], ["failure", "OBSERVATION", 139, 146], ["renal", "ANATOMY", 148, 153], ["disease", "OBSERVATION", 154, 161], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["respiratory insufficiency", "OBSERVATION", 183, 208], ["asthma", "OBSERVATION", 212, 218], ["cystic", "OBSERVATION_MODIFIER", 222, 228], ["fibrosis", "OBSERVATION", 229, 237], ["cancer", "OBSERVATION", 243, 249]]], ["Clinical severity features within 24h after admission were also recorded: ICU transfer within the first 24h, oxygen saturation, partial pressure of oxygen (PaO 2 mmHg), and carbon dioxyde (PCO 2 ).", [["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 148, 154], ["carbon dioxyde", "CHEMICAL", 173, 187], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 148, 154], ["carbon dioxyde", "CHEMICAL", 173, 187], ["PCO 2", "CHEMICAL", 189, 194], ["oxygen", "SIMPLE_CHEMICAL", 109, 115], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["carbon dioxyde", "SIMPLE_CHEMICAL", 173, 187], ["Clinical severity features", "PROBLEM", 0, 26], ["oxygen saturation", "TEST", 109, 126], ["partial pressure of oxygen", "TREATMENT", 128, 154], ["PaO", "TEST", 156, 159], ["carbon dioxyde (PCO", "TREATMENT", 173, 192], ["partial", "OBSERVATION_MODIFIER", 128, 135], ["pressure", "OBSERVATION_MODIFIER", 136, 144]]], ["Lastly, biologic values were also recorded at the index date using their LOINC (Logical Observation Identifiers Names and Codes).", [["biologic values", "TEST", 8, 23]]], ["Biological values were recorded for neutrophils, lymphocytes, C reactive protein, D-Dimer, prothrombin time, creatine, and lacticodesydrogenase.", [["neutrophils", "ANATOMY", 36, 47], ["lymphocytes", "ANATOMY", 49, 60], ["creatine", "CHEMICAL", 109, 117], ["creatine", "CHEMICAL", 109, 117], ["neutrophils", "CELL", 36, 47], ["lymphocytes", "CELL", 49, 60], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 62, 80], ["D-Dimer", "SIMPLE_CHEMICAL", 82, 89], ["prothrombin", "GENE_OR_GENE_PRODUCT", 91, 102], ["creatine", "SIMPLE_CHEMICAL", 109, 117], ["lacticodesydrogenase", "SIMPLE_CHEMICAL", 123, 143], ["neutrophils", "CELL_TYPE", 36, 47], ["lymphocytes", "CELL_TYPE", 49, 60], ["C reactive protein", "PROTEIN", 62, 80], ["D-Dimer", "PROTEIN", 82, 89], ["prothrombin", "PROTEIN", 91, 102], ["Biological values", "TEST", 0, 17], ["neutrophils", "TEST", 36, 47], ["lymphocytes", "TEST", 49, 60], ["C", "TEST", 62, 63], ["reactive protein", "TEST", 64, 80], ["D", "TEST", 82, 83], ["prothrombin time", "TEST", 91, 107], ["creatine", "TEST", 109, 117], ["lacticodesydrogenase", "TEST", 123, 143]]], ["Detailed definitions of the covariates are available in Supplemental Table 1 .Statistical analysisAll analyses were performed considering the three main treatment modalities of interest, as previously described (HCQ/HCQ+AZI/Neither drug), in the entire population or after stratifying by the level of severity of COVID-19 at admission, considering (i) early ICU admission as defined as occurring within the first 24 hours of admission or (ii) not.Descriptive statisticsDescriptive results are given as medians [interquartile range (IQR)] for continuous variables, and counts (%) for categorical variables.", [["HCQ", "CHEMICAL", 212, 215], ["HCQ", "CHEMICAL", 216, 219], ["AZI", "CHEMICAL", 220, 223], ["HCQ", "CHEMICAL", 212, 215], ["HCQ", "CHEMICAL", 216, 219], ["AZI", "CHEMICAL", 220, 223], ["HCQ", "SIMPLE_CHEMICAL", 212, 215], ["HCQ", "SIMPLE_CHEMICAL", 216, 219], ["Statistical analysis", "TEST", 78, 98], ["All analyses", "TEST", 98, 110], ["AZI", "TREATMENT", 220, 223], ["COVID", "TEST", 313, 318], ["continuous variables", "TEST", 542, 562], ["counts", "TEST", 568, 574], ["categorical variables", "TEST", 583, 604]]], ["Unadjusted between-groups comparisons were performed using the Chi-square test for comparing categorical variables, the Kruskal-Wallis (three-groups comparisons) and Mann-Whitney rank sum tests (pairwise comparisons, correcting for test multiplicity with the Benjamini-Hochberg procedure) for continuous variables, as appropriate.", [["the Chi-square test", "TEST", 59, 78], ["categorical variables", "TEST", 93, 114], ["test multiplicity", "TEST", 232, 249], ["the Benjamini-Hochberg procedure", "TREATMENT", 255, 287]]], ["For time-to-event analyses, non-parametric Nelson-Aalen estimates of the cumulative cause-specific hazards were plotted for the occurrence of death or hospital discharge.Causal inference modelingDue to the influence on treatment assignment of baseline characteristics of patients included in non-randomized observational studies, it is essential to account for such differences when estimating treatment effects to address bias arising from confounding.", [["death", "DISEASE", 142, 147], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["death", "PROBLEM", 142, 147], ["Causal inference modeling", "PROBLEM", 170, 195], ["treatment", "TREATMENT", 219, 228], ["non-randomized observational studies", "TEST", 292, 328], ["bias arising", "PROBLEM", 423, 435]]], ["16 Under assumptions of unconfoundedness (i.e., potential outcomes are independent of the treatment assignment conditionally on a vector of covariates) 17 and its extension in the presence of missing values, 18 the average treatment effect (ATE) can be identified.", [["unconfoundedness", "DISEASE", 24, 40], ["unconfoundedness", "PROBLEM", 24, 40], ["the treatment", "TREATMENT", 86, 99], ["a vector of covariates)", "TREATMENT", 128, 151], ["missing values", "PROBLEM", 192, 206]]], ["19 For the present analysis, causal inference modeling relied on doubly robust estimators, combining an outcome regression with a model for the treatment (i.e., propensity score) to derive augmented inverse probability of treatment weighting (AIPTW) estimators, a more effective approach in minimizing bias due to model misspecification than only IPTW.", [["the present analysis", "TEST", 7, 27], ["the treatment", "TREATMENT", 140, 153], ["treatment weighting (AIPTW) estimators", "TREATMENT", 222, 260], ["model misspecification", "PROBLEM", 314, 336]]], ["20 The selection of the relevant covariates to be used in causal inference modeling was based on available published data at the time of analysis 21 and expert a priori knowledge on key prognostic factors and determinants of treatment assignment, including patients' demographics, comorbidities, hospital and time period of admission.", [["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["analysis", "TEST", 137, 145]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprint DAGitty, 22 shows the causal inference model we applied, differentiating between variables assessed as predictors of the treatment assignment, unrelated to the outcome (brown), predictors of the outcome, unrelated to the treatment assignment (blue), predictors of both treatment and outcome (violet).(which was not certified by peer review)As the primary analysis, we constructed cause-specific Cox proportional hazards regression models to account for the competing risk between all-cause death and hospital discharge.", [["CC", "CHEMICAL", 0, 2], ["death", "DISEASE", 833, 838], ["brown", "ORGANISM_SUBDIVISION", 512, 517], ["violet", "SIMPLE_CHEMICAL", 635, 641], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["the treatment", "TREATMENT", 460, 473], ["both treatment", "TREATMENT", 607, 621], ["the primary analysis", "TEST", 686, 706], ["death", "PROBLEM", 833, 838], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Doubly-robust estimation equations were derived based on regression models for the outcome and the censoring (using Cox modeling), and the treatment distribution (using a generalized linear model with a logit link function), conditional on baseline covariates.", [["Cox modeling)", "TREATMENT", 116, 129], ["a generalized linear model", "TREATMENT", 169, 195]]], ["23 ATEs were calculated as the absolute difference and ratios in the standardized absolute risks, 24 along with their 95% confidence intervals.Sensitivity analyses and missing data handlingWe conducted several sensitivity analyses to check the stability of our results under varying approaches.", [["ratios", "TEST", 55, 61], ["Sensitivity analyses", "TEST", 143, 163], ["missing data handling", "PROBLEM", 168, 189], ["several sensitivity analyses", "TEST", 202, 230]]], ["First, we assessed 28-day mortality as a binary endpoint, considering patients discharged home before day 28 as alive at that date and excluding patients transferred to hospitals outside AP-HP or to follow-up care and rehabilitation services before day 28.", [["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 145, 153]]], ["To do so, we used the causal forest implementation based on the generalized random forests (GRF) method 25 to compute forest-based weighting functions and derive AIPTW estimates for doubly robust inference of the average treatment effect (ATE).", [["the causal forest implementation", "TREATMENT", 18, 50]]], ["Second, conventional multivariable and IPT-weighted analyses ('singly robust') using cause specific Cox models and Fine-Gray competing risks analyses were also performed, computing IPT-weighted and adjusted hazard ratios (HR) and subhazard ratios (SHR), respectively, and plotting raw and adjusted cumulative incidence curves to illustrate the associations.", [["IPT-weighted analyses", "TEST", 39, 60], ["specific Cox models", "TEST", 91, 110], ["adjusted hazard ratios", "TEST", 198, 220], ["HR", "TEST", 222, 224], ["subhazard ratios", "TEST", 230, 246]]], ["For all IPT-weighting based analyses, standardized differences of the means were computed before and after IPTW to assess imbalance of the covariates between treatment groups.", [["all IPT-weighting based analyses", "TEST", 4, 36], ["IPTW", "TREATMENT", 107, 111], ["treatment groups", "TREATMENT", 158, 174]]], ["Standardized differences less than 10% were considered negligible following common practice when using IPTW to estimate causal treatment effects in observational studies.", [["IPTW", "TREATMENT", 103, 107], ["observational studies", "TEST", 148, 169]]], ["26 To account for the potential influence of missing data on causal inference procedures, we used single imputation with a (regularized) iterative Factorial Analysis for Mixed Data model (FAMD), accounting for similarities between both individuals and relationships between covariates, treatment assignment and the outcome.", [["a (regularized)", "TREATMENT", 121, 136], ["iterative Factorial Analysis", "TEST", 137, 165], ["Mixed Data model", "TEST", 170, 186], ["treatment assignment", "TREATMENT", 286, 306]]], ["Variables showing departure from normality using graphical methods and kurtosis/skewness statistics were log-transformed prior to imputation.", [["departure from normality", "PROBLEM", 18, 42], ["graphical methods", "TEST", 49, 66], ["kurtosis/skewness statistics", "TEST", 71, 99]]], ["For the GRF method, the GRF-MIA approach which enables the computation of ATE without any imputation of the data was used for missing data handling.Sensitivity analyses and missing data handlingA two-tailed p-value of less than 0.05 was considered significant.", [["ATE", "DNA", 74, 77], ["the GRF method", "TEST", 4, 18], ["the GRF-MIA approach", "TREATMENT", 20, 40], ["the data", "TEST", 104, 112], ["Sensitivity analyses", "TEST", 148, 168], ["missing data", "TEST", 173, 185]]], ["Statistical analyses were performed using R v3.6.4 (R Foundation for Statistical Computing, Vienna, Austria; packages grf, riskRegression).", [["Statistical analyses", "TEST", 0, 20]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprintStudy populationFrom February 1 st to April 6, 2020, 5,556 adult patients were hospitalized at AP-HP for a Covid-19 infection and did not receive specific COVID-19 treatments other than HCQ or AZI.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 458, 467], ["HCQ", "CHEMICAL", 528, 531], ["AZI", "CHEMICAL", 535, 538], ["HCQ", "CHEMICAL", 528, 531], ["AZI", "CHEMICAL", 535, 538], ["patients", "ORGANISM", 407, 415], ["HCQ", "SIMPLE_CHEMICAL", 528, 531], ["AZI", "SIMPLE_CHEMICAL", 535, 538], ["patients", "SPECIES", 407, 415], ["Covid-19", "SPECIES", 449, 457], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["a Covid-19 infection", "PROBLEM", 447, 467], ["specific COVID-19 treatments", "TREATMENT", 488, 516], ["HCQ", "TREATMENT", 528, 531], ["AZI", "TREATMENT", 535, 538], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 458, 467]]], ["Patients who died (n=91) or who were discharged (n=196) within 24 hours after their admission were excluded, as well as patients receiving AZI alone (n=582) or patients who did not initiate HCQ and AZI the same day (more or less 24 hours, n=45).", [["AZI", "CHEMICAL", 139, 142], ["HCQ", "CHEMICAL", 190, 193], ["AZI", "CHEMICAL", 198, 201], ["AZI", "CHEMICAL", 139, 142], ["HCQ", "CHEMICAL", 190, 193], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 160, 168], ["HCQ", "SIMPLE_CHEMICAL", 190, 193], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 160, 168], ["HCQ", "TREATMENT", 190, 193], ["AZI", "TREATMENT", 198, 201]]], ["Thus, a total of 4,642 patients (mean age: 66.1\u00b118; males: 2,738 (59%)) were included in the study population, of whom 623 (13.4%) received HCQ alone, 227 (5.9%) received HCQ plus AZI, and 3,792 (81.7%) neither HCQ nor HCS plus AZI (Figure 1) .", [["HCQ", "CHEMICAL", 140, 143], ["HCQ", "CHEMICAL", 171, 174], ["AZI", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 211, 214], ["AZI", "CHEMICAL", 228, 231], ["HCQ", "CHEMICAL", 140, 143], ["HCQ", "CHEMICAL", 171, 174], ["HCQ", "CHEMICAL", 211, 214], ["patients", "ORGANISM", 23, 31], ["HCQ", "SIMPLE_CHEMICAL", 140, 143], ["HCQ", "SIMPLE_CHEMICAL", 171, 174], ["HCQ", "SIMPLE_CHEMICAL", 211, 214], ["patients", "SPECIES", 23, 31], ["males", "TEST", 52, 57], ["the study population", "TEST", 89, 109], ["HCQ", "TREATMENT", 140, 143], ["HCQ plus AZI", "TREATMENT", 171, 183]]], ["In the 'HCQ alone' and 'HCQ plus AZI' groups, median timing of the first dose of HCQ after the admission was 0.42 days, IQR (0 to 2.3).Descriptive resultsThe main characteristics of the study population are summarized in Table 1 .", [["HCQ", "CHEMICAL", 8, 11], ["HCQ", "CHEMICAL", 24, 27], ["AZI", "CHEMICAL", 33, 36], ["HCQ", "CHEMICAL", 81, 84], ["HCQ", "CHEMICAL", 8, 11], ["HCQ", "CHEMICAL", 24, 27], ["HCQ", "CHEMICAL", 81, 84], ["HCQ", "SIMPLE_CHEMICAL", 8, 11], ["HCQ", "SIMPLE_CHEMICAL", 24, 27], ["AZI", "SIMPLE_CHEMICAL", 33, 36], ["HCQ", "SIMPLE_CHEMICAL", 81, 84], ["AZI' groups", "TREATMENT", 33, 44], ["HCQ", "TREATMENT", 81, 84], ["the study population", "TEST", 182, 202], ["main", "OBSERVATION_MODIFIER", 158, 162]]], ["Patients receiving 'HCQ alone' or 'HCQ plus AZI' were more likely younger, males, current smokers and overall presented with slightly more co-morbidities (obesity, diabetes, any chronic pulmonary diseases, liver diseases) than the 'Neither drug' group, while no major difference was apparent in biological parameters.", [["pulmonary", "ANATOMY", 186, 195], ["liver", "ANATOMY", 206, 211], ["HCQ", "CHEMICAL", 20, 23], ["HCQ", "CHEMICAL", 35, 38], ["AZI", "CHEMICAL", 44, 47], ["co-morbidities", "DISEASE", 139, 153], ["obesity", "DISEASE", 155, 162], ["diabetes", "DISEASE", 164, 172], ["chronic pulmonary diseases", "DISEASE", 178, 204], ["liver diseases", "DISEASE", 206, 220], ["HCQ", "CHEMICAL", 20, 23], ["HCQ", "CHEMICAL", 35, 38], ["Patients", "ORGANISM", 0, 8], ["HCQ", "SIMPLE_CHEMICAL", 20, 23], ["HCQ", "SIMPLE_CHEMICAL", 35, 38], ["pulmonary", "ORGAN", 186, 195], ["liver", "ORGAN", 206, 211], ["Patients", "SPECIES", 0, 8], ["'HCQ alone", "TREATMENT", 19, 29], ["'HCQ plus AZI'", "TREATMENT", 34, 48], ["slightly more co-morbidities (obesity", "PROBLEM", 125, 162], ["diabetes", "PROBLEM", 164, 172], ["any chronic pulmonary diseases", "PROBLEM", 174, 204], ["liver diseases", "PROBLEM", 206, 220], ["obesity", "OBSERVATION", 155, 162], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["pulmonary", "ANATOMY", 186, 195], ["diseases", "OBSERVATION", 196, 204], ["liver", "ANATOMY", 206, 211], ["diseases", "OBSERVATION", 212, 220]]], ["Table 2 shows unadjusted clinical outcomes by treatment group.", [["treatment group", "TREATMENT", 46, 61]]], ["Raw 28-day mortality rates statistically differed between the three groups (number of deaths: 111 (17.8%), 54 (23.8%) and 830 (21.9%) for 'HCQ alone', 'HCQ plus AZI' and 'Neither drug' groups, respectively; p<0.001).", [["deaths", "DISEASE", 86, 92], ["HCQ", "CHEMICAL", 139, 142], ["HCQ", "CHEMICAL", 152, 155], ["AZI", "CHEMICAL", 161, 164], ["HCQ", "CHEMICAL", 139, 142], ["HCQ", "CHEMICAL", 152, 155], ["HCQ", "SIMPLE_CHEMICAL", 139, 142], ["HCQ", "SIMPLE_CHEMICAL", 152, 155], ["AZI'", "TREATMENT", 161, 165]]], ["Of the 4,642 patients, 777 (16.7%) were transferred to ICU within 24h after the admission, more markedly so in the 'HCQ plus AZI' group (27.3%; p<0.001).", [["HCQ", "CHEMICAL", 116, 119], ["AZI", "CHEMICAL", 125, 128], ["HCQ", "CHEMICAL", 116, 119], ["patients", "ORGANISM", 13, 21], ["HCQ", "SIMPLE_CHEMICAL", 116, 119], ["patients", "SPECIES", 13, 21]]], ["Groups main characteristics stratified by early ICU transfer are summarized in Supplemental Tables S2 and S3 .", [["S3", "ANATOMY", 106, 108]]], ["Discharge rates at day 28 significantly varied across groups, ranging from 39.7% (neither drug) to 56.3% (HCQ alone; p<0.001), with corresponding lengths of stay among patients who lived ranging in median (IQR) from 9.8 to 10.9 and in mean\u00b1SD from 14.7\u00b112 (HCQ+AZI) to 17.6\u00b115.7 (neither drug, p<0.001).Multivariable analysesResults from competing risks multivariable analyses for 28-day mortality and hospital discharge are displayed in Table 3 , showing both raw unadjusted estimates for the average treatment effect of 'HCQ alone 'or 'HCQ plus AZI', and AIPTW results from double robust estimation accounting for confounders for the outcome and the treatment allocation.Multivariable analysesIn the whole population, the raw difference in average treatment effect for 'HCQ' versus 'neither drug' comparison was -5.59% (-9.12 to -2.05); in other words, there was a 5.59% absolute reduction in the 28-day mortality rate in the 'HCQ alone' group when compared to patients in the 'Neither drug' group, with a corresponding ratio in ATE of 0.78 (0.64 to 0.91).", [["HCQ", "CHEMICAL", 106, 109], ["SD", "DISEASE", 240, 242], ["HCQ", "CHEMICAL", 257, 260], ["HCQ", "CHEMICAL", 523, 526], ["HCQ", "CHEMICAL", 538, 541], ["HCQ", "CHEMICAL", 772, 775], ["HCQ", "CHEMICAL", 929, 932], ["HCQ", "CHEMICAL", 106, 109], ["HCQ", "CHEMICAL", 257, 260], ["HCQ", "CHEMICAL", 523, 526], ["HCQ", "CHEMICAL", 538, 541], ["HCQ", "CHEMICAL", 772, 775], ["HCQ", "CHEMICAL", 929, 932], ["patients", "ORGANISM", 168, 176], ["HCQ", "SIMPLE_CHEMICAL", 523, 526], ["HCQ", "SIMPLE_CHEMICAL", 538, 541], ["HCQ", "SIMPLE_CHEMICAL", 929, 932], ["patients", "ORGANISM", 963, 971], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 963, 971], ["Discharge rates", "TEST", 0, 15], ["SD", "TEST", 240, 242], ["HCQ", "TEST", 257, 260], ["AZI", "TEST", 261, 264], ["multivariable analyses", "TEST", 354, 376], ["the average treatment effect", "TREATMENT", 490, 518], ["'HCQ alone", "TREATMENT", 522, 532], ["AZI'", "TREATMENT", 547, 551], ["the treatment allocation", "TREATMENT", 648, 672], ["Multivariable analyses", "TEST", 673, 695], ["a 5.59% absolute reduction", "PROBLEM", 865, 891], ["a corresponding ratio", "TEST", 1006, 1027], ["reduction", "OBSERVATION_MODIFIER", 882, 891]]], ["After accounting for confounding, no significant difference was observed between the 'HCQ alone' and 'Neither drug' groups: AIPTW difference in ATE of +1.24% (-5.63 to 8.12), ratio in ATE of 1.05 (0.77 to .", [["HCQ", "CHEMICAL", 86, 89], ["HCQ", "CHEMICAL", 86, 89], ["HCQ", "SIMPLE_CHEMICAL", 86, 89], ["ATE", "TEST", 144, 147], ["ratio", "TEST", 175, 180], ["ATE", "TEST", 184, 187], ["no", "UNCERTAINTY", 34, 36], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["difference", "OBSERVATION", 49, 59]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In subgroup analyses stratified by early ICU tranfer or not, results were close to those described above, with no statistically significant difference observed in AIPTW ATE between 'HCQ alone' and 'Neither drug' groups for the 28-day mortality, a trend towards higher discharge rates for the 'HCQ alone' group in the not-early ICU transfer subpopulation (ratio in AIPTW ATE 1.13 [0.98 to 1.33]; p=0.075), and apparent worse mortality rates in the 'HCQ plus AZI' group but without reaching statistical significance.Sensitivity analysesResults from double robust analyses considering 28-day mortality as a binary endpoint analyzed at a fixed timepoint are shown in Supplemental Table S4 , with corresponding balance plots of covariates before and after IPT-weighting depicted in Supplemental Figure S4 .", [["ATE", "DISEASE", 169, 172], ["HCQ", "CHEMICAL", 182, 185], ["HCQ", "CHEMICAL", 293, 296], ["HCQ", "CHEMICAL", 448, 451], ["AZI", "CHEMICAL", 457, 460], ["HCQ", "CHEMICAL", 182, 185], ["HCQ", "CHEMICAL", 293, 296], ["HCQ", "CHEMICAL", 448, 451], ["HCQ", "SIMPLE_CHEMICAL", 182, 185], ["HCQ", "SIMPLE_CHEMICAL", 293, 296], ["HCQ", "SIMPLE_CHEMICAL", 448, 451], ["AZI", "SIMPLE_CHEMICAL", 457, 460], ["Sensitivity analysesResults", "TEST", 514, 541], ["double robust analyses", "TEST", 547, 569], ["IPT", "TEST", 751, 754]]], ["These analyses confirmed those obtained for 'HCQ alone' group from the main analysis with no statistically significant difference in mortality, but found no excess of mortality for the 'HCQ plus AZI' group compared with 'Neither drug' group.Sensitivity analysesResults from multivariable analyses using conventional adjustment and/or IPT weighting are shown in Figure 2 for the cause specific Cox proportional hazards models.", [["HCQ", "CHEMICAL", 45, 48], ["HCQ", "CHEMICAL", 186, 189], ["AZI", "CHEMICAL", 195, 198], ["HCQ", "CHEMICAL", 45, 48], ["HCQ", "CHEMICAL", 186, 189], ["HCQ", "SIMPLE_CHEMICAL", 45, 48], ["HCQ", "SIMPLE_CHEMICAL", 186, 189], ["AZI", "SIMPLE_CHEMICAL", 195, 198], ["These analyses", "TEST", 0, 14], ["the main analysis", "TEST", 67, 84], ["the 'HCQ plus AZI' group", "TREATMENT", 181, 205], ["Sensitivity analysesResults", "TEST", 241, 268], ["multivariable analyses", "TEST", 274, 296], ["conventional adjustment", "TREATMENT", 303, 326], ["IPT weighting", "TREATMENT", 334, 347], ["no", "UNCERTAINTY", 90, 92], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["difference", "OBSERVATION", 119, 129]]], ["Using these approaches, results essentially confirmed those obtained from double robust estimates, illustrating for the 'HCQ alone' vs.", [["HCQ", "CHEMICAL", 121, 124], ["HCQ", "CHEMICAL", 121, 124], ["HCQ", "SIMPLE_CHEMICAL", 121, 124], ["the 'HCQ", "TREATMENT", 116, 124]]], ["'Neither drug' comparison ( Figure 2A ) the influence of confounders on estimations as indicated by the progressive alignment of death incidence curves according to treatment after adjustement and/or IPT weighting, and the persistence of statistically significant differences in discharge rates after adjustment, but not when using IPT weighting (p=0.073) or combining both approaches (p=0.116).", [["death", "DISEASE", 129, 134], ["death incidence curves", "PROBLEM", 129, 151], ["treatment", "TREATMENT", 165, 174], ["adjustement", "TREATMENT", 181, 192], ["IPT weighting", "TREATMENT", 200, 213], ["IPT weighting", "TREATMENT", 332, 345]]], ["Regarding the 'HCQ plus AZI' vs.", [["HCQ", "CHEMICAL", 15, 18], ["AZI", "CHEMICAL", 24, 27], ["HCQ", "CHEMICAL", 15, 18], ["HCQ", "SIMPLE_CHEMICAL", 15, 18], ["AZI", "SIMPLE_CHEMICAL", 24, 27], ["the 'HCQ", "TREATMENT", 10, 18], ["AZI'", "TREATMENT", 24, 28]]], ["'Neither drug' comparison ( Figure 2B) , a trend for a statistically significant difference was found for mortality after multiple adjustment and IPT weighting (HR=1.53; p=0.057), but not for discharge (HR=0.98; p=0.923).", [["IPT weighting", "TEST", 146, 159], ["HR", "TEST", 161, 163], ["p", "TEST", 170, 171], ["HR", "TEST", 203, 205], ["p", "TEST", 212, 213]]], ["Results from Fine-Gray models identified similar but not significant trends for the excess risk of mortality in the 'HCQ plus AZI' group.", [["HCQ", "CHEMICAL", 117, 120], ["AZI", "CHEMICAL", 126, 129], ["HCQ", "CHEMICAL", 117, 120], ["HCQ", "SIMPLE_CHEMICAL", 117, 120], ["Fine-Gray models", "TEST", 13, 29]]], ["(Supplemental Figures S2 and S3) .Sensitivity analyses.", [["Sensitivity analyses", "TEST", 34, 54], ["S3", "ANATOMY", 29, 31]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprintDiscussionUsing a large non-selected population of 4,642 hospitalized for COVID-19 infection in 39 hospitals in France, we found no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 425, 434], ["HCQ", "CHEMICAL", 499, 502], ["HCQ", "CHEMICAL", 506, 509], ["AZI", "CHEMICAL", 524, 527], ["HCQ", "CHEMICAL", 499, 502], ["HCQ", "CHEMICAL", 506, 509], ["AZI", "CHEMICAL", 524, 527], ["HCQ", "SIMPLE_CHEMICAL", 499, 502], ["HCQ", "SIMPLE_CHEMICAL", 506, 509], ["AZI", "SIMPLE_CHEMICAL", 524, 527], ["COVID-19", "SPECIES", 416, 424], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 326, 333], ["COVID-19 infection", "PROBLEM", 416, 434], ["efficacy of HCQ", "PROBLEM", 487, 502], ["HCQ", "TREATMENT", 506, 509], ["AZI", "TREATMENT", 524, 527], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["large", "OBSERVATION_MODIFIER", 360, 365], ["infection", "OBSERVATION", 425, 434], ["no evidence for", "UNCERTAINTY", 471, 486]]], ["Our findings suggest that patients treated by association of HCQ and AZI are at greater risk of mortality compared with the 'Neither drug' group.", [["HCQ", "CHEMICAL", 61, 64], ["AZI", "CHEMICAL", 69, 72], ["HCQ", "CHEMICAL", 61, 64], ["AZI", "CHEMICAL", 69, 72], ["patients", "ORGANISM", 26, 34], ["HCQ", "SIMPLE_CHEMICAL", 61, 64], ["AZI", "SIMPLE_CHEMICAL", 69, 72], ["patients", "SPECIES", 26, 34], ["HCQ", "TREATMENT", 61, 64], ["AZI", "TREATMENT", 69, 72]]], ["Interestingly, significantly higher rates of discharge home were observed in patients treated by HCQ when using competing risks survival analyses, a finding whose statistical significance persisted after multivariable adjustment and propensity-score weighting.", [["HCQ", "CHEMICAL", 97, 100], ["HCQ", "CHEMICAL", 97, 100], ["patients", "ORGANISM", 77, 85], ["HCQ", "SIMPLE_CHEMICAL", 97, 100], ["patients", "SPECIES", 77, 85], ["significantly", "OBSERVATION_MODIFIER", 15, 28], ["higher", "OBSERVATION_MODIFIER", 29, 35]]], ["These results were found to be robust to a variety of methodological approaches conducted regarding missing data handling and causal inference modeling to properly account for potential confounders.DiscussionThe absence of difference on mortality between hospitalized patients receiving HCQ and those receiving neither drug is consistent with previous observational studies led in hospitalized patients.", [["HCQ", "CHEMICAL", 287, 290], ["HCQ", "CHEMICAL", 287, 290], ["patients", "ORGANISM", 268, 276], ["HCQ", "SIMPLE_CHEMICAL", 287, 290], ["patients", "ORGANISM", 394, 402], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 394, 402], ["methodological approaches", "TREATMENT", 54, 79], ["missing data handling", "PROBLEM", 100, 121], ["causal inference modeling", "PROBLEM", 126, 151], ["HCQ", "TREATMENT", 287, 290]]], ["[8] [9] [10] [11] Similarly to two recent studies with a >1000 sample size, patients from the present report had a median age around 65 years, with substantial differences at baseline between patients being prescribed HCQ and those being not, including higher prevalence in the former group of comorbidities and risk factors such as obesity, diabetes, hypertension, 10 chronic lung and cardiovascular diseases.", [["lung", "ANATOMY", 377, 381], ["cardiovascular", "ANATOMY", 386, 400], ["HCQ", "CHEMICAL", 218, 221], ["obesity", "DISEASE", 333, 340], ["diabetes", "DISEASE", 342, 350], ["hypertension", "DISEASE", 352, 364], ["chronic lung and cardiovascular diseases", "DISEASE", 369, 409], ["HCQ", "CHEMICAL", 218, 221], ["[8] [9] [10", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 192, 200], ["HCQ", "SIMPLE_CHEMICAL", 218, 221], ["lung", "ORGAN", 377, 381], ["cardiovascular", "ANATOMICAL_SYSTEM", 386, 400], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 192, 200], ["recent studies", "TEST", 35, 49], ["HCQ", "TREATMENT", 218, 221], ["risk factors", "PROBLEM", 312, 324], ["obesity", "PROBLEM", 333, 340], ["diabetes", "PROBLEM", 342, 350], ["hypertension", "PROBLEM", 352, 364], ["10 chronic lung and cardiovascular diseases", "PROBLEM", 366, 409], ["size", "OBSERVATION_MODIFIER", 70, 74], ["substantial", "OBSERVATION_MODIFIER", 148, 159], ["differences", "OBSERVATION", 160, 171], ["obesity", "OBSERVATION", 333, 340], ["diabetes", "OBSERVATION", 342, 350], ["hypertension", "OBSERVATION", 352, 364], ["chronic", "OBSERVATION_MODIFIER", 369, 376], ["lung", "ANATOMY", 377, 381], ["cardiovascular", "ANATOMY", 386, 400], ["diseases", "OBSERVATION", 401, 409]]], ["11 However, patients with either drug in our study were remarkably younger (63 [HCQ], 61 [HCQ+AZI], 69 [neither drug]) and fared significantly better in raw analyses, in contrast with findings from the two previous studies where worse raw outcomes were observed in the groups receiving HCQ.", [["HCQ", "CHEMICAL", 80, 83], ["HCQ", "CHEMICAL", 90, 93], ["HCQ", "CHEMICAL", 286, 289], ["HCQ", "CHEMICAL", 80, 83], ["HCQ", "CHEMICAL", 90, 93], ["HCQ", "CHEMICAL", 286, 289], ["patients", "ORGANISM", 12, 20], ["HCQ", "SIMPLE_CHEMICAL", 286, 289], ["patients", "SPECIES", 12, 20], ["our study", "TEST", 41, 50], ["HCQ", "TEST", 80, 83], ["the two previous studies", "TEST", 198, 222], ["HCQ", "TREATMENT", 286, 289]]], ["Yet in all studies, including ours, no statistically significant difference was eventually found after accounting for confounding by multivariable analyses potentially combined with propensity score weighting, matching or adjustment methods.", [["all studies", "TEST", 7, 18], ["multivariable analyses", "TEST", 133, 155], ["adjustment methods", "TREATMENT", 222, 240]]], ["Finally, it should be stressed out that findings from these reports pertain to hospitalized patients and do not provide information on the efficacy of either drug when administered in earlier forms of the disease.DiscussionRegarding the association of HCQ and AZI, our findings indicate a trend towards higher risk of death for the 'HCQ plus AZI' group compared with the 'Neither drug' group (ratio in ATE at 1.40 [0.98 to 1.81]).", [["HCQ", "CHEMICAL", 252, 255], ["death", "DISEASE", 318, 323], ["HCQ", "CHEMICAL", 333, 336], ["AZI", "CHEMICAL", 342, 345], ["HCQ", "CHEMICAL", 252, 255], ["HCQ", "CHEMICAL", 333, 336], ["patients", "ORGANISM", 92, 100], ["HCQ", "SIMPLE_CHEMICAL", 252, 255], ["AZI", "SIMPLE_CHEMICAL", 260, 263], ["HCQ", "SIMPLE_CHEMICAL", 333, 336], ["AZI", "SIMPLE_CHEMICAL", 342, 345], ["patients", "SPECIES", 92, 100], ["the disease", "PROBLEM", 201, 212], ["HCQ", "PROBLEM", 252, 255], ["AZI", "TREATMENT", 260, 263], ["death", "PROBLEM", 318, 323], ["the 'HCQ plus AZI' group", "TREATMENT", 328, 352], ["disease", "OBSERVATION", 205, 212]]], ["This finding is consistent with the results from Rosenberg et al study (adjusted HR for mortality 1.35 [0.76 to 2.40]).", [["mortality", "TEST", 88, 97], ["consistent with", "UNCERTAINTY", 16, 31]]], ["Because of a limited sample size for this subgroup in our study, our results should be taken with caution.", [["our study", "TEST", 54, 63], ["size", "OBSERVATION_MODIFIER", 28, 32]]], ["However, among possible hypotheses that could be discussed, an increased risk of serious adverse events such as arrhythmia has been advocated in several studies.", [["arrhythmia", "DISEASE", 112, 122], ["serious adverse events", "PROBLEM", 81, 103], ["arrhythmia", "PROBLEM", 112, 122], ["serious", "OBSERVATION_MODIFIER", 81, 88]]], ["11,28 Among 90 consecutively included patients receiving HCQ for Covid-19 infection in Israel, Mercuro et al detected change in QTc in 21 patients (23%), and more evidently so in the 'HCQ plus AZI' subgroup.", [["HCQ", "CHEMICAL", 57, 60], ["Covid-19 infection", "DISEASE", 65, 83], ["HCQ", "CHEMICAL", 184, 187], ["AZI", "DISEASE", 193, 196], ["HCQ", "CHEMICAL", 57, 60], ["HCQ", "CHEMICAL", 184, 187], ["patients", "ORGANISM", 38, 46], ["HCQ", "SIMPLE_CHEMICAL", 57, 60], ["patients", "ORGANISM", 138, 146], ["HCQ", "SIMPLE_CHEMICAL", 184, 187], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 138, 146], ["HCQ", "TREATMENT", 57, 60], ["Covid", "TEST", 65, 70], ["infection", "PROBLEM", 74, 83], ["QTc", "TEST", 128, 131], ["AZI' subgroup", "TREATMENT", 193, 206], ["infection", "OBSERVATION", 74, 83]]], ["28 HCQ is already known to inhibit voltage-gated sodium and potassium channels, prolonging the QT interval and increasing the risk of torsades de pointes, syncope and sudden cardiac death.", [["cardiac", "ANATOMY", 174, 181], ["HCQ", "CHEMICAL", 3, 6], ["sodium", "CHEMICAL", 49, 55], ["potassium", "CHEMICAL", 60, 69], ["torsades de pointes", "DISEASE", 134, 153], ["syncope", "DISEASE", 155, 162], ["sudden cardiac death", "DISEASE", 167, 187], ["HCQ", "CHEMICAL", 3, 6], ["sodium", "CHEMICAL", 49, 55], ["potassium", "CHEMICAL", 60, 69], ["HCQ", "SIMPLE_CHEMICAL", 3, 6], ["sodium", "SIMPLE_CHEMICAL", 49, 55], ["potassium", "SIMPLE_CHEMICAL", 60, 69], ["cardiac", "ORGAN", 174, 181], ["voltage-gated sodium and potassium channels", "PROTEIN", 35, 78], ["voltage", "TEST", 35, 42], ["gated sodium", "TEST", 43, 55], ["potassium channels", "TEST", 60, 78], ["prolonging the QT interval", "PROBLEM", 80, 106], ["torsades de pointes", "PROBLEM", 134, 153], ["syncope", "PROBLEM", 155, 162], ["sudden cardiac death", "PROBLEM", 167, 187], ["cardiac", "ANATOMY", 174, 181], ["death", "OBSERVATION", 182, 187]]], ["29 Azithromycin has also been implicated in QTc prolongation and proarrhythmic events.", [["Azithromycin", "CHEMICAL", 3, 15], ["QTc prolongation", "DISEASE", 44, 60], ["Azithromycin", "CHEMICAL", 3, 15], ["Azithromycin", "SIMPLE_CHEMICAL", 3, 15], ["QTc", "SIMPLE_CHEMICAL", 44, 47], ["Azithromycin", "TREATMENT", 3, 15], ["QTc prolongation", "PROBLEM", 44, 60], ["proarrhythmic events", "PROBLEM", 65, 85]]], ["29 In addition to HCQ and AZI interaction, patients hospitalized with severe COVID-19 pneumonia are also at risk to present clinical characteristics leading to QT prolongation such as hypokalemia or congestive heart failure.DiscussionOne original finding of the present paper lays in the assessment of discharge and in-hospital death in a competing events survival analysis framework.", [["heart", "ANATOMY", 210, 215], ["HCQ", "CHEMICAL", 18, 21], ["pneumonia", "DISEASE", 86, 95], ["QT prolongation", "DISEASE", 160, 175], ["hypokalemia", "DISEASE", 184, 195], ["congestive heart failure", "DISEASE", 199, 223], ["death", "DISEASE", 328, 333], ["HCQ", "CHEMICAL", 18, 21], ["HCQ", "SIMPLE_CHEMICAL", 18, 21], ["AZI", "SIMPLE_CHEMICAL", 26, 29], ["patients", "ORGANISM", 43, 51], ["heart", "ORGAN", 210, 215], ["patients", "SPECIES", 43, 51], ["HCQ", "TREATMENT", 18, 21], ["severe COVID-19 pneumonia", "PROBLEM", 70, 95], ["QT prolongation", "PROBLEM", 160, 175], ["hypokalemia", "PROBLEM", 184, 195], ["congestive heart failure", "PROBLEM", 199, 223], ["the assessment", "TEST", 284, 298], ["pneumonia", "OBSERVATION", 86, 95], ["hypokalemia", "OBSERVATION", 184, 195], ["congestive", "OBSERVATION_MODIFIER", 199, 209], ["heart", "ANATOMY", 210, 215], ["failure", "OBSERVATION", 216, 223]]], ["This analysis allowed us to investigate both events separately, to provide insights beyond that provided by mortality rates alone.", [["This analysis", "TEST", 0, 13]]], ["In our study, .", [["our study", "TEST", 3, 12]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["16.20132597 doi: medRxiv preprint we identified increased discharge rates at day-28 in the HCQ group, corresponding to a ratio in average treatment effect of 1.28 in favor of HCQ, with corresponding predicted day-28 discharge rates of 56% [HCQ] vs. 45% [neither drug] in the whole study population.", [["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 175, 178], ["HCQ", "CHEMICAL", 240, 243], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 175, 178], ["HCQ", "SIMPLE_CHEMICAL", 91, 94], ["HCQ", "SIMPLE_CHEMICAL", 175, 178], ["increased discharge rates", "PROBLEM", 48, 73], ["discharge rates", "TEST", 216, 231], ["HCQ", "TEST", 240, 243], ["increased", "OBSERVATION_MODIFIER", 48, 57]]], ["To our knowledge, this is the first report from a large observational study specifically addressing this issue in addition to mortality and ICU-related outcomes, [8] [9] [10] [11] whereas a similar endpoint was used for remdesivir randomized controlled trials for COVID 19 infection as a primary outcome.", [["infection", "DISEASE", 273, 282], ["remdesivir", "CHEMICAL", 220, 230], ["[8] [9] [10", "SIMPLE_CHEMICAL", 162, 173], ["a large observational study", "TEST", 48, 75], ["remdesivir randomized controlled trials", "TREATMENT", 220, 259], ["COVID 19 infection", "PROBLEM", 264, 282]]], ["30 While mortality remains the ultimate clinical endpoint, assessing discharge rates and determinants may inform decision making for optimizing organization of inpatient services in the context of a pandemic.", [["inpatient services", "TREATMENT", 160, 178], ["a pandemic", "PROBLEM", 197, 207], ["pandemic", "OBSERVATION", 199, 207]]], ["31 Our results could be supported by in vitro and in vivo studies which established a decrease of the viral load in patients receiving HCQ and HCQ plus AZI.", [["HCQ", "CHEMICAL", 135, 138], ["HCQ", "CHEMICAL", 143, 146], ["AZI", "CHEMICAL", 152, 155], ["HCQ", "CHEMICAL", 135, 138], ["HCQ", "CHEMICAL", 143, 146], ["AZI", "CHEMICAL", 152, 155], ["patients", "ORGANISM", 116, 124], ["HCQ", "SIMPLE_CHEMICAL", 135, 138], ["HCQ", "SIMPLE_CHEMICAL", 143, 146], ["AZI", "SIMPLE_CHEMICAL", 152, 155], ["patients", "SPECIES", 116, 124], ["vivo studies", "TEST", 53, 65], ["the viral load", "PROBLEM", 98, 112], ["HCQ", "TREATMENT", 135, 138], ["HCQ plus AZI", "TREATMENT", 143, 155], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["viral load", "OBSERVATION", 102, 112]]], ["3, 6 Causal interpretation should here again remain cautious, but should such results be replicated and validated in randomized studies, it would provide useful information to draw a balanced assessment of the risks and benefits associated with HCQ-based regimens.", [["HCQ", "CHEMICAL", 245, 248], ["HCQ", "CHEMICAL", 245, 248], ["HCQ", "SIMPLE_CHEMICAL", 245, 248], ["randomized studies", "TEST", 117, 135], ["a balanced assessment", "TEST", 181, 202], ["HCQ-based regimens", "TREATMENT", 245, 263]]], ["From a methodological standpoint, the concomitant examination of inhospital mortality and discharge and length of stay through survival analyses require to account for the effect of competing risks to avoid overestimation of the probability of the events of interest.", [["the concomitant examination", "TEST", 34, 61], ["inhospital mortality", "PROBLEM", 65, 85], ["survival analyses", "TEST", 127, 144]]], ["32 With that regard, we used two approaches to competing risks, primarily using cause specific Cox models for causal inference, and further confirming our results by using the Fine-Gray approach with IPT weighting and multivariable adjustment.(which was not certified by peer review)Among the strengths of our study is the use of advanced causal inference approaches both considering time-to-event survival analyses and binary endpoints at a single timepoint.", [["IPT weighting", "TREATMENT", 200, 213], ["multivariable adjustment", "TREATMENT", 218, 242], ["our study", "TEST", 306, 315], ["survival analyses", "PROBLEM", 398, 415], ["binary endpoints", "PROBLEM", 420, 436]]], ["Because inappropriately accounting for confounders can drastically modify results, we performed several sensitivity analyses to check the stability of our results under varying approaches, including so called double robust estimations relying on both multivariable modeling of the outcome and of the treatment (including propensity score-based approaches), which offer better robustness to model misspecification, and use of varying missing data imputation techniques confirming the stability of our findings.", [["several sensitivity analyses", "TEST", 96, 124], ["the treatment", "TREATMENT", 296, 309], ["propensity score", "TEST", 321, 337]]], ["Other strengths of this work include the assessment of a large, representative sample study population in the Greater Paris area from 39 hospitals.", [["the assessment", "TEST", 37, 51], ["a large, representative sample study population", "PROBLEM", 55, 102], ["large", "OBSERVATION_MODIFIER", 57, 62], ["Greater", "OBSERVATION_MODIFIER", 110, 117]]], ["Study's limitations include the absence of direct, clinical information on regimen duration and dosages, and respiratory parameters of COVID-19 infection, including oxygen requirement, non-invasive or mechanical ventilation, which are potential confounders.", [["respiratory", "ANATOMY", 109, 120], ["infection", "DISEASE", 144, 153], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "SIMPLE_CHEMICAL", 165, 171], ["regimen duration", "TREATMENT", 75, 91], ["dosages", "TREATMENT", 96, 103], ["respiratory parameters", "TEST", 109, 131], ["COVID", "TEST", 135, 140], ["19 infection", "PROBLEM", 141, 153], ["oxygen requirement", "TREATMENT", 165, 183], ["mechanical ventilation", "TREATMENT", 201, 223], ["infection", "OBSERVATION", 144, 153], ["oxygen requirement", "OBSERVATION", 165, 183], ["mechanical ventilation", "OBSERVATION", 201, 223]]], ["However, we used biological parameters proxy to assess the severity of the COVID-19 infection including creatine, lymphocyte count and inflammatory markers (D-Dimer and C-Reactive protein) well known to be associated with severity of COVID- 19 .", [["lymphocyte", "ANATOMY", 114, 124], ["infection", "DISEASE", 84, 93], ["creatine", "CHEMICAL", 104, 112], ["creatine", "CHEMICAL", 104, 112], ["COVID- 19", "CHEMICAL", 234, 243], ["creatine", "SIMPLE_CHEMICAL", 104, 112], ["lymphocyte", "CELL", 114, 124], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 157, 164], ["C-Reactive protein", "GENE_OR_GENE_PRODUCT", 169, 187], ["inflammatory markers", "PROTEIN", 135, 155], ["D-Dimer", "PROTEIN", 157, 164], ["C-Reactive protein", "PROTEIN", 169, 187], ["COVID-19", "SPECIES", 75, 83], ["the COVID-19 infection", "PROBLEM", 71, 93], ["creatine", "TEST", 104, 112], ["lymphocyte count", "TEST", 114, 130], ["inflammatory markers", "TEST", 135, 155], ["D-Dimer", "TEST", 157, 164], ["C-Reactive protein", "PROBLEM", 169, 187], ["COVID", "TEST", 234, 239], ["infection", "OBSERVATION", 84, 93], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147]]], ["21 Yet, causal interpretation of our findings relying on retrospective evaluation of medical records should remain cautious considering the observational nature of the study design.ConclusionUsing a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found neither evidence for reduced or excess risk of 28-day mortality with the use of HCQ alone.", [["COVID-19", "CHEMICAL", 260, 268], ["infection", "DISEASE", 269, 278], ["HCQ", "CHEMICAL", 432, 435], ["HCQ", "CHEMICAL", 432, 435], ["inpatients", "ORGANISM", 232, 242], ["HCQ", "SIMPLE_CHEMICAL", 432, 435], ["retrospective evaluation", "TEST", 57, 81], ["the study", "TEST", 164, 173], ["COVID-19 infection", "PROBLEM", 260, 278], ["HCQ", "TREATMENT", 432, 435], ["large", "OBSERVATION_MODIFIER", 199, 204], ["non-selected", "OBSERVATION_MODIFIER", 205, 217], ["population", "OBSERVATION_MODIFIER", 218, 228], ["infection", "OBSERVATION", 269, 278]]], ["Our findings suggest a possible higher risk of death for patients receiving HCQ combined with AZI.", [["death", "DISEASE", 47, 52], ["HCQ", "CHEMICAL", 76, 79], ["AZI", "CHEMICAL", 94, 97], ["HCQ", "CHEMICAL", 76, 79], ["AZI", "CHEMICAL", 94, 97], ["patients", "ORGANISM", 57, 65], ["HCQ", "SIMPLE_CHEMICAL", 76, 79], ["AZI", "SIMPLE_CHEMICAL", 94, 97], ["patients", "SPECIES", 57, 65], ["death", "PROBLEM", 47, 52], ["HCQ", "TREATMENT", 76, 79], ["AZI", "TREATMENT", 94, 97], ["suggest a possible", "UNCERTAINTY", 13, 31]]], ["Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies.Conclusion.", [["HCQ", "CHEMICAL", 82, 85], ["HCQ", "CHEMICAL", 82, 85], ["patients", "ORGANISM", 62, 70], ["HCQ", "SIMPLE_CHEMICAL", 82, 85], ["patients", "SPECIES", 62, 70], ["further confirmation", "TEST", 114, 134], ["replicative studies", "TEST", 138, 157]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprintAcknowledgmentsWe thank Susan Wilkinson for editorial assistance.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["A complete listing of ECAI members can be found at (https://eds.aphp.fr/covid-19).Acknowledgments.", [["ECAI", "GENE_OR_GENE_PRODUCT", 22, 26], ["ECAI members", "PROTEIN", 22, 34]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprint Figure 2 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Death and discharge cumulative incidence curves: results from cause specific Cox competing risks analysis.Panel A -HCQ vs. Neither drug; Panel B -HCQ+AZI vs. Neither drug;Adjusted results are based on the adjustment strategy for the outcome detailed in Figure S1 .", [["Death", "DISEASE", 0, 5], ["HCQ", "CHEMICAL", 115, 118], ["HCQ", "CHEMICAL", 146, 149], ["AZI", "CHEMICAL", 150, 153], ["HCQ", "CHEMICAL", 115, 118], ["HCQ", "CHEMICAL", 146, 149], ["AZI", "CHEMICAL", 150, 153], ["HCQ", "SIMPLE_CHEMICAL", 115, 118], ["B -HCQ", "SIMPLE_CHEMICAL", 143, 149], ["AZI", "SIMPLE_CHEMICAL", 150, 153], ["Death", "PROBLEM", 0, 5], ["Panel", "TEST", 106, 111], ["A", "TEST", 112, 113], ["HCQ", "TEST", 115, 118], ["Panel", "TEST", 137, 142], ["HCQ", "PROBLEM", 146, 149], ["AZI", "PROBLEM", 150, 153], ["the adjustment strategy", "TREATMENT", 201, 224]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Panel A -HCQ vs. Neither drug; Panel B -HCQ+AZI vs. Neither drug;The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.16.20132597 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["HCQ", "CHEMICAL", 211, 214], ["HCQ", "CHEMICAL", 242, 245], ["AZI", "CHEMICAL", 246, 249], ["HCQ", "CHEMICAL", 211, 214], ["HCQ", "CHEMICAL", 242, 245], ["AZI", "CHEMICAL", 246, 249], ["HCQ", "SIMPLE_CHEMICAL", 211, 214], ["B -HCQ", "SIMPLE_CHEMICAL", 239, 245], ["AZI", "SIMPLE_CHEMICAL", 246, 249], ["ND", "PROBLEM", 9, 11], ["Panel", "TEST", 202, 207], ["A", "TEST", 208, 209], ["HCQ", "TEST", 211, 214], ["Panel", "TEST", 233, 238], ["AZI", "PROBLEM", 246, 249], ["medRxiv", "TREATMENT", 392, 399], ["med", "ANATOMY", 105, 108]]]], "68c1ae772623ae47a341652d0fe29f7a728c9694": [["IntroductionInfection is a major cause of morbidity and mortality in intensive care units (ICU) [1] .", [["IntroductionInfection", "DISEASE", 0, 21], ["morbidity", "PROBLEM", 42, 51], ["morbidity", "OBSERVATION", 42, 51]]], ["The most common ICU-acquired infections are due to hospital-associated pneumonia (HAP), which were reported to be 15 to 18 episodes per 1000 ventilator days in Europe and 12% in French healthcare Networks [2, 3] .IntroductionIn selective digestive decontamination (SDD), an enteral and oropharyngeal paste containing antimicrobials is combined with short-term systemic prophylactic antibiotics.", [["digestive", "ANATOMY", 238, 247], ["oropharyngeal", "ANATOMY", 286, 299], ["infections", "DISEASE", 29, 39], ["pneumonia", "DISEASE", 71, 80], ["HAP", "DISEASE", 82, 85], ["digestive", "ORGAN", 238, 247], ["acquired infections", "PROBLEM", 20, 39], ["hospital-associated pneumonia", "PROBLEM", 51, 80], ["IntroductionIn selective digestive decontamination (SDD)", "TREATMENT", 213, 269], ["an enteral", "TREATMENT", 271, 281], ["oropharyngeal paste containing antimicrobials", "TREATMENT", 286, 331], ["short-term systemic prophylactic antibiotics", "TREATMENT", 349, 393], ["infections", "OBSERVATION", 29, 39], ["pneumonia", "OBSERVATION", 71, 80]]], ["In ICU patients, SDD has been associated with reductions in hospital mortality, HAP, and the duration of mechanical ventilation [4] [5] [6] [7] [8] .", [["HAP", "DISEASE", 80, 83], ["patients", "ORGANISM", 7, 15], ["5] [6] [7", "SIMPLE_CHEMICAL", 133, 142], ["patients", "SPECIES", 7, 15], ["SDD", "PROBLEM", 17, 20], ["HAP", "PROBLEM", 80, 83], ["mechanical ventilation", "TREATMENT", 105, 127]]], ["The French guidelines for HAP suggest the routine use of SDD to prevent HAP in units with low levels of antibiotic resistance [9] .", [["HAP", "DISEASE", 26, 29], ["HAP", "DISEASE", 72, 75], ["The French guidelines", "TREATMENT", 0, 21], ["HAP", "PROBLEM", 26, 29], ["SDD", "TREATMENT", 57, 60], ["HAP in units", "TREATMENT", 72, 84], ["low levels of antibiotic resistance", "TREATMENT", 90, 125]]], ["Historically, the duration of systemic prophylactic antibiotic administration has been 4 days, but this duration has ranged from 2 to 5 days in previous studies [10] .IntroductionProlonged antibiotic therapy may lead to the emergence of multi-drug-resistant (MDR) organisms [11, 12] .", [["multi-drug-resistant (MDR) organisms", "DISEASE", 237, 273], ["systemic prophylactic antibiotic administration", "TREATMENT", 30, 77], ["previous studies", "TEST", 144, 160], ["Prolonged antibiotic therapy", "TREATMENT", 179, 207], ["multi-drug-resistant (MDR) organisms", "PROBLEM", 237, 273]]], ["Because the major fear associated with SDD use is the development of MDR organisms, reduction in the exposure to systemic antibiotics could decrease this risk, but it could be associated with the decreased efficiency of the procedure.IntroductionWe hypothesized that the reduction in the duration of the systemic prophylactic antibiotic would not affect the patient outcomes.", [["patient", "ORGANISM", 358, 365], ["patient", "SPECIES", 358, 365], ["SDD", "PROBLEM", 39, 42], ["MDR organisms", "PROBLEM", 69, 82], ["systemic antibiotics", "TREATMENT", 113, 133], ["the procedure", "TREATMENT", 220, 233], ["the reduction", "TREATMENT", 267, 280], ["the systemic prophylactic antibiotic", "TREATMENT", 300, 336], ["decreased", "OBSERVATION_MODIFIER", 196, 205], ["efficiency", "OBSERVATION_MODIFIER", 206, 216], ["reduction", "OBSERVATION_MODIFIER", 271, 280]]], ["In this before-and-after study, we aimed to evaluate the effects on the occurrence of HAP of the decrease in the duration of a systemic prophylactic antibiotic in the SDD setting from 3 to 2 days.", [["HAP", "DISEASE", 86, 89], ["study", "TEST", 25, 30], ["HAP", "PROBLEM", 86, 89], ["a systemic prophylactic antibiotic", "TREATMENT", 125, 159], ["decrease", "OBSERVATION_MODIFIER", 97, 105]]], ["The secondary goals were to assess the rates of ICU-acquired infections, the number of antibiotic-free days, ventilator-free days, vasopressor-free days, and ICUfree days, in addition to the septic shock and ICU-and 28day mortality rates in the 2-day and 3-day study periods.Study design and patientsFrom February 2014 to March 2018, we conducted a retrospective before-and-after study in the 15-bed ICU of a 625bed university hospital (H\u00f4pital Nord, Marseille, France).", [["infections", "DISEASE", 61, 71], ["shock", "DISEASE", 198, 203], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["acquired infections", "PROBLEM", 52, 71], ["vasopressor", "TREATMENT", 131, 142], ["the septic shock", "PROBLEM", 187, 203], ["Study design", "TEST", 275, 287], ["study", "TEST", 380, 385], ["infections", "OBSERVATION", 61, 71], ["septic shock", "OBSERVATION", 191, 203]]], ["All patients admitted to the ICU for trauma, coma, or cardiac arrest with a length of stay of at least 3 days and requiring tracheal intubation at admission were included.", [["cardiac", "ANATOMY", 54, 61], ["tracheal", "ANATOMY", 124, 132], ["trauma", "DISEASE", 37, 43], ["coma", "DISEASE", 45, 49], ["cardiac arrest", "DISEASE", 54, 68], ["patients", "ORGANISM", 4, 12], ["tracheal", "ORGAN", 124, 132], ["patients", "SPECIES", 4, 12], ["trauma", "PROBLEM", 37, 43], ["coma", "PROBLEM", 45, 49], ["cardiac arrest", "PROBLEM", 54, 68], ["tracheal intubation", "TREATMENT", 124, 143], ["cardiac", "ANATOMY", 54, 61], ["arrest", "OBSERVATION", 62, 68], ["tracheal", "ANATOMY", 124, 132], ["intubation", "OBSERVATION", 133, 143]]], ["Patients admitted for infection and receiving curative antibiotics or patients with inappropriate treatment (incomplete, duration error) were not included.", [["infection", "DISEASE", 22, 31], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 70, 78], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 70, 78], ["infection", "PROBLEM", 22, 31], ["curative antibiotics", "TREATMENT", 46, 66], ["inappropriate treatment", "TREATMENT", 84, 107], ["infection", "OBSERVATION", 22, 31]]], ["The SDD regimen was started on the day of tracheal intubation.Study design and patientsThe oropharyngeal paste contained polymyxin E (2%), tobramycin (2%), and amphotericin B (2%).", [["tracheal", "ANATOMY", 42, 50], ["oropharyngeal", "ANATOMY", 91, 104], ["polymyxin E", "CHEMICAL", 121, 132], ["tobramycin", "CHEMICAL", 139, 149], ["amphotericin B", "CHEMICAL", 160, 174], ["polymyxin E", "CHEMICAL", 121, 132], ["tobramycin", "CHEMICAL", 139, 149], ["amphotericin B", "CHEMICAL", 160, 174], ["tracheal", "ORGAN", 42, 50], ["patients", "ORGANISM", 79, 87], ["polymyxin E", "SIMPLE_CHEMICAL", 121, 132], ["tobramycin", "SIMPLE_CHEMICAL", 139, 149], ["amphotericin B", "SIMPLE_CHEMICAL", 160, 174], ["patients", "SPECIES", 79, 87], ["The SDD regimen", "TREATMENT", 0, 15], ["tracheal intubation", "TREATMENT", 42, 61], ["Study design", "TEST", 62, 74], ["The oropharyngeal paste", "TREATMENT", 87, 110], ["polymyxin E", "TREATMENT", 121, 132], ["tobramycin", "TREATMENT", 139, 149], ["amphotericin B", "TREATMENT", 160, 174], ["tracheal", "ANATOMY", 42, 50], ["intubation", "OBSERVATION", 51, 61], ["oropharyngeal", "ANATOMY", 91, 104]]], ["Enteral mixture was administered through a nasogastric tube in 10 ml of a suspension containing 100-mg polymyxin E, 80-mg tobramycin, and 500-mg amphotericin B. The application was performed three times daily until tracheal extubation in all patients.", [["Enteral", "ANATOMY", 0, 7], ["tracheal", "ANATOMY", 215, 223], ["polymyxin E", "CHEMICAL", 103, 114], ["tobramycin", "CHEMICAL", 122, 132], ["amphotericin", "CHEMICAL", 145, 157], ["polymyxin E", "CHEMICAL", 103, 114], ["tobramycin", "CHEMICAL", 122, 132], ["amphotericin B.", "CHEMICAL", 145, 160], ["polymyxin E", "SIMPLE_CHEMICAL", 103, 114], ["tobramycin", "SIMPLE_CHEMICAL", 122, 132], ["amphotericin B.", "SIMPLE_CHEMICAL", 145, 160], ["tracheal", "ORGAN", 215, 223], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["Enteral mixture", "TREATMENT", 0, 15], ["a nasogastric tube", "TREATMENT", 41, 59], ["a suspension", "TREATMENT", 72, 84], ["100-mg polymyxin E", "TREATMENT", 96, 114], ["tobramycin", "TREATMENT", 122, 132], ["500-mg amphotericin B.", "TREATMENT", 138, 160], ["The application", "TREATMENT", 161, 176], ["tracheal extubation", "TREATMENT", 215, 234], ["nasogastric tube", "OBSERVATION", 43, 59], ["tracheal", "ANATOMY", 215, 223], ["extubation", "OBSERVATION", 224, 234]]], ["The systemic prophylactic antibiotic was cefazolin, which was administered intravenously at 1 g every 8 h, except in patients reporting an allergy (no systematic antibiotic in these patients).", [["cefazolin", "CHEMICAL", 41, 50], ["allergy", "DISEASE", 139, 146], ["cefazolin", "CHEMICAL", 41, 50], ["cefazolin", "SIMPLE_CHEMICAL", 41, 50], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 182, 190], ["The systemic prophylactic antibiotic", "TREATMENT", 0, 36], ["cefazolin", "TREATMENT", 41, 50], ["an allergy", "PROBLEM", 136, 146], ["systematic antibiotic", "TREATMENT", 151, 172]]], ["The patients were managed according to international guidelines [9] .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["In our ICU, antimicrobial stewardship is based on the protocols described elsewhere [13, 14] .Study design and patientsIn February 2016, the duration of systemic prophylactic antibiotic administration was reduced from 3 to 2 days to decrease the patients' exposure to the antibiotic.", [["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 246, 254], ["antimicrobial stewardship", "TREATMENT", 12, 37], ["Study design", "TEST", 94, 106], ["systemic prophylactic antibiotic administration", "TREATMENT", 153, 200], ["the antibiotic", "TREATMENT", 268, 282]]], ["The patients admitted from February 1, 2014, to February 1, 2016, were included in the 3-day SDD group, and those admitted from March 1, 2016, to March 1, 2018, were included in the 2-day SDD group.Data collectionDemographic and clinical features, including age, gender, simplified acute physiology score (SAPS II), and the reason for admission were collected from our electronic database.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["Data collectionDemographic", "TEST", 198, 224], ["simplified acute physiology score", "PROBLEM", 271, 304], ["acute", "OBSERVATION_MODIFIER", 282, 287]]], ["We recorded HAP and other ICU-acquired infections, including catheter-associated urinary tract infection (CAUTI), bloodstream infection, and others (e.g., meningitis and intraabdominal infection) between the day of admission and day 28.", [["urinary", "ANATOMY", 81, 88], ["bloodstream", "ANATOMY", 114, 125], ["intraabdominal", "ANATOMY", 170, 184], ["HAP", "DISEASE", 12, 15], ["infections", "DISEASE", 39, 49], ["urinary tract infection", "DISEASE", 81, 104], ["CAUTI", "DISEASE", 106, 111], ["bloodstream infection", "DISEASE", 114, 135], ["meningitis", "DISEASE", 155, 165], ["intraabdominal infection", "DISEASE", 170, 194], ["urinary tract", "ORGANISM_SUBDIVISION", 81, 94], ["HAP", "PROBLEM", 12, 15], ["acquired infections", "PROBLEM", 30, 49], ["catheter", "TREATMENT", 61, 69], ["urinary tract infection", "PROBLEM", 81, 104], ["CAUTI)", "PROBLEM", 106, 112], ["bloodstream infection", "PROBLEM", 114, 135], ["meningitis", "PROBLEM", 155, 165], ["intraabdominal infection", "PROBLEM", 170, 194], ["HAP", "OBSERVATION_MODIFIER", 12, 15], ["infections", "OBSERVATION", 39, 49], ["catheter", "OBSERVATION", 61, 69], ["urinary tract", "ANATOMY", 81, 94], ["infection", "OBSERVATION", 95, 104], ["bloodstream", "OBSERVATION_MODIFIER", 114, 125], ["infection", "OBSERVATION", 126, 135], ["meningitis", "OBSERVATION", 155, 165], ["intraabdominal", "ANATOMY", 170, 184], ["infection", "OBSERVATION", 185, 194]]], ["Once a week, all diagnosis of infection are discussed and reviewed by the same group of senior intensivists and an infectious diseases physician, and decisions are based according to international definitions (Supplemental data 1).", [["infection", "DISEASE", 30, 39], ["infectious diseases", "DISEASE", 115, 134], ["infection", "PROBLEM", 30, 39], ["infection", "OBSERVATION", 30, 39]]], ["We also recorded bacterial and Candida spp. colonization in the lung and urine, MDR organism infection and/or colonization, candidemia, and Clostridium difficile infection.", [["lung", "ANATOMY", 64, 68], ["urine", "ANATOMY", 73, 78], ["MDR organism infection", "DISEASE", 80, 102], ["candidemia", "DISEASE", 124, 134], ["Clostridium difficile infection", "DISEASE", 140, 171], ["Candida spp", "ORGANISM", 31, 42], ["lung", "ORGAN", 64, 68], ["urine", "ORGANISM_SUBSTANCE", 73, 78], ["Clostridium difficile", "ORGANISM", 140, 161], ["Clostridium difficile", "SPECIES", 140, 161], ["Clostridium difficile", "SPECIES", 140, 161], ["bacterial and Candida spp", "PROBLEM", 17, 42], ["colonization in the lung and urine", "PROBLEM", 44, 78], ["MDR organism infection", "PROBLEM", 80, 102], ["colonization", "PROBLEM", 110, 122], ["candidemia", "PROBLEM", 124, 134], ["Clostridium difficile infection", "PROBLEM", 140, 171], ["bacterial", "OBSERVATION_MODIFIER", 17, 26], ["Candida spp", "OBSERVATION", 31, 42], ["lung", "ANATOMY", 64, 68], ["urine", "ANATOMY", 73, 78], ["MDR organism infection", "OBSERVATION", 80, 102], ["colonization", "OBSERVATION_MODIFIER", 110, 122], ["candidemia", "OBSERVATION", 124, 134], ["Clostridium", "OBSERVATION_MODIFIER", 140, 151], ["difficile", "OBSERVATION_MODIFIER", 152, 161], ["infection", "OBSERVATION", 162, 171]]], ["We recorded the number of patients who received narrow-spectrum \u03b2lactams, which were then defined by the use of cloxacillin, amoxicillin, amoxicillin-clavulanate, and cephalosporin; broad-spectrum \u03b2-lactams defined by use of piperacillin-tazobactam, ceftazidime, cefepime, carbapenem; and other antibiotics defined by use of fluoroquinolone, gentamicin, amikacin, vancomycin, linezolid, and metronidazole.", [["cloxacillin", "CHEMICAL", 112, 123], ["amoxicillin", "CHEMICAL", 125, 136], ["amoxicillin-clavulanate", "CHEMICAL", 138, 161], ["cephalosporin", "CHEMICAL", 167, 180], ["piperacillin-tazobactam", "CHEMICAL", 225, 248], ["ceftazidime", "CHEMICAL", 250, 261], ["cefepime", "CHEMICAL", 263, 271], ["carbapenem", "CHEMICAL", 273, 283], ["fluoroquinolone", "CHEMICAL", 325, 340], ["gentamicin", "CHEMICAL", 342, 352], ["amikacin", "CHEMICAL", 354, 362], ["vancomycin", "CHEMICAL", 364, 374], ["linezolid", "CHEMICAL", 376, 385], ["metronidazole", "CHEMICAL", 391, 404], ["cloxacillin", "CHEMICAL", 112, 123], ["amoxicillin", "CHEMICAL", 125, 136], ["amoxicillin-clavulanate", "CHEMICAL", 138, 161], ["cephalosporin", "CHEMICAL", 167, 180], ["piperacillin-tazobactam", "CHEMICAL", 225, 248], ["ceftazidime", "CHEMICAL", 250, 261], ["cefepime", "CHEMICAL", 263, 271], ["carbapenem", "CHEMICAL", 273, 283], ["fluoroquinolone", "CHEMICAL", 325, 340], ["gentamicin", "CHEMICAL", 342, 352], ["amikacin", "CHEMICAL", 354, 362], ["vancomycin", "CHEMICAL", 364, 374], ["linezolid", "CHEMICAL", 376, 385], ["metronidazole", "CHEMICAL", 391, 404], ["patients", "ORGANISM", 26, 34], ["cloxacillin", "SIMPLE_CHEMICAL", 112, 123], ["amoxicillin", "SIMPLE_CHEMICAL", 125, 136], ["amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 138, 161], ["cephalosporin", "SIMPLE_CHEMICAL", 167, 180], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 225, 248], ["ceftazidime", "SIMPLE_CHEMICAL", 250, 261], ["cefepime", "SIMPLE_CHEMICAL", 263, 271], ["carbapenem", "SIMPLE_CHEMICAL", 273, 283], ["fluoroquinolone", "SIMPLE_CHEMICAL", 325, 340], ["gentamicin", "SIMPLE_CHEMICAL", 342, 352], ["amikacin", "SIMPLE_CHEMICAL", 354, 362], ["vancomycin", "SIMPLE_CHEMICAL", 364, 374], ["linezolid", "SIMPLE_CHEMICAL", 376, 385], ["metronidazole", "SIMPLE_CHEMICAL", 391, 404], ["patients", "SPECIES", 26, 34], ["narrow-spectrum \u03b2lactams", "TREATMENT", 48, 72], ["cloxacillin", "TREATMENT", 112, 123], ["amoxicillin", "TREATMENT", 125, 136], ["amoxicillin", "TREATMENT", 138, 149], ["clavulanate", "TREATMENT", 150, 161], ["cephalosporin", "TREATMENT", 167, 180], ["broad-spectrum \u03b2-lactams", "TREATMENT", 182, 206], ["piperacillin", "TREATMENT", 225, 237], ["tazobactam", "TREATMENT", 238, 248], ["ceftazidime", "TREATMENT", 250, 261], ["cefepime", "TREATMENT", 263, 271], ["carbapenem", "TREATMENT", 273, 283], ["other antibiotics", "TREATMENT", 289, 306], ["fluoroquinolone", "TREATMENT", 325, 340], ["gentamicin", "TREATMENT", 342, 352], ["amikacin", "TREATMENT", 354, 362], ["vancomycin", "TREATMENT", 364, 374], ["linezolid", "TREATMENT", 376, 385], ["metronidazole", "TREATMENT", 391, 404]]], ["The number of antibiotic-free days (excluding the antibiotics used in SDD), ventilator-free days, vasopressor-free days, and ICU-free days were reported from the day of admission to day 28 or the day of death, as applicable.", [["death", "DISEASE", 203, 208], ["antibiotic-free days", "TREATMENT", 14, 34], ["the antibiotics", "TREATMENT", 46, 61], ["vasopressor", "TREATMENT", 98, 109]]], ["Septic shock was defined according to the international definition [15] .", [["Septic shock", "DISEASE", 0, 12], ["Septic shock", "PROBLEM", 0, 12], ["shock", "OBSERVATION", 7, 12]]], ["We recorded the ICU readmission rates, ICU rates, and 28-day mortality rates.", [["ICU rates", "TEST", 39, 48]]], ["Patients with missing data were excluded from the analysis.Statistical analysisThe statistical analyses were performed using the R-Project 3.4.4 software for Ubuntu Linux.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["missing data", "TEST", 14, 26], ["the analysis", "TEST", 46, 58], ["Statistical analysis", "TEST", 59, 79], ["The statistical analyses", "TEST", 79, 103]]], ["The quantitative data were expressed in means with standard deviation.", [["The quantitative data", "TEST", 0, 21]]], ["The quantitative data were compared using an analysis of variance ANOVA.", [["The quantitative data", "TEST", 0, 21], ["an analysis", "TEST", 42, 53]]], ["A Student's t test was used when the data distribution was normal.", [["A Student's t test", "TEST", 0, 18], ["the data distribution", "TEST", 33, 54], ["normal", "OBSERVATION", 59, 65]]], ["A Kruskal-Wallis (or Mann-Whitney) test was used if it was not normal.", [["normal", "OBSERVATION", 63, 69]]], ["The qualitative data were expressed as absolute numbers and percentages.", [["The qualitative data", "TEST", 0, 20]]], ["Proportion comparisons were made using a chi-squared test or an exact Fisher test.", [["a chi-squared test", "TEST", 39, 57], ["an exact Fisher test", "TEST", 61, 81]]], ["A value of p < 0.05 was used as the final significance threshold.", [["A value", "TEST", 0, 7]]], ["A multivariate logistic regression analysis was performed.", [["A multivariate logistic regression analysis", "TEST", 0, 43]]], ["The relevant variables of p < 0.2 in the univariate analysis were included in a stepwise variable selection model.", [["the univariate analysis", "TEST", 37, 60]]], ["A value of p < 0.05 was used as the final significance threshold.", [["A value", "TEST", 0, 7]]], ["Our study was based on a before-and-after design and included all patients who met the inclusion criteria during the two study periods.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Our study", "TEST", 0, 9], ["the two study", "TEST", 113, 126]]], ["However, to ensure a power of 90% with an alpha value of 5% and a 12% rate of hospital-associated pneumonia [3] , the sample size required per group was 93 patients.Ethical considerationsIn this observational retrospective study, based on the French legislation on biomedical research (articles L. 1121-1 paragraph 1 and R. 1121-3, Public Health Code), no ethical problems were present, which was confirmed by the Comit\u00e9 d'Ethique pour la Recherche en Anesth\u00e9sie-R\u00e9animation (CERAR) [16] .", [["pneumonia", "DISEASE", 98, 107], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["an alpha value", "TEST", 39, 53], ["pneumonia", "PROBLEM", 98, 107], ["the sample size", "TEST", 114, 129], ["this observational retrospective study", "TEST", 190, 228], ["ethical problems", "PROBLEM", 356, 372], ["pneumonia", "OBSERVATION", 98, 107], ["size", "OBSERVATION_MODIFIER", 125, 129], ["no", "UNCERTAINTY", 353, 355]]], ["The patients and their families were informed that their data could be used in this study during their ICU stay.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["this study", "TEST", 79, 89]]], ["The data were stored and treated according to the Commission Nationale de l'Informatique et des Libert\u00e9s (CNIL) authorization number 2018-32.ResultsDuring the study period, 3233 patients were admitted to our ICU.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186]]], ["Of these patients, 1471 were admitted between February 1, 2014, and February 1, 2016, and 1762 were admitted between March 1, 2016, and March 1, 2018, (Fig. 1 ).", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["Among these patients, 505 were admitted for trauma, coma, or cardiac arrest with mechanical ventilation and an ICU length of stay of 3 days or more.", [["cardiac", "ANATOMY", 61, 68], ["trauma", "DISEASE", 44, 50], ["coma", "DISEASE", 52, 56], ["cardiac arrest", "DISEASE", 61, 75], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["trauma", "PROBLEM", 44, 50], ["coma", "PROBLEM", 52, 56], ["cardiac arrest", "PROBLEM", 61, 75], ["mechanical ventilation", "TREATMENT", 81, 103], ["cardiac", "ANATOMY", 61, 68], ["arrest", "OBSERVATION", 69, 75], ["mechanical ventilation", "OBSERVATION", 81, 103]]], ["Fifty-eight patients were not included because they required antibiotic therapy at admission for a (suspected) infection or inappropriate treatment (absence or incomplete).", [["infection", "DISEASE", 111, 120], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["antibiotic therapy", "TREATMENT", 61, 79], ["a (suspected) infection", "PROBLEM", 97, 120], ["inappropriate treatment", "TREATMENT", 124, 147], ["infection", "OBSERVATION", 111, 120]]], ["Finally, 199 and 248 patients were included in the 3-day SDD group and the 2-day SDD group, respectively.ResultsThe results of the univariate analysis are shown in Table 1 .", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["the univariate analysis", "TEST", 127, 150]]], ["The demographic data were similar in both groups.", [["The demographic data", "TEST", 0, 20]]], ["Although the number of HAPs was similar in both groups, the rate of bloodstream infections was lower in the 2-day SDD group than in the 3-day SDD group (10 [4%] and 21 [11%], respectively; p = 0.012).", [["bloodstream", "ANATOMY", 68, 79], ["bloodstream infections", "DISEASE", 68, 90], ["HAPs", "PATHOLOGICAL_FORMATION", 23, 27], ["HAPs", "PROBLEM", 23, 27], ["bloodstream infections", "PROBLEM", 68, 90], ["HAPs", "OBSERVATION_MODIFIER", 23, 27], ["bloodstream", "OBSERVATION_MODIFIER", 68, 79], ["infections", "OBSERVATION", 80, 90], ["lower", "OBSERVATION_MODIFIER", 95, 100]]], ["The number of MDR organisms collected in the urine, lungs, and infected sites was similar in both groups (10 [5%] and 10 [4%], respectively, p = 0.784).ResultsCandida colonization and C. difficile infections did not differ between the two groups ( Table 1 ).", [["urine", "ANATOMY", 45, 50], ["lungs", "ANATOMY", 52, 57], ["sites", "ANATOMY", 72, 77], ["C. difficile infections", "DISEASE", 184, 207], ["urine", "ORGANISM_SUBSTANCE", 45, 50], ["lungs", "ORGAN", 52, 57], ["C. difficile", "ORGANISM", 184, 196], ["C. difficile", "SPECIES", 184, 196], ["C. difficile", "SPECIES", 184, 196], ["MDR organisms", "PROBLEM", 14, 27], ["infected sites", "PROBLEM", 63, 77], ["Candida colonization", "PROBLEM", 159, 179], ["C. difficile infections", "PROBLEM", 184, 207], ["MDR organisms", "OBSERVATION", 14, 27], ["urine", "ANATOMY", 45, 50], ["lungs", "ANATOMY", 52, 57], ["infected", "OBSERVATION", 63, 71], ["similar", "OBSERVATION_MODIFIER", 82, 89], ["difficile", "OBSERVATION_MODIFIER", 187, 196], ["infections", "OBSERVATION", 197, 207]]], ["The number of bacteriuria was significantly lower in the 2-day SDD group than in the 3day SDD group (14 [6%)] and 28 [14%], respectively; p = 0.004).ResultsIn the 2-day SDD group, the numbers of antibiotic-free days, mechanical ventilator-free days, and ICU-free days were higher than in the 3-day SDD group.", [["bacteriuria", "DISEASE", 14, 25], ["bacteriuria", "PROBLEM", 14, 25], ["mechanical ventilator", "TREATMENT", 217, 238], ["bacteriuria", "OBSERVATION", 14, 25], ["significantly", "OBSERVATION_MODIFIER", 30, 43], ["lower", "OBSERVATION_MODIFIER", 44, 49]]], ["The ICU-mortality and 28-day mortality rates did not differ significantly in the two groups.ResultsThe multivariate analysis showed that the 3-day SDD group was an independent factor associated with the increased risk of bacteriuria and bloodstream infection, whereas it was a protective factor associated with the number of ventilator-free days ( Table 2 ).DiscussionIn our study, the reduced duration of the administration of a systemic prophylactic antibiotic from 3 to 2 days was not 3 In the SDD setting, topical antimicrobials alone decreased the rate of respiratory infection, but this strategy did not affect the mortality rates [5] .", [["bloodstream", "ANATOMY", 237, 248], ["respiratory", "ANATOMY", 561, 572], ["bacteriuria", "DISEASE", 221, 232], ["bloodstream infection", "DISEASE", 237, 258], ["respiratory infection", "DISEASE", 561, 582], ["The multivariate analysis", "TEST", 99, 124], ["an independent factor", "PROBLEM", 161, 182], ["bacteriuria", "PROBLEM", 221, 232], ["bloodstream infection", "PROBLEM", 237, 258], ["our study", "TEST", 371, 380], ["a systemic prophylactic antibiotic", "TREATMENT", 428, 462], ["topical antimicrobials", "TREATMENT", 510, 532], ["respiratory infection", "PROBLEM", 561, 582], ["bacteriuria", "OBSERVATION", 221, 232], ["bloodstream", "OBSERVATION_MODIFIER", 237, 248], ["infection", "OBSERVATION", 249, 258], ["respiratory infection", "OBSERVATION", 561, 582]]], ["An effect on mortality was found in patients treated using a combination of topical and systemic prophylactic antimicrobials [5, 6, 17] .", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["topical and systemic prophylactic antimicrobials", "TREATMENT", 76, 124]]], ["In most previous studies, the duration of systemic treatment was 4 days.", [["systemic treatment", "TREATMENT", 42, 60]]], ["The rational was a systemic prophylaxis administration until most potentially pathogenic microorganisms colonizing the patient are eliminated by SDD [10, 18] .", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["a systemic prophylaxis administration", "TREATMENT", 17, 54], ["pathogenic microorganisms", "PROBLEM", 78, 103]]], ["Many studies compared short-versus long-term antibiotic prophylaxis in surgery [19] [20] [21] .", [["Many studies", "TEST", 0, 12], ["long-term antibiotic prophylaxis", "TREATMENT", 35, 67]]], ["To our knowledge, this study is the first to investigate the duration of systemic antibiotics in SDD.", [["this study", "TEST", 18, 28], ["systemic antibiotics", "TREATMENT", 73, 93]]], ["The use of SDD is controversial, particularly a systemic prophylactic antibiotic.", [["SDD", "TREATMENT", 11, 14], ["a systemic prophylactic antibiotic", "TREATMENT", 46, 80]]], ["The European guidelines for the management of HAP suggest the use of selective oral decontamination, but not SDD [22] .", [["oral", "ANATOMY", 79, 83], ["HAP", "DISEASE", 46, 49], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["The European guidelines", "TREATMENT", 0, 23], ["the management", "TREATMENT", 28, 42], ["HAP", "PROBLEM", 46, 49], ["selective oral decontamination", "TREATMENT", 69, 99]]], ["The main reason for the restriction on its use is the uncertain effect on bacterial resistance, especially in parts of the world where the prevalence of resistant microorganisms is higher [23] .", [["the restriction", "PROBLEM", 20, 35], ["bacterial resistance", "PROBLEM", 74, 94], ["resistant microorganisms", "PROBLEM", 153, 177], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bacterial resistance", "OBSERVATION", 74, 94]]], ["However, SDD has been found to be effective and safe in environments with low levels of resistance [23] [24] [25] .", [["SDD", "CHEMICAL", 9, 12], ["SDD", "PROBLEM", 9, 12], ["effective", "OBSERVATION_MODIFIER", 34, 43]]], ["In trauma patients, prophylactic antibiotic days were identified as an independent predictor of MDR organism development [12] , where patients who developed MDR organism pneumonia received on average 7 days of prophylactic antibiotics, whereas those who developed susceptible HAP received only 2 days of prophylactic antibiotics [12] .", [["trauma", "DISEASE", 3, 9], ["pneumonia", "DISEASE", 170, 179], ["HAP", "DISEASE", 276, 279], ["patients", "ORGANISM", 10, 18], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 134, 142], ["prophylactic antibiotic days", "TREATMENT", 20, 48], ["MDR organism development", "PROBLEM", 96, 120], ["MDR organism pneumonia", "PROBLEM", 157, 179], ["prophylactic antibiotics", "TREATMENT", 210, 234], ["susceptible HAP", "PROBLEM", 264, 279], ["prophylactic antibiotics", "TREATMENT", 304, 328], ["MDR organism", "OBSERVATION", 157, 169], ["pneumonia", "OBSERVATION", 170, 179]]], ["In the present study, we modified our protocol by reducing the number of prophylactic antibiotic days.", [["prophylactic antibiotic days", "TREATMENT", 73, 101]]], ["In our study, the prevalence of MDR organisms in the lung, urine, or blood of the patients in our sample was around 5%.", [["lung", "ANATOMY", 53, 57], ["urine", "ANATOMY", 59, 64], ["blood", "ANATOMY", 69, 74], ["lung", "ORGAN", 53, 57], ["urine", "ORGANISM_SUBSTANCE", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["our study", "TEST", 3, 12], ["MDR organisms in the lung", "PROBLEM", 32, 57], ["MDR organisms", "OBSERVATION", 32, 45], ["lung", "ANATOMY", 53, 57], ["urine", "OBSERVATION", 59, 64]]], ["In our ICU, systematic rectal sampling for MDR organisms during the stay was implemented in 2018.", [["rectal", "ANATOMY", 23, 29], ["rectal", "MULTI-TISSUE_STRUCTURE", 23, 29], ["systematic rectal sampling", "TEST", 12, 38], ["MDR organisms", "PROBLEM", 43, 56], ["rectal", "ANATOMY", 23, 29]]], ["Therefore, we were unable to compare the ecological effects over the two periods of the study.", [["the study", "TEST", 84, 93]]], ["However, the analysis of other sites did not show significant differences in MDR organism colonization or infection; therefore, it could be hypothesized that decreased antimicrobial exposure would not have deleterious effects on the ecology.DiscussionPrevious studies showed that SDD decreased the number of bloodstream infections [26, 27] .", [["bloodstream", "ANATOMY", 308, 319], ["infection", "DISEASE", 106, 115], ["bloodstream infections", "DISEASE", 308, 330], ["the analysis", "TEST", 9, 21], ["MDR organism colonization", "PROBLEM", 77, 102], ["infection", "PROBLEM", 106, 115], ["DiscussionPrevious studies", "TEST", 241, 267], ["SDD", "PROBLEM", 280, 283], ["bloodstream infections", "PROBLEM", 308, 330], ["MDR organism", "OBSERVATION", 77, 89], ["infection", "OBSERVATION", 106, 115], ["SDD", "OBSERVATION_MODIFIER", 280, 283], ["decreased", "OBSERVATION_MODIFIER", 284, 293], ["number", "OBSERVATION_MODIFIER", 298, 304], ["bloodstream", "OBSERVATION_MODIFIER", 308, 319], ["infections", "OBSERVATION", 320, 330]]], ["In our study, the decrease in the duration of the systemic prophylactic antibiotic was associated with decreased numbers of bloodstream infections, bacteriuria, exposure to antibiotics (excluding those used for SDD), and days without mechanical ventilation.", [["bloodstream", "ANATOMY", 124, 135], ["bloodstream infections", "DISEASE", 124, 146], ["bacteriuria", "DISEASE", 148, 159], ["our study", "TEST", 3, 12], ["the systemic prophylactic antibiotic", "TREATMENT", 46, 82], ["bloodstream infections", "PROBLEM", 124, 146], ["bacteriuria", "PROBLEM", 148, 159], ["antibiotics", "TREATMENT", 173, 184], ["SDD", "PROBLEM", 211, 214], ["mechanical ventilation", "TREATMENT", 234, 256], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["numbers", "OBSERVATION_MODIFIER", 113, 120], ["bloodstream infections", "OBSERVATION", 124, 146], ["bacteriuria", "OBSERVATION", 148, 159], ["mechanical ventilation", "OBSERVATION", 234, 256]]], ["It should be noted that variables not included in our analyses may have affected these findings.", [["our analyses", "TEST", 50, 62]]], ["Although these results may also have been due to a change in practice between the two periods, they confirmed the efficacy of administering systemic prophylactic antibiotics for SDD during a short period.DiscussionOur study has several limitations.", [["systemic prophylactic antibiotics", "TREATMENT", 140, 173], ["SDD", "PROBLEM", 178, 181], ["DiscussionOur study", "TEST", 204, 223]]], ["Hence, although our protocols and practices were similar during the two study periods, unrecognized changes may have affected our findings.", [["the two study", "TEST", 64, 77]]], ["However, the two study populations were similar.", [["the two study populations", "TEST", 9, 34], ["similar", "OBSERVATION_MODIFIER", 40, 47]]], ["It is possible that other factors that could influence the results were not included such as co-morbidities and the use of catheters.", [["co-morbidities", "PROBLEM", 93, 107], ["catheters", "TREATMENT", 123, 132], ["catheters", "OBSERVATION", 123, 132]]], ["However, the rates of catheter-associated bloodstream infections and catheter-associated urinary tract infections were stable during the study period (around 2% and 5-6% in 2016 and 2018, respectively).", [["bloodstream", "ANATOMY", 42, 53], ["urinary tract", "ANATOMY", 89, 102], ["bloodstream infections", "DISEASE", 42, 64], ["urinary tract infections", "DISEASE", 89, 113], ["urinary tract", "ORGANISM_SUBDIVISION", 89, 102], ["catheter", "TREATMENT", 22, 30], ["bloodstream infections", "PROBLEM", 42, 64], ["catheter", "TREATMENT", 69, 77], ["urinary tract infections", "PROBLEM", 89, 113], ["the study", "TEST", 133, 142], ["catheter", "OBSERVATION", 22, 30], ["bloodstream", "OBSERVATION_MODIFIER", 42, 53], ["infections", "OBSERVATION", 54, 64], ["catheter", "OBSERVATION", 69, 77], ["urinary tract", "ANATOMY", 89, 102], ["infections", "OBSERVATION", 103, 113], ["stable", "OBSERVATION_MODIFIER", 119, 125]]], ["Colonization was defined by isolation of a micro-organism without evidence of infection.", [["infection", "DISEASE", 78, 87], ["Colonization", "PROBLEM", 0, 12], ["a micro-organism", "PROBLEM", 41, 57], ["infection", "PROBLEM", 78, 87], ["without evidence of", "UNCERTAINTY", 58, 77], ["infection", "OBSERVATION", 78, 87]]], ["As the samples were ordered by the judgment of a clinician, these results have to be interpreted with caution.", [["samples", "ANATOMY", 7, 14]]], ["In addition, because this study was conducted in a single ICU, further research is required to confirm the generalizability of the results to other ICUs.", [["this study", "TEST", 21, 31]]], ["The ecology of our patients cannot be assumed to reflect that in other ICUs because only 5% of pathogens were considered MDR organisms.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["pathogens", "PROBLEM", 95, 104], ["MDR organisms", "PROBLEM", 121, 134]]], ["The French guidelines on HAP in ICUs were published in November 2017.", [["HAP", "PROBLEM", 25, 28]]], ["Because our study period was from February 2014 to March 2018, the influence of these guidelines on our results was probably limited; moreover, SDD has been used in our ICU for several years [28] [29] [30] .", [["SDD", "CHEMICAL", 144, 147]]], ["Bundles of care for the prevention of HAP have also been widely used in our ICU [9] .", [["HAP", "DISEASE", 38, 41], ["HAP", "PROBLEM", 38, 41]]], ["As explained above, the systematic use of rectal sampling was reintroduced in 2018, which made it difficult to assess the rectal colonization of the patients in our study.", [["rectal", "ANATOMY", 42, 48], ["rectal", "ANATOMY", 122, 128], ["rectal", "ORGAN", 42, 48], ["rectal", "ORGANISM_SUBDIVISION", 122, 128], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["rectal sampling", "TREATMENT", 42, 57], ["our study", "TEST", 161, 170], ["rectal", "ANATOMY", 42, 48], ["rectal", "ANATOMY", 122, 128], ["colonization", "OBSERVATION", 129, 141]]], ["Finally, to limit the potential for bias, possible confounding factors were included in the analysis.DiscussionIn conclusion, although unmeasured confounding factors may account for our results, the decrease in the duration of systemic prophylactic antibiotic SDD from 3 to 2 days was not associated with an increase in ICU infections.", [["infections", "DISEASE", 324, 334], ["confounding factors", "PROBLEM", 51, 70], ["the analysis", "TEST", 88, 100], ["systemic prophylactic antibiotic SDD", "TREATMENT", 227, 263], ["ICU infections", "PROBLEM", 320, 334], ["decrease", "OBSERVATION_MODIFIER", 199, 207], ["increase", "OBSERVATION_MODIFIER", 308, 316], ["ICU infections", "OBSERVATION", 320, 334]]], ["So, this strategy seems safe while reducing the amount of systemic antibiotics used.", [["systemic antibiotics", "TREATMENT", 58, 78]]], ["A prospective and multi-center randomized controlled trial should be conducted to evaluate the optimal duration of the administration of systemic prophylactic antibiotics as a component of the SDD regimen.Compliance with ethical standardsConflict of interest ML received fees from 3 M, Aguettant, Amomed, Aspen, BioMerieux, MSD, Octapharma, Orion, Pfizer.Compliance with ethical standardsEthical approval In this observational retrospective study, based on the French legislation on biomedical research (articles L. 1121-1 paragraph 1 and R. 1121-3, Public Health Code), no ethical problems were present, which was confirmed by the Comit\u00e9 d'Ethique pour la Recherche en Anesth\u00e9sie-R\u00e9animation (CERAR) [16] .", [["A prospective and multi-center randomized controlled trial", "TREATMENT", 0, 58], ["systemic prophylactic antibiotics", "TREATMENT", 137, 170], ["the SDD regimen", "TREATMENT", 189, 204], ["ethical standards", "TREATMENT", 221, 238], ["ethical standards", "TREATMENT", 371, 388], ["Ethical approval", "TREATMENT", 388, 404], ["this observational retrospective study", "TEST", 408, 446], ["ethical problems", "PROBLEM", 574, 590], ["MSD", "ANATOMY", 324, 327], ["Octapharma", "ANATOMY", 329, 339], ["no", "UNCERTAINTY", 571, 573]]], ["The patients and their families were informed that their data could be used in this study during their ICU stay.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["this study", "TEST", 79, 89]]], ["The data were stored and treated according to the Commission Nationale de l'Informatique et des Libert\u00e9s (CNIL) authorization number 2018-32.Compliance with ethical standardsInformed consent The patients and their families were informed that their data could be used in this study during their ICU stay.", [["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["ethical standards", "TREATMENT", 157, 174], ["this study", "TEST", 270, 280]]]], "90b346cdbf21b53196c7b236fc1e228ad9dbdaa2": [["IntroductionOral diseases, including periodontitis (gum disease), are one of the most prevalent diseases globally [1, 2] .IntroductionThey also represent a significant public health problem and have major health and economic burdens for individuals, communities and society [2] .", [["IntroductionOral diseases", "DISEASE", 0, 25], ["periodontitis", "DISEASE", 37, 50], ["gum disease", "DISEASE", 52, 63], ["IntroductionOral diseases", "PROBLEM", 0, 25], ["periodontitis (gum disease)", "PROBLEM", 37, 64], ["a significant public health problem", "PROBLEM", 154, 189], ["diseases", "OBSERVATION", 17, 25], ["periodontitis", "OBSERVATION", 37, 50], ["gum disease", "OBSERVATION", 52, 63], ["most prevalent", "OBSERVATION_MODIFIER", 81, 95], ["diseases", "OBSERVATION", 96, 104], ["significant", "OBSERVATION_MODIFIER", 156, 167]]], ["In 2017, there were almost 800 million people globally with severe periodontitis [1] .", [["periodontitis", "DISEASE", 67, 80], ["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45], ["severe periodontitis", "PROBLEM", 60, 80], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["periodontitis", "OBSERVATION", 67, 80]]], ["Periodontitis is a chronic multifactorial infectious and inflammatory disease that not only leads to the destruction of tooth supporting tissues but can also have adverse systemic effects [3] .", [["tooth", "ANATOMY", 120, 125], ["tissues", "ANATOMY", 137, 144], ["Periodontitis", "DISEASE", 0, 13], ["tooth", "TISSUE", 120, 125], ["tissues", "TISSUE", 137, 144], ["Periodontitis", "PROBLEM", 0, 13], ["a chronic multifactorial infectious", "PROBLEM", 17, 52], ["inflammatory disease", "PROBLEM", 57, 77], ["the destruction of tooth supporting tissues", "PROBLEM", 101, 144], ["adverse systemic effects", "PROBLEM", 163, 187], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["multifactorial", "OBSERVATION_MODIFIER", 27, 41], ["infectious", "OBSERVATION", 42, 52], ["inflammatory", "OBSERVATION_MODIFIER", 57, 69], ["destruction", "OBSERVATION", 105, 116]]], ["Mounting 3 evidence in the literature suggests that periodontitis as a chronic low-burden inflammation is associated with several chronic systemic diseases, including diabetes, cardiovascular diseases (CVD), chronic obstructive pulmonary disease (COPD), hypertension, and cancer [4] [5] [6] [7] [8] [9] [10] .", [["cardiovascular", "ANATOMY", 177, 191], ["pulmonary", "ANATOMY", 228, 237], ["cancer", "ANATOMY", 272, 278], ["periodontitis", "DISEASE", 52, 65], ["inflammation", "DISEASE", 90, 102], ["systemic diseases", "DISEASE", 138, 155], ["diabetes", "DISEASE", 167, 175], ["cardiovascular diseases", "DISEASE", 177, 200], ["CVD", "DISEASE", 202, 205], ["chronic obstructive pulmonary disease", "DISEASE", 208, 245], ["COPD", "DISEASE", 247, 251], ["hypertension", "DISEASE", 254, 266], ["cancer", "DISEASE", 272, 278], ["[4] [5] [6] [7] [8] [9", "CHEMICAL", 279, 301], ["pulmonary", "ORGAN", 228, 237], ["cancer [4] [5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 272, 307], ["periodontitis", "PROBLEM", 52, 65], ["a chronic low-burden inflammation", "PROBLEM", 69, 102], ["several chronic systemic diseases", "PROBLEM", 122, 155], ["diabetes", "PROBLEM", 167, 175], ["cardiovascular diseases (CVD)", "PROBLEM", 177, 206], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 208, 252], ["hypertension", "PROBLEM", 254, 266], ["cancer", "PROBLEM", 272, 278], ["periodontitis", "OBSERVATION", 52, 65], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["low", "OBSERVATION_MODIFIER", 79, 82], ["burden", "OBSERVATION_MODIFIER", 83, 89], ["inflammation", "OBSERVATION", 90, 102], ["associated with", "UNCERTAINTY", 106, 121], ["several", "OBSERVATION_MODIFIER", 122, 129], ["chronic", "OBSERVATION_MODIFIER", 130, 137], ["systemic", "OBSERVATION_MODIFIER", 138, 146], ["diseases", "OBSERVATION", 147, 155], ["cardiovascular diseases", "OBSERVATION", 177, 200], ["chronic", "OBSERVATION_MODIFIER", 208, 215], ["obstructive", "OBSERVATION_MODIFIER", 216, 227], ["pulmonary", "ANATOMY", 228, 237], ["disease", "OBSERVATION", 238, 245], ["COPD", "OBSERVATION", 247, 251], ["hypertension", "OBSERVATION", 254, 266]]], ["These same systemic diseases, as well as old age, have been identified as risk factors for severe COVID-19 infections [11, 12] .IntroductionRecently, several studies have suggested hypotheses for the potential link between periodontitis and COVID-19 complications [13] [14] [15] [16] [17] [18] [19] [20] [21] .", [["systemic diseases", "DISEASE", 11, 28], ["COVID", "DISEASE", 98, 103], ["infections", "DISEASE", 107, 117], ["periodontitis", "DISEASE", 223, 236], ["COVID", "DISEASE", 241, 246], ["[13] [14] [15] [16] [17] [18] [19] [20]", "CHEMICAL", 264, 303], ["[13] [14] [15] [16] [17] [18] [19] [20]", "CHEMICAL", 264, 303], ["[13] [14] [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 264, 308], ["These same systemic diseases", "PROBLEM", 0, 28], ["severe COVID-19 infections", "PROBLEM", 91, 117], ["several studies", "TEST", 150, 165], ["the potential link between periodontitis", "PROBLEM", 196, 236], ["COVID", "TEST", 241, 246], ["systemic", "OBSERVATION_MODIFIER", 11, 19], ["diseases", "OBSERVATION", 20, 28]]], ["For example, bacterial superinfections have been common in severe COVID-19 cases, and the bacteria seem to be associated with the oral cavity [13] [14] [15] .", [["oral", "ANATOMY", 130, 134], ["COVID", "DISEASE", 66, 71], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["bacterial superinfections", "PROBLEM", 13, 38], ["severe COVID-19 cases", "PROBLEM", 59, 80], ["the bacteria", "PROBLEM", 86, 98], ["the oral cavity", "PROBLEM", 126, 141], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["superinfections", "OBSERVATION", 23, 38], ["severe", "OBSERVATION_MODIFIER", 59, 65]]], ["Periodontitis may elevate the risk of invasion by bacterial pathogens [3] , and potentially also viral pathogens such as SARS-CoV-2 [4, 20, 21] , as periodontitis leads, even in mild to moderate forms, to the ulceration of the gingival epithelium.IntroductionThis exposed, ulcerated and inflamed surface area can be of substantial size and is comparable with the surface area of the palm of a hand (8-20 cm 2 vs. 78 cm 2 , respectively) [22] .", [["gingival epithelium", "ANATOMY", 227, 246], ["surface area", "ANATOMY", 296, 308], ["surface area", "ANATOMY", 363, 375], ["hand", "ANATOMY", 393, 397], ["Periodontitis", "DISEASE", 0, 13], ["periodontitis", "DISEASE", 149, 162], ["SARS-CoV-2", "ORGANISM", 121, 131], ["gingival epithelium", "TISSUE", 227, 246], ["palm", "ORGANISM_SUBDIVISION", 383, 387], ["hand", "ORGANISM_SUBDIVISION", 393, 397], ["SARS-CoV", "SPECIES", 121, 129], ["Periodontitis", "PROBLEM", 0, 13], ["invasion", "PROBLEM", 38, 46], ["bacterial pathogens", "PROBLEM", 50, 69], ["viral pathogens", "PROBLEM", 97, 112], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["periodontitis leads", "PROBLEM", 149, 168], ["mild to moderate forms", "PROBLEM", 178, 200], ["the ulceration of the gingival epithelium", "PROBLEM", 205, 246], ["ulcerated and inflamed surface area", "PROBLEM", 273, 308], ["invasion", "OBSERVATION", 38, 46], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["pathogens", "OBSERVATION", 60, 69], ["viral pathogens", "OBSERVATION", 97, 112], ["periodontitis", "OBSERVATION", 149, 162], ["mild", "OBSERVATION_MODIFIER", 178, 182], ["moderate", "OBSERVATION_MODIFIER", 186, 194], ["ulceration", "OBSERVATION", 209, 219], ["gingival epithelium", "ANATOMY", 227, 246], ["ulcerated", "OBSERVATION_MODIFIER", 273, 282], ["inflamed", "OBSERVATION_MODIFIER", 287, 295], ["surface", "OBSERVATION_MODIFIER", 296, 303], ["substantial", "OBSERVATION_MODIFIER", 319, 330], ["size", "OBSERVATION_MODIFIER", 331, 335], ["comparable", "OBSERVATION_MODIFIER", 343, 353], ["surface", "OBSERVATION_MODIFIER", 363, 370], ["area", "OBSERVATION_MODIFIER", 371, 375], ["palm", "ANATOMY_MODIFIER", 383, 387], ["hand", "ANATOMY", 393, 397]]], ["Furthermore, periodontitis also increases the systemic inflammatory burden, as the inflamed periodontal tissues release host-derived proinflammatory cytokines and tissue destruction mediators to the circulatory system [3] .", [["periodontal tissues", "ANATOMY", 92, 111], ["tissue", "ANATOMY", 163, 169], ["circulatory system", "ANATOMY", 199, 217], ["periodontitis", "DISEASE", 13, 26], ["periodontal tissues", "TISSUE", 92, 111], ["tissue", "TISSUE", 163, 169], ["proinflammatory cytokines", "PROTEIN", 133, 158], ["periodontitis", "PROBLEM", 13, 26], ["the systemic inflammatory burden", "PROBLEM", 42, 74], ["the inflamed periodontal tissues", "PROBLEM", 79, 111], ["tissue destruction mediators", "PROBLEM", 163, 191], ["periodontitis", "OBSERVATION", 13, 26], ["increases", "OBSERVATION_MODIFIER", 32, 41], ["systemic", "OBSERVATION_MODIFIER", 46, 54], ["inflammatory", "OBSERVATION_MODIFIER", 55, 67], ["inflamed", "OBSERVATION_MODIFIER", 83, 91], ["periodontal tissues", "ANATOMY", 92, 111], ["proinflammatory cytokines", "OBSERVATION", 133, 158], ["circulatory system", "ANATOMY", 199, 217]]], ["This can activate acute-phase response in the liver and amplify systemic inflammation [3] .", [["liver", "ANATOMY", 46, 51], ["inflammation", "DISEASE", 73, 85], ["liver", "ORGAN", 46, 51], ["acute-phase response in the liver", "PROBLEM", 18, 51], ["systemic inflammation", "PROBLEM", 64, 85], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["liver", "ANATOMY", 46, 51], ["systemic", "OBSERVATION_MODIFIER", 64, 72], ["inflammation", "OBSERVATION", 73, 85]]], ["The cytokine storm in severe COVID-19 infections has many components common with the cytokine expression profile of periodontitis suggesting a possible link between periodontitis and COVID-19 infection and complications, as well [16] .IntroductionThe aforementioned studies support the importance of good oral health also during the current COVID-19 pandemic.", [["oral", "ANATOMY", 305, 309], ["infections", "DISEASE", 38, 48], ["periodontitis", "DISEASE", 116, 129], ["periodontitis", "DISEASE", 165, 178], ["infection", "DISEASE", 192, 201], ["oral", "ORGANISM_SUBDIVISION", 305, 309], ["cytokine", "PROTEIN", 4, 12], ["cytokine", "PROTEIN", 85, 93], ["The cytokine storm", "PROBLEM", 0, 18], ["severe COVID-19 infections", "PROBLEM", 22, 48], ["periodontitis", "PROBLEM", 116, 129], ["periodontitis", "PROBLEM", 165, 178], ["COVID-19 infection", "PROBLEM", 183, 201], ["complications", "PROBLEM", 206, 219], ["The aforementioned studies", "TEST", 247, 273], ["cytokine storm", "OBSERVATION", 4, 18], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["periodontitis", "OBSERVATION", 116, 129], ["periodontitis", "OBSERVATION", 165, 178], ["infection", "OBSERVATION", 192, 201]]], ["The spread of SARS-CoV-2 has been rapid.", [["SARS", "DISEASE", 14, 18], ["SARS-CoV-2", "ORGANISM", 14, 24], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "TEST", 14, 18], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["rapid", "OBSERVATION_MODIFIER", 34, 39]]], ["Already over 10 million people have been infected and more than 500,000 people have died of the COVID-19 disease globally.", [["people", "ORGANISM", 24, 30], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 24, 30], ["people", "SPECIES", 72, 78], ["the COVID-19 disease globally", "PROBLEM", 92, 121], ["infected", "OBSERVATION_MODIFIER", 41, 49]]], ["Senior citizens and individuals with underlying health conditions have been at higher risk of severe COVID-19 infections [23] [24] [25] .", [["COVID", "DISEASE", 101, 106], ["infections", "DISEASE", 110, 120], ["COVID-19", "CHEMICAL", 101, 109], ["underlying health conditions", "PROBLEM", 37, 65], ["severe COVID-19 infections", "PROBLEM", 94, 120]]], ["Moreover, the prevalence of underlying health conditions and periodontitis are higher among older individuals [1, 25] .IntroductionThis underscores the role of preventive oral health strategies with improvements in risk assessment and targeted disease prevention in reducing the disease burden of the COVID-19 pandemic.", [["oral", "ANATOMY", 171, 175], ["periodontitis", "DISEASE", 61, 74], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["underlying health conditions", "PROBLEM", 28, 56], ["periodontitis", "PROBLEM", 61, 74], ["preventive oral health strategies", "TREATMENT", 160, 193], ["risk assessment", "TEST", 215, 230], ["targeted disease prevention", "TREATMENT", 235, 262], ["the disease burden", "PROBLEM", 275, 293], ["the COVID", "TEST", 297, 306], ["pandemic", "PROBLEM", 310, 318], ["periodontitis", "OBSERVATION", 61, 74], ["disease", "OBSERVATION", 279, 286]]], ["4 This study proposes to evaluate if non-invasive oral fluid point-of-care tests based on biomarkers, such as active matrix metalloproteinase-8 (aMMP-8), could be beneficial for interdisciplinary screening and identification of individuals with severe periodontitis and active periodontal breakdown during COVID-19 pandemic to refer them to targeted periodontal disease prevention ( Figure 1 ).", [["oral", "ANATOMY", 50, 54], ["periodontal", "ANATOMY", 277, 288], ["periodontal", "ANATOMY", 350, 361], ["periodontitis", "DISEASE", 252, 265], ["periodontal disease", "DISEASE", 350, 369], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["matrix metalloproteinase-8", "GENE_OR_GENE_PRODUCT", 117, 143], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 145, 151], ["periodontal", "ORGAN", 277, 288], ["matrix metalloproteinase-8", "PROTEIN", 117, 143], ["aMMP", "PROTEIN", 145, 149], ["This study", "TEST", 2, 12], ["non-invasive oral fluid point", "TEST", 37, 66], ["care tests", "TEST", 70, 80], ["biomarkers", "TEST", 90, 100], ["active matrix metalloproteinase", "TEST", 110, 141], ["aMMP", "TEST", 145, 149], ["interdisciplinary screening", "TEST", 178, 205], ["individuals", "PROBLEM", 228, 239], ["severe periodontitis", "PROBLEM", 245, 265], ["active periodontal breakdown", "PROBLEM", 270, 298], ["COVID", "TEST", 306, 311], ["targeted periodontal disease prevention", "PROBLEM", 341, 380], ["severe", "OBSERVATION_MODIFIER", 245, 251], ["periodontitis", "OBSERVATION", 252, 265], ["active", "OBSERVATION_MODIFIER", 270, 276], ["periodontal", "ANATOMY", 277, 288], ["periodontal", "ANATOMY", 350, 361], ["disease", "OBSERVATION", 362, 369]]], ["Periodontitis could be associated with severe COVID-19 infections.", [["Periodontitis", "DISEASE", 0, 13], ["infections", "DISEASE", 55, 65], ["Periodontitis", "PROBLEM", 0, 13], ["severe COVID-19 infections", "PROBLEM", 39, 65], ["could be associated with", "UNCERTAINTY", 14, 38], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["infections", "OBSERVATION", 55, 65]]], ["Thus, the proposed preventive oral health strategy with point-of-care testing could mitigate the risk of adverse systemic effects of periodontitis and possibly also the risk of severe COVID-19 infections, especially among older patients and those with underlying health conditions.", [["oral", "ANATOMY", 30, 34], ["periodontitis", "DISEASE", 133, 146], ["infections", "DISEASE", 193, 203], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["care testing", "TEST", 65, 77], ["adverse systemic effects", "PROBLEM", 105, 129], ["periodontitis", "PROBLEM", 133, 146], ["severe COVID-19 infections", "PROBLEM", 177, 203], ["underlying health conditions", "PROBLEM", 252, 280], ["periodontitis", "OBSERVATION", 133, 146], ["severe", "OBSERVATION_MODIFIER", 177, 183]]], ["Moreover, it could also increase awareness of periodontal disease among individuals and encourage them to seek oral care before disease has progressed to severe stage.Point-of-care oral fluid testing in periodontitis diagnosticsTypically, patients suffering from periodontitis are mostly not aware of their disease especially in the early phase because the oral symptoms are often painless and subclinical.", [["periodontal", "ANATOMY", 46, 57], ["oral", "ANATOMY", 111, 115], ["oral", "ANATOMY", 181, 185], ["oral", "ANATOMY", 357, 361], ["periodontal disease", "DISEASE", 46, 65], ["periodontitis", "DISEASE", 203, 216], ["periodontitis", "DISEASE", 263, 276], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["oral", "ORGANISM_SUBDIVISION", 181, 185], ["patients", "ORGANISM", 239, 247], ["oral", "ORGANISM_SUBDIVISION", 357, 361], ["patients", "SPECIES", 239, 247], ["periodontal disease", "PROBLEM", 46, 65], ["oral care", "TREATMENT", 111, 120], ["disease", "PROBLEM", 128, 135], ["severe stage", "PROBLEM", 154, 166], ["oral fluid testing", "TEST", 181, 199], ["periodontitis diagnostics", "TEST", 203, 228], ["periodontitis", "PROBLEM", 263, 276], ["their disease", "PROBLEM", 301, 314], ["the oral symptoms", "PROBLEM", 353, 370], ["painless", "PROBLEM", 381, 389], ["periodontal", "ANATOMY", 46, 57], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["periodontitis", "OBSERVATION", 203, 216], ["periodontitis", "OBSERVATION", 263, 276], ["disease", "OBSERVATION", 307, 314]]], ["As periodontitis advances and symptoms become more apparent that is usually the time when patients start to seek care.", [["periodontitis", "DISEASE", 3, 16], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["periodontitis", "PROBLEM", 3, 16], ["symptoms", "PROBLEM", 30, 38], ["periodontitis", "OBSERVATION", 3, 16]]], ["However, the loss of tooth supporting periodontal tissues is usually irreversible in periodontitis.", [["tooth", "ANATOMY", 21, 26], ["periodontal tissues", "ANATOMY", 38, 57], ["periodontitis", "DISEASE", 85, 98], ["tooth", "TISSUE", 21, 26], ["periodontal tissues", "TISSUE", 38, 57], ["the loss of tooth supporting periodontal tissues", "PROBLEM", 9, 57], ["periodontitis", "PROBLEM", 85, 98], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["tooth", "ANATOMY", 21, 26], ["periodontal tissues", "ANATOMY", 38, 57], ["irreversible", "OBSERVATION_MODIFIER", 69, 81], ["periodontitis", "OBSERVATION", 85, 98]]], ["As periodontitis becomes more generalized, the local inflammation might markedly extend its effect into the systemic circulation.", [["periodontitis", "DISEASE", 3, 16], ["inflammation", "DISEASE", 53, 65], ["periodontitis", "PROBLEM", 3, 16], ["the local inflammation", "PROBLEM", 43, 65], ["periodontitis", "OBSERVATION", 3, 16], ["more", "OBSERVATION_MODIFIER", 25, 29], ["generalized", "OBSERVATION_MODIFIER", 30, 41], ["local", "OBSERVATION_MODIFIER", 47, 52], ["inflammation", "OBSERVATION", 53, 65], ["systemic circulation", "ANATOMY", 108, 128]]], ["Therefore, early and accurate diagnosis of periodontitis is crucial in controlling periodontitis and preventing further attachment loss and disease progression.Point-of-care oral fluid testing in periodontitis diagnosticsPeriodontitis is diagnosed based on clinical and radiographic examination [26, 27] .", [["oral", "ANATOMY", 174, 178], ["periodontitis", "DISEASE", 43, 56], ["periodontitis", "DISEASE", 83, 96], ["attachment loss", "DISEASE", 120, 135], ["periodontitis", "DISEASE", 196, 209], ["Periodontitis", "DISEASE", 221, 234], ["oral", "ORGANISM_SUBDIVISION", 174, 178], ["periodontitis", "PROBLEM", 43, 56], ["controlling periodontitis", "PROBLEM", 71, 96], ["further attachment loss", "PROBLEM", 112, 135], ["disease progression", "PROBLEM", 140, 159], ["oral fluid testing", "TEST", 174, 192], ["periodontitis diagnostics", "TEST", 196, 221], ["Periodontitis", "PROBLEM", 221, 234], ["radiographic examination", "TEST", 270, 294], ["periodontitis", "OBSERVATION", 43, 56], ["periodontitis", "OBSERVATION", 83, 96], ["attachment loss", "OBSERVATION", 120, 135], ["disease", "OBSERVATION_MODIFIER", 140, 147], ["progression", "OBSERVATION_MODIFIER", 148, 159], ["periodontitis", "OBSERVATION", 196, 209]]], ["The examination includes clinical measurements such as clinical attachment level and bleeding on probing by using a periodontal probe.", [["bleeding", "DISEASE", 85, 93], ["The examination", "TEST", 0, 15], ["clinical measurements", "TEST", 25, 46], ["clinical attachment level", "TEST", 55, 80], ["bleeding", "PROBLEM", 85, 93], ["a periodontal probe", "TREATMENT", 114, 133], ["bleeding", "OBSERVATION", 85, 93]]], ["These classical oral diagnostic methods provide information about the extent and severity of periodontitis and the degree of past attachment loss.", [["oral", "ANATOMY", 16, 20], ["periodontitis", "DISEASE", 93, 106], ["attachment loss", "DISEASE", 130, 145], ["oral", "ORGANISM_SUBDIVISION", 16, 20], ["periodontitis", "PROBLEM", 93, 106], ["past attachment loss", "PROBLEM", 125, 145], ["periodontitis", "OBSERVATION", 93, 106], ["attachment loss", "OBSERVATION", 130, 145]]], ["However, accurately identifying patients with periodontitis, especially its initial/early stage, requires lots of training and experience [27] .", [["periodontitis", "DISEASE", 46, 59], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["periodontitis", "PROBLEM", 46, 59], ["periodontitis", "OBSERVATION", 46, 59]]], ["Furthermore, it is 5 still unclear whether the clinical measurements alone are accurate enough to monitor disease activity, progression and treatment effects for all patients [27] [28] [29] .", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["the clinical measurements", "TEST", 43, 68], ["disease activity", "PROBLEM", 106, 122]]], ["This is where accurate biomarkers come in.Point-of-care oral fluid testing in periodontitis diagnosticsPoint-of-care oral fluid biomarker research has actively sought for suitable biomarker(s) and methods to improve the accuracy of oral health and periodontal disease diagnostics [27] [28] [29] .", [["oral", "ANATOMY", 56, 60], ["oral", "ANATOMY", 117, 121], ["oral", "ANATOMY", 232, 236], ["periodontal", "ANATOMY", 248, 259], ["periodontitis", "DISEASE", 78, 91], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["oral", "ORGANISM_SUBDIVISION", 117, 121], ["oral", "ORGANISM_SUBDIVISION", 232, 236], ["oral fluid testing", "TEST", 56, 74], ["periodontitis diagnostics", "TEST", 78, 103], ["oral fluid biomarker", "TEST", 117, 137], ["periodontal disease diagnostics", "TEST", 248, 279], ["periodontitis", "OBSERVATION", 78, 91], ["periodontal", "ANATOMY", 248, 259]]], ["This is very important because of the aforementioned limitations related to the classical oral diagnostic methods.", [["oral", "ANATOMY", 90, 94], ["oral", "ORGANISM_SUBDIVISION", 90, 94]]], ["Oral fluids (e.g., mouth rinse, saliva, gingival crevicular fluid [GCF], peri-implant sulcular fluid [PISF]) contain several locally and systemically derived biomarkers associated with periodontitis, which makes them a potential diagnostic medium for periodontitis [30, 31] .", [["Oral", "ANATOMY", 0, 4], ["mouth", "ANATOMY", 19, 24], ["saliva", "ANATOMY", 32, 38], ["gingival crevicular fluid", "ANATOMY", 40, 65], ["GCF", "ANATOMY", 67, 70], ["peri-implant sulcular fluid", "ANATOMY", 73, 100], ["PISF", "ANATOMY", 102, 106], ["periodontitis", "DISEASE", 185, 198], ["periodontitis", "DISEASE", 251, 264], ["saliva", "ORGANISM_SUBSTANCE", 32, 38], ["gingival crevicular fluid", "ORGANISM_SUBSTANCE", 40, 65], ["GCF", "ORGANISM_SUBSTANCE", 67, 70], ["Oral fluids (e.g., mouth rinse", "TREATMENT", 0, 30], ["saliva, gingival crevicular fluid [GCF], peri-implant sulcular fluid [PISF])", "TREATMENT", 32, 108], ["periodontitis", "PROBLEM", 185, 198], ["periodontitis", "PROBLEM", 251, 264], ["gingival crevicular", "ANATOMY", 40, 59], ["periodontitis", "OBSERVATION", 185, 198]]], ["Unlike periodontal probing and associated bacteremia [32] , collection of oral fluids can be done in an atraumatic, non-invasive and sterile way that reduces the risk of bacteremia to the barest minimum [28, 29, 31] .", [["periodontal", "ANATOMY", 7, 18], ["oral", "ANATOMY", 74, 78], ["bacteremia", "DISEASE", 42, 52], ["bacteremia", "DISEASE", 170, 180], ["oral", "ORGANISM_SUBDIVISION", 74, 78], ["periodontal probing", "PROBLEM", 7, 26], ["associated bacteremia", "PROBLEM", 31, 52], ["oral fluids", "TREATMENT", 74, 85], ["an atraumatic, non-invasive and sterile way", "TREATMENT", 101, 144], ["bacteremia", "PROBLEM", 170, 180], ["periodontal", "OBSERVATION_MODIFIER", 7, 18], ["probing", "OBSERVATION", 19, 26], ["bacteremia", "OBSERVATION", 42, 52], ["atraumatic", "OBSERVATION", 104, 114], ["bacteremia", "OBSERVATION", 170, 180]]], ["Many potential biomarkers for periodontal disease have been studied and identified including, but not limiting to, macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1), neutrophil elastase, interleukin-1\u03b2 (IL-1\u03b2), myeloperoxidase and neutrophil collagenase, also known as matrix metalloproteinase-8 (MMP-8) and gelatinase B, also known as matrix metalloproteinase-9 (MMP-9) [33] [34] [35] .", [["periodontal", "ANATOMY", 30, 41], ["periodontal disease", "DISEASE", 30, 49], ["macrophage inflammatory protein-1\u03b1", "GENE_OR_GENE_PRODUCT", 115, 149], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 151, 157], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 160, 179], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 181, 195], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 197, 202], ["myeloperoxidase", "SIMPLE_CHEMICAL", 205, 220], ["neutrophil collagenase", "GENE_OR_GENE_PRODUCT", 225, 247], ["matrix metalloproteinase-8", "GENE_OR_GENE_PRODUCT", 263, 289], ["MMP-8", "GENE_OR_GENE_PRODUCT", 291, 296], ["gelatinase B", "GENE_OR_GENE_PRODUCT", 302, 314], ["matrix metalloproteinase-9", "GENE_OR_GENE_PRODUCT", 330, 356], ["MMP-9", "GENE_OR_GENE_PRODUCT", 358, 363], ["[33] [34] [35]", "SIMPLE_CHEMICAL", 365, 379], ["macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1", "PROTEIN", 115, 157], ["neutrophil elastase", "PROTEIN", 160, 179], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 181, 202], ["myeloperoxidase", "PROTEIN", 205, 220], ["neutrophil collagenase", "PROTEIN", 225, 247], ["matrix metalloproteinase-8 (MMP-8", "PROTEIN", 263, 296], ["gelatinase B", "PROTEIN", 302, 314], ["matrix metalloproteinase-9 (MMP-9", "PROTEIN", 330, 363], ["periodontal disease", "PROBLEM", 30, 49], ["macrophage inflammatory protein", "TEST", 115, 146], ["MIP", "TEST", 151, 154], ["neutrophil elastase", "TEST", 160, 179], ["interleukin", "TEST", 181, 192], ["IL", "TEST", 197, 199], ["myeloperoxidase", "TEST", 205, 220], ["neutrophil collagenase", "TEST", 225, 247], ["matrix metalloproteinase", "TEST", 263, 287], ["MMP", "TEST", 291, 294], ["gelatinase B", "TEST", 302, 314], ["matrix metalloproteinase", "TEST", 330, 354], ["MMP", "TEST", 358, 361], ["not limiting", "UNCERTAINTY", 98, 110], ["neutrophil elastase", "ANATOMY", 160, 179], ["neutrophil collagenase", "OBSERVATION", 225, 247]]], ["Most potential biomarkers, in saliva, include MMP-8, MMP-9, IL-1\u03b2, MIP-1\u03b1 and, in GCF, MMP-8 and neutrophil elastase [33] [34] [35] .", [["saliva", "ORGANISM_SUBSTANCE", 30, 36], ["MMP-8", "GENE_OR_GENE_PRODUCT", 46, 51], ["MMP-9", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 60, 65], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 67, 73], ["GCF", "GENE_OR_GENE_PRODUCT", 82, 85], ["MMP-8", "GENE_OR_GENE_PRODUCT", 87, 92], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 97, 116], ["MMP-8", "PROTEIN", 46, 51], ["MMP-9", "PROTEIN", 53, 58], ["IL-1\u03b2", "PROTEIN", 60, 65], ["MIP-1\u03b1", "PROTEIN", 67, 73], ["GCF", "PROTEIN", 82, 85], ["MMP-8", "PROTEIN", 87, 92], ["neutrophil elastase", "PROTEIN", 97, 116], ["potential biomarkers", "TEST", 5, 25], ["saliva", "TEST", 30, 36], ["MMP", "TEST", 46, 49], ["MMP", "TEST", 53, 56], ["IL", "TEST", 60, 62], ["MIP", "TEST", 67, 70], ["GCF", "TEST", 82, 85], ["MMP", "TEST", 87, 90], ["neutrophil elastase", "TEST", 97, 116]]], ["Recently, aMMP-8 was proposed as a diagnostic biomarker for the updated periodontitis classification system [27] and presented a lower risk of false positives compared to traditionally used clinical measures of bleeding on probing [36] .Matrix metalloproteinase-8 (MMP-8)Matrix metalloproteinase-8 (MMP-8, neutrophil collagenase or collagenase-2) is a member of matrix metalloproteinases (MMPs) family of genetically distinct but structurally related endopeptidases.", [["periodontitis", "DISEASE", 72, 85], ["bleeding", "DISEASE", 211, 219], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 10, 16], ["Matrix metalloproteinase-8", "GENE_OR_GENE_PRODUCT", 237, 263], ["MMP-8", "GENE_OR_GENE_PRODUCT", 265, 270], ["Matrix metalloproteinase-8", "GENE_OR_GENE_PRODUCT", 271, 297], ["MMP-8", "GENE_OR_GENE_PRODUCT", 299, 304], ["neutrophil collagenase", "GENE_OR_GENE_PRODUCT", 306, 328], ["collagenase-2", "GENE_OR_GENE_PRODUCT", 332, 345], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 362, 387], ["MMPs", "GENE_OR_GENE_PRODUCT", 389, 393], ["aMMP", "PROTEIN", 10, 14], ["Matrix metalloproteinase-8 (MMP-8)Matrix metalloproteinase-8", "PROTEIN", 237, 297], ["MMP-8", "PROTEIN", 299, 304], ["neutrophil collagenase", "PROTEIN", 306, 328], ["collagenase", "PROTEIN", 332, 343], ["matrix metalloproteinases (MMPs) family", "PROTEIN", 362, 401], ["endopeptidases", "PROTEIN", 451, 465], ["aMMP", "TEST", 10, 14], ["a diagnostic biomarker", "TEST", 33, 55], ["the updated periodontitis classification system", "PROBLEM", 60, 107], ["false positives", "PROBLEM", 143, 158], ["bleeding", "PROBLEM", 211, 219], ["Matrix metalloproteinase", "TEST", 237, 261], ["MMP", "TEST", 265, 268], ["Matrix metalloproteinase", "TEST", 271, 295], ["MMP", "TEST", 299, 302], ["neutrophil collagenase or collagenase", "TREATMENT", 306, 343], ["matrix metalloproteinases (MMPs)", "TREATMENT", 362, 394], ["structurally related endopeptidases", "PROBLEM", 430, 465], ["false positives", "OBSERVATION", 143, 158]]], ["MMPs have catalytic properties responsible for tissue remodeling and degradation of structural components of the extracellular matrix (ECM) [37] .", [["tissue", "ANATOMY", 47, 53], ["extracellular matrix", "ANATOMY", 113, 133], ["ECM", "ANATOMY", 135, 138], ["MMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue", "TISSUE", 47, 53], ["extracellular matrix", "CELLULAR_COMPONENT", 113, 133], ["ECM", "CELLULAR_COMPONENT", 135, 138], ["MMPs", "PROTEIN", 0, 4], ["tissue remodeling", "PROBLEM", 47, 64], ["for tissue", "OBSERVATION_MODIFIER", 43, 53], ["remodeling", "OBSERVATION", 54, 64], ["structural", "OBSERVATION_MODIFIER", 84, 94], ["components", "OBSERVATION_MODIFIER", 95, 105], ["extracellular matrix", "ANATOMY", 113, 133]]], ["MMP-8 degrades particularly interstitial collagens (types I-III), which are important structural components of the extracellular matrix [37] [38] [39] .", [["interstitial collagens", "ANATOMY", 28, 50], ["extracellular matrix", "ANATOMY", 115, 135], ["MMP-8", "GENE_OR_GENE_PRODUCT", 0, 5], ["collagens", "GENE_OR_GENE_PRODUCT", 41, 50], ["types I-III", "GENE_OR_GENE_PRODUCT", 52, 63], ["extracellular matrix", "CELLULAR_COMPONENT", 115, 135], ["MMP-8", "PROTEIN", 0, 5], ["interstitial collagens", "PROTEIN", 28, 50], ["I-III", "PROTEIN", 58, 63], ["MMP", "TEST", 0, 3], ["interstitial collagens", "PROBLEM", 28, 50], ["interstitial", "ANATOMY_MODIFIER", 28, 40], ["collagens", "OBSERVATION", 41, 50]]], ["The enzyme also degrades non-matrix bioactive proteins such as pro-and anti-inflammatory cytokines, chemokines, insulin-receptor, fibrinogen, angiotensin, bradykinin and several others [37] [38] [39] .", [["angiotensin", "CHEMICAL", 142, 153], ["bradykinin", "CHEMICAL", 155, 165], ["bradykinin", "CHEMICAL", 155, 165], ["insulin-receptor", "GENE_OR_GENE_PRODUCT", 112, 128], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 130, 140], ["angiotensin", "SIMPLE_CHEMICAL", 142, 153], ["bradykinin", "SIMPLE_CHEMICAL", 155, 165], ["[37] [38] [39]", "SIMPLE_CHEMICAL", 185, 199], ["non-matrix bioactive proteins", "PROTEIN", 25, 54], ["pro-and anti-inflammatory cytokines", "PROTEIN", 63, 98], ["chemokines", "PROTEIN", 100, 110], ["insulin-receptor", "PROTEIN", 112, 128], ["fibrinogen", "PROTEIN", 130, 140], ["The enzyme", "TEST", 0, 10], ["non-matrix bioactive proteins", "PROBLEM", 25, 54], ["pro-and anti-inflammatory cytokines", "TREATMENT", 63, 98], ["chemokines", "TREATMENT", 100, 110], ["insulin", "TREATMENT", 112, 119], ["fibrinogen", "TEST", 130, 140], ["angiotensin", "TREATMENT", 142, 153], ["bradykinin", "TEST", 155, 165]]], ["MMP-8 was first found/identified in neutrophils, but 6 MMP-8 expression has been observed in other cells such as chondrocytes, human rheumatoid synovial fibroblasts, smooth muscle cells and activated macrophages [37] .", [["neutrophils", "ANATOMY", 36, 47], ["cells", "ANATOMY", 99, 104], ["chondrocytes", "ANATOMY", 113, 125], ["rheumatoid synovial fibroblasts", "ANATOMY", 133, 164], ["smooth muscle cells", "ANATOMY", 166, 185], ["macrophages", "ANATOMY", 200, 211], ["MMP-8", "GENE_OR_GENE_PRODUCT", 0, 5], ["neutrophils", "CELL", 36, 47], ["MMP-8", "GENE_OR_GENE_PRODUCT", 55, 60], ["cells", "CELL", 99, 104], ["chondrocytes", "CELL", 113, 125], ["human", "ORGANISM", 127, 132], ["rheumatoid synovial fibroblasts", "CELL", 133, 164], ["smooth muscle cells", "CELL", 166, 185], ["macrophages", "CELL", 200, 211], ["MMP-8", "PROTEIN", 0, 5], ["neutrophils", "CELL_TYPE", 36, 47], ["MMP", "PROTEIN", 55, 58], ["chondrocytes", "CELL_TYPE", 113, 125], ["human rheumatoid synovial fibroblasts", "CELL_TYPE", 127, 164], ["smooth muscle cells", "CELL_TYPE", 166, 185], ["activated macrophages", "CELL_TYPE", 190, 211], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["MMP", "TEST", 0, 3], ["neutrophils", "TEST", 36, 47], ["MMP", "TEST", 55, 58], ["chondrocytes", "PROBLEM", 113, 125], ["human rheumatoid synovial fibroblasts", "PROBLEM", 127, 164], ["smooth muscle cells", "PROBLEM", 166, 185], ["activated macrophages", "PROBLEM", 190, 211], ["neutrophils", "ANATOMY", 36, 47], ["chondrocytes", "ANATOMY", 113, 125], ["rheumatoid synovial fibroblasts", "OBSERVATION", 133, 164], ["smooth muscle cells", "OBSERVATION", 166, 185], ["macrophages", "OBSERVATION_MODIFIER", 200, 211]]], ["Furthermore, various inflammatory cytokines, for example, IL-1\u03b2, tumor necrosis factor-\uf061 CD40 ligand (CD40L), can induce and upregulate the expression of MMP-8 [37] .", [["necrosis", "DISEASE", 71, 79], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["tumor necrosis factor-\uf061 CD40 ligand", "GENE_OR_GENE_PRODUCT", 65, 100], ["CD40L", "GENE_OR_GENE_PRODUCT", 102, 107], ["MMP-8", "GENE_OR_GENE_PRODUCT", 154, 159], ["inflammatory cytokines", "PROTEIN", 21, 43], ["IL-1\u03b2", "PROTEIN", 58, 63], ["tumor necrosis factor-\uf061 CD40 ligand", "PROTEIN", 65, 100], ["CD40L", "PROTEIN", 102, 107], ["MMP", "PROTEIN", 154, 157], ["various inflammatory cytokines", "PROBLEM", 13, 43], ["IL", "TEST", 58, 60], ["tumor necrosis factor", "PROBLEM", 65, 86], ["MMP", "TEST", 154, 157], ["various", "OBSERVATION_MODIFIER", 13, 20], ["inflammatory cytokines", "OBSERVATION", 21, 43], ["tumor", "OBSERVATION_MODIFIER", 65, 70], ["necrosis", "OBSERVATION", 71, 79]]], ["PMN-derived MMP-8 is stored in latent pro-MMP-8 form and is activated to aMMP-8 when released at inflammatory sites.", [["PMN", "ANATOMY", 0, 3], ["PMN", "CELL", 0, 3], ["MMP-8", "GENE_OR_GENE_PRODUCT", 12, 17], ["pro-MMP-8", "GENE_OR_GENE_PRODUCT", 38, 47], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 73, 79], ["PMN", "CELL_TYPE", 0, 3], ["MMP-8", "PROTEIN", 12, 17], ["latent pro-MMP-8 form", "PROTEIN", 31, 52], ["aMMP-8", "PROTEIN", 73, 79], ["PMN", "TEST", 0, 3], ["MMP", "TEST", 12, 15], ["aMMP", "TEST", 73, 77], ["inflammatory", "OBSERVATION", 97, 109]]], ["The activity of MMP-8 in the tissue is regulated by a complex network of enzymatic activators and inhibitors and degranulating stimuli [37, 38] .", [["tissue", "ANATOMY", 29, 35], ["MMP-8", "GENE_OR_GENE_PRODUCT", 16, 21], ["tissue", "TISSUE", 29, 35], ["MMP-8", "PROTEIN", 16, 21], ["MMP", "TEST", 16, 19], ["enzymatic activators", "TREATMENT", 73, 93], ["inhibitors", "TREATMENT", 98, 108], ["degranulating stimuli", "TEST", 113, 134], ["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["The imbalance between MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs) is believed to initiate the degradation of the ECM, basement membrane, and alveolar bone, and eventually periodontal disease [37, 38] .", [["ECM", "ANATOMY", 133, 136], ["basement membrane", "ANATOMY", 138, 155], ["alveolar bone", "ANATOMY", 161, 174], ["periodontal", "ANATOMY", 191, 202], ["periodontal disease", "DISEASE", 191, 210], ["MMPs", "GENE_OR_GENE_PRODUCT", 22, 26], ["tissue inhibitors of matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 31, 77], ["TIMPs", "GENE_OR_GENE_PRODUCT", 79, 84], ["ECM", "CELLULAR_COMPONENT", 133, 136], ["basement membrane", "CELLULAR_COMPONENT", 138, 155], ["alveolar bone", "TISSUE", 161, 174], ["MMPs", "PROTEIN", 22, 26], ["tissue inhibitors of matrix metalloproteinases", "PROTEIN", 31, 77], ["TIMPs", "PROTEIN", 79, 84], ["The imbalance", "PROBLEM", 0, 13], ["MMPs and tissue inhibitors of matrix metalloproteinases", "TREATMENT", 22, 77], ["the degradation of the ECM, basement membrane, and alveolar bone", "PROBLEM", 110, 174], ["eventually periodontal disease", "PROBLEM", 180, 210], ["imbalance", "OBSERVATION", 4, 13], ["alveolar bone", "ANATOMY", 161, 174]]], ["Moreover, periodontopathogenic bacteria T. denticola and P. gingivalis can increase the activation of MMP-8 with their proteases, as well [37, 38] .", [["T. denticola", "ORGANISM", 40, 52], ["P. gingivalis", "ORGANISM", 57, 70], ["MMP-8", "GENE_OR_GENE_PRODUCT", 102, 107], ["MMP-8", "PROTEIN", 102, 107], ["proteases", "PROTEIN", 119, 128], ["T. denticola", "SPECIES", 40, 52], ["P. gingivalis", "SPECIES", 57, 70], ["T. denticola", "SPECIES", 40, 52], ["P. gingivalis", "SPECIES", 57, 70], ["periodontopathogenic bacteria T. denticola", "PROBLEM", 10, 52], ["P. gingivalis", "PROBLEM", 57, 70], ["MMP", "TEST", 102, 105]]], ["MMP-8 seems to have a role in several chronic inflammatory diseases such as diabetes, rheumatoid arthritis, dental peri-implantitis, and particularly periodontal disease [37] [38] [39] .Active MMP-8 (aMMP-8) mouthrinse point-of-care testAccording to several studies, the excessive elevation and activation of MMP-8 (aMMP-8) is linked to the progression of periodontitis, which is also reflected in oral fluids [40] [41] [42] .", [["periodontal", "ANATOMY", 150, 161], ["oral", "ANATOMY", 398, 402], ["diabetes", "DISEASE", 76, 84], ["rheumatoid arthritis", "DISEASE", 86, 106], ["dental peri-implantitis", "DISEASE", 108, 131], ["periodontal disease", "DISEASE", 150, 169], ["aMMP-8", "CHEMICAL", 200, 206], ["periodontitis", "DISEASE", 356, 369], ["MMP-8", "GENE_OR_GENE_PRODUCT", 0, 5], ["MMP-8", "GENE_OR_GENE_PRODUCT", 193, 198], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 200, 206], ["MMP-8", "GENE_OR_GENE_PRODUCT", 309, 314], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 316, 322], ["oral", "ORGANISM_SUBDIVISION", 398, 402], ["MMP-8", "PROTEIN", 0, 5], ["MMP", "PROTEIN", 193, 196], ["MMP-8", "PROTEIN", 309, 314], ["aMMP-8", "PROTEIN", 316, 322], ["MMP", "TEST", 0, 3], ["several chronic inflammatory diseases", "PROBLEM", 30, 67], ["diabetes", "PROBLEM", 76, 84], ["rheumatoid arthritis", "PROBLEM", 86, 106], ["dental peri-implantitis", "PROBLEM", 108, 131], ["particularly periodontal disease", "PROBLEM", 137, 169], ["Active MMP", "TEST", 186, 196], ["aMMP", "TEST", 200, 204], ["several studies", "TEST", 250, 265], ["the excessive elevation", "PROBLEM", 267, 290], ["MMP", "TEST", 309, 312], ["aMMP", "TEST", 316, 320], ["periodontitis", "PROBLEM", 356, 369], ["several", "OBSERVATION_MODIFIER", 30, 37], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["inflammatory", "OBSERVATION", 46, 58], ["diabetes", "OBSERVATION", 76, 84], ["rheumatoid arthritis", "OBSERVATION", 86, 106], ["dental", "ANATOMY", 108, 114], ["peri-implantitis", "OBSERVATION", 115, 131], ["periodontal", "ANATOMY", 150, 161], ["excessive", "OBSERVATION_MODIFIER", 271, 280], ["elevation", "OBSERVATION", 281, 290], ["progression", "OBSERVATION_MODIFIER", 341, 352], ["periodontitis", "OBSERVATION", 356, 369]]], ["However, this is not the case regarding total or latent MMP-8 [40] [41] [42] [43] [44] .", [["MMP-8 [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 56, 86], ["MMP", "PROTEIN", 56, 59], ["latent MMP", "TEST", 49, 59]]], ["Monitoring aMMP-8 levels in oral fluids can be utilized in the assessment of the risk of increased collagenolytic activity and disease progression [36] .", [["oral fluids", "ANATOMY", 28, 39], ["aMMP-8", "CHEMICAL", 11, 17], ["aMMP-8", "CHEMICAL", 11, 17], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 11, 17], ["oral", "ORGANISM_SUBDIVISION", 28, 32], ["aMMP", "PROTEIN", 11, 15], ["Monitoring aMMP", "TEST", 0, 15], ["oral fluids", "TREATMENT", 28, 39], ["the assessment", "TEST", 59, 73], ["increased collagenolytic activity", "PROBLEM", 89, 122], ["disease progression", "PROBLEM", 127, 146], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["collagenolytic activity", "OBSERVATION", 99, 122]]], ["Increased levels of aMMP-8 indicate patients at risk of periodontal disease and requiring periodontal examination and evaluation of treatment needs [36] .", [["periodontal", "ANATOMY", 56, 67], ["periodontal", "ANATOMY", 90, 101], ["periodontal disease", "DISEASE", 56, 75], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 20, 26], ["patients", "ORGANISM", 36, 44], ["periodontal", "ORGAN", 56, 67], ["aMMP-8", "PROTEIN", 20, 26], ["patients", "SPECIES", 36, 44], ["Increased levels", "PROBLEM", 0, 16], ["aMMP", "TEST", 20, 24], ["periodontal disease", "PROBLEM", 56, 75], ["periodontal examination", "TEST", 90, 113], ["evaluation", "TEST", 118, 128], ["treatment needs", "TREATMENT", 132, 147], ["periodontal", "ANATOMY", 56, 67], ["disease", "OBSERVATION", 68, 75]]], ["Low levels of aMMP-8 represent a low risk of periodontal disease activity, which can be interpreted as a sign of controlled or eliminated active periodontal disease in the periodontal treatment and maintenance phase [36, 45] .Active MMP-8 (aMMP-8) mouthrinse point-of-care testThe screening procedure with the aMMP-8 mouthrinse point-of-care test is simple, low-cost and requires no professional dental equipment and expertise.", [["periodontal", "ANATOMY", 45, 56], ["periodontal", "ANATOMY", 145, 156], ["periodontal", "ANATOMY", 172, 183], ["periodontal disease", "DISEASE", 145, 164], ["aMMP-8", "CHEMICAL", 240, 246], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 14, 20], ["periodontal", "ORGAN", 45, 56], ["MMP-8", "GENE_OR_GENE_PRODUCT", 233, 238], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 240, 246], ["aMMP-8", "PROTEIN", 14, 20], ["MMP", "PROTEIN", 233, 236], ["aMMP", "TEST", 14, 18], ["periodontal disease activity", "PROBLEM", 45, 73], ["eliminated active periodontal disease", "PROBLEM", 127, 164], ["the periodontal treatment", "TREATMENT", 168, 193], ["Active MMP", "TEST", 226, 236], ["aMMP", "TEST", 240, 244], ["The screening procedure", "TREATMENT", 277, 300], ["the aMMP", "TEST", 306, 314], ["professional dental equipment", "TREATMENT", 383, 412], ["low risk", "OBSERVATION_MODIFIER", 33, 41], ["periodontal disease", "OBSERVATION", 45, 64], ["active", "OBSERVATION_MODIFIER", 138, 144], ["periodontal disease", "OBSERVATION", 145, 164], ["periodontal", "ANATOMY", 172, 183]]], ["Patients simply rinse with the provided sterile water, which is then quantitatively analyzed by using a reader-equipped lateral flow immunoassay within five minutes [45, 46] .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["sterile water", "TREATMENT", 40, 53], ["lateral flow immunoassay", "TEST", 120, 144]]], ["Previous studies have demonstrated successful results for aMMP-8 mouthrinse point-of-care testing in identifying patients with periodontitis [36, [45] [46] [47] [48] [49] [50] [51] [52] .", [["periodontitis", "DISEASE", 127, 140], ["patients", "ORGANISM", 113, 121], ["[45] [46] [47] [48] [49", "SIMPLE_CHEMICAL", 146, 169], ["patients", "SPECIES", 113, 121], ["Previous studies", "TEST", 0, 16], ["aMMP", "TEST", 58, 62], ["periodontitis", "PROBLEM", 127, 140]]], ["A recent pilot study also demonstrated promising results 7 of the possibility to screen and identify patients at risk of prediabetes by an aMMP-8 mouthrinse point-of-care test [53] .", [["prediabetes", "DISEASE", 121, 132], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["A recent pilot study", "TEST", 0, 20], ["prediabetes", "PROBLEM", 121, 132], ["an aMMP", "TEST", 136, 143]]], ["Severe periodontal disease status and problems in HbA1c levels were reflected in elevated aMMP-8 levels ( Figure 2 ) [53] .Preventive oral health strategyDue to the rapid spread of COVID-19, we need to think of new ways of strengthening the health care system.", [["periodontal", "ANATOMY", 7, 18], ["oral", "ANATOMY", 134, 138], ["HbA1c", "GENE_OR_GENE_PRODUCT", 50, 55], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 90, 96], ["oral", "ORGANISM_SUBDIVISION", 134, 138], ["aMMP", "PROTEIN", 90, 94], ["Severe periodontal disease status", "PROBLEM", 0, 33], ["HbA1c levels", "TEST", 50, 62], ["elevated aMMP", "TEST", 81, 94], ["Preventive oral health strategy", "TREATMENT", 123, 154], ["COVID", "TEST", 181, 186], ["periodontal", "ANATOMY", 7, 18], ["disease", "OBSERVATION", 19, 26], ["rapid", "OBSERVATION_MODIFIER", 165, 170], ["spread", "OBSERVATION_MODIFIER", 171, 177]]], ["Oral health seems to be one part of the puzzles.", [["Oral", "ANATOMY", 0, 4], ["Oral", "ORGANISM_SUBDIVISION", 0, 4]]], ["Periodontitis is associated with several underlying health conditions that are also considered as risk factors for severe COVID-19 disease [4] [5] [6] [7] [8] [9] [10] 54] .", [["Periodontitis", "DISEASE", 0, 13], ["COVID-19 disease [4] [5] [6] [7] [8] [9] [10] 54", "CHEMICAL", 122, 170], ["COVID-19", "CHEMICAL", 122, 130], ["[4] [5] [6] [7] [8] [9] [10] 54", "CHEMICAL", 139, 170], ["[4] [5] [6] [7] [8] [9] [10] 54", "SIMPLE_CHEMICAL", 139, 170], ["Periodontitis", "PROBLEM", 0, 13], ["several underlying health conditions", "PROBLEM", 33, 69], ["severe COVID-19 disease", "PROBLEM", 115, 138]]], ["Therefore, next to the typical recommendations of social distancing and respiratory, hand, and surface hygiene from the official health organizations, targeted prevention of periodontal disease among COVID-19 risk groups based on individual oral health risk seems important and becomes even more important as the epidemic may last longer than expected.Preventive oral health strategyThe preventive oral health strategy consists of screening and identifying COVID-19 risk patients with elevated risk profile (older age, underlying health conditions, and active periodontal disease) to offer them selective proper dental care and/or regular anti-inflammatory treatment, e.g., antimicrobial mouthwash.Preventive oral health strategyPeriodontal disease activity and the risk of progression could be screened in various situations and locations, such as in the dental, medical, or even at-home settings (Figure 1 ).", [["hand", "ANATOMY", 85, 89], ["surface", "ANATOMY", 95, 102], ["periodontal", "ANATOMY", 174, 185], ["oral", "ANATOMY", 241, 245], ["oral", "ANATOMY", 363, 367], ["oral", "ANATOMY", 398, 402], ["periodontal", "ANATOMY", 560, 571], ["oral", "ANATOMY", 709, 713], ["Periodontal", "ANATOMY", 729, 740], ["periodontal disease", "DISEASE", 174, 193], ["periodontal disease", "DISEASE", 560, 579], ["hand", "ORGANISM_SUBDIVISION", 85, 89], ["oral", "ORGANISM_SUBDIVISION", 241, 245], ["oral", "ORGANISM_SUBDIVISION", 363, 367], ["oral", "ORGANISM_SUBDIVISION", 398, 402], ["patients", "ORGANISM", 471, 479], ["oral", "ORGANISM_SUBDIVISION", 709, 713], ["patients", "SPECIES", 471, 479], ["periodontal disease", "PROBLEM", 174, 193], ["COVID", "TEST", 200, 205], ["Preventive oral health strategy", "TREATMENT", 352, 383], ["screening", "TEST", 431, 440], ["COVID", "TEST", 457, 462], ["elevated risk profile", "PROBLEM", 485, 506], ["underlying health conditions", "PROBLEM", 519, 547], ["active periodontal disease)", "PROBLEM", 553, 580], ["selective proper dental care", "TREATMENT", 595, 623], ["regular anti-inflammatory treatment", "TREATMENT", 631, 666], ["antimicrobial mouthwash", "TREATMENT", 674, 697], ["Preventive oral health strategy", "TREATMENT", 698, 729], ["Periodontal disease activity", "PROBLEM", 729, 757], ["respiratory", "ANATOMY", 72, 83], ["hand", "ANATOMY", 85, 89], ["periodontal", "ANATOMY", 174, 185], ["active", "OBSERVATION_MODIFIER", 553, 559], ["periodontal disease", "OBSERVATION", 560, 579], ["disease", "OBSERVATION", 741, 748]]], ["The identified risk patients could be then referred to a dentist for further evaluation and confirmation of the diagnosis.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["further evaluation", "TEST", 69, 87]]], ["The goal should be to get their periodontal disease under control and to lower its adverse systemic effects in relation to various chronic systemic diseases such as diabetes.", [["periodontal", "ANATOMY", 32, 43], ["periodontal disease", "DISEASE", 32, 51], ["diabetes", "DISEASE", 165, 173], ["their periodontal disease", "PROBLEM", 26, 51], ["its adverse systemic effects", "PROBLEM", 79, 107], ["various chronic systemic diseases", "PROBLEM", 123, 156], ["diabetes", "PROBLEM", 165, 173], ["various", "OBSERVATION_MODIFIER", 123, 130], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["systemic", "OBSERVATION_MODIFIER", 139, 147], ["diseases", "OBSERVATION", 148, 156], ["diabetes", "OBSERVATION", 165, 173]]], ["This could aid in reducing the severity of the COVID-19 infection and related complications among these patients.Preventive oral health strategyDentists have the best expertise and equipment for diagnosing periodontitis.", [["oral", "ANATOMY", 124, 128], ["infection", "DISEASE", 56, 65], ["periodontitis", "DISEASE", 206, 219], ["patients", "ORGANISM", 104, 112], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["patients", "SPECIES", 104, 112], ["the COVID-19 infection", "PROBLEM", 43, 65], ["Preventive oral health strategy", "TREATMENT", 113, 144], ["diagnosing periodontitis", "PROBLEM", 195, 219], ["infection", "OBSERVATION", 56, 65], ["periodontitis", "OBSERVATION", 206, 219]]], ["Based on the examination, the stage and grade of periodontitis are defined to offer precise treatment for an individual patient [27] .Preventive oral health strategyHowever, dental professionals are most likely enough to make the screening of periodontitis patients feasible, even if targeted directly to the COVID-19 risk groups.", [["oral", "ANATOMY", 145, 149], ["periodontitis", "DISEASE", 49, 62], ["periodontitis", "DISEASE", 243, 256], ["patient", "ORGANISM", 120, 127], ["oral", "ORGANISM_SUBDIVISION", 145, 149], ["patients", "ORGANISM", 257, 265], ["patient", "SPECIES", 120, 127], ["patients", "SPECIES", 257, 265], ["the examination", "TEST", 9, 24], ["periodontitis", "PROBLEM", 49, 62], ["precise treatment", "TREATMENT", 84, 101], ["Preventive oral health strategy", "TREATMENT", 134, 165], ["periodontitis", "PROBLEM", 243, 256], ["periodontitis", "OBSERVATION", 49, 62], ["periodontitis", "OBSERVATION", 243, 256]]], ["Modern rapid point-of-care diagnostics technologies based on biomarkers in oral fluids, such as aMMP-8, could offer a solution to this problem [36, [45] [46] [47] [48] [49] [50] [51] [52] .", [["oral fluids", "ANATOMY", 75, 86], ["aMMP-8", "CHEMICAL", 96, 102], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 96, 102], ["[45] [46] [47] [48] [49] [50] [51] [52]", "SIMPLE_CHEMICAL", 148, 187], ["biomarkers in oral fluids", "TEST", 61, 86], ["aMMP", "TEST", 96, 100]]], ["The 8 ability to screen and identify patients at risk of active periodontal disease point-of-care and non-invasively could extend the periodontal disease screening to places and situations where professional dental expertise and equipment are limited or not available (Figure 1 ).", [["periodontal", "ANATOMY", 64, 75], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["active periodontal disease point", "PROBLEM", 57, 89], ["the periodontal disease screening", "PROBLEM", 130, 163], ["active", "OBSERVATION_MODIFIER", 57, 63], ["periodontal", "ANATOMY", 64, 75], ["disease", "OBSERVATION", 76, 83], ["periodontal", "ANATOMY", 134, 145], ["disease", "OBSERVATION", 146, 153]]], ["COVID-19 has also inspired the use of novel approaches, namely teledentistry [55, 56] , to provide medical and dental care remotely using information technology that reduces the need for direct person-to-person contacts with patients and infection transmission routes [56] .", [["infection", "DISEASE", 238, 247], ["patients", "ORGANISM", 225, 233], ["person", "SPECIES", 194, 200], ["person", "SPECIES", 204, 210], ["patients", "SPECIES", 225, 233]]], ["Yet, there is still much work needed to make teledentistry a routine among the dentists and patients [56] .", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["Teledentistry with point-of-care testing could help to extend periodontal diagnostics and access to oral health care even to rural and distant places and also to developing countries, where dental care diagnostic resources can be insufficient [Nwhator=46, 58] .", [["periodontal", "ANATOMY", 62, 73], ["oral", "ANATOMY", 100, 104], ["oral", "ORGANISM_SUBDIVISION", 100, 104], ["periodontal diagnostics", "TEST", 62, 85], ["oral health care", "TREATMENT", 100, 116]]], ["A positive test result would indicate risk of active periodontal disease and need to contact a dentist for oral care.Preventive oral health strategyPoint-of-care testing could be particularly effective among the institutionalized, nursing and care home senior citizens.", [["periodontal", "ANATOMY", 53, 64], ["oral", "ANATOMY", 107, 111], ["oral", "ANATOMY", 128, 132], ["periodontal disease", "DISEASE", 53, 72], ["periodontal", "ORGAN", 53, 64], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["oral", "ORGANISM_SUBDIVISION", 128, 132], ["A positive test result", "TEST", 0, 22], ["active periodontal disease", "PROBLEM", 46, 72], ["oral care", "TREATMENT", 107, 116], ["Preventive oral health strategy", "TREATMENT", 117, 148], ["care testing", "TEST", 157, 169], ["active", "OBSERVATION_MODIFIER", 46, 52], ["periodontal disease", "OBSERVATION", 53, 72]]], ["Poor oral health and comorbidities are common among them [59] , which makes them especially vulnerable against COVID-19 [60] .", [["oral", "ANATOMY", 5, 9], ["COVID-19", "CHEMICAL", 111, 119], ["oral", "ORGANISM_SUBDIVISION", 5, 9], ["comorbidities", "PROBLEM", 21, 34], ["COVID", "TEST", 111, 116]]], ["The evidence supports that the systemic inflammation connects periodontitis to several chronic diseases of aging [10] .", [["inflammation", "DISEASE", 40, 52], ["periodontitis", "DISEASE", 62, 75], ["chronic diseases of aging", "DISEASE", 87, 112], ["the systemic inflammation", "PROBLEM", 27, 52], ["periodontitis", "PROBLEM", 62, 75], ["several chronic diseases", "PROBLEM", 79, 103], ["systemic", "OBSERVATION_MODIFIER", 31, 39], ["inflammation", "OBSERVATION", 40, 52], ["periodontitis", "OBSERVATION", 62, 75], ["several", "OBSERVATION_MODIFIER", 79, 86], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["diseases", "OBSERVATION", 95, 103]]], ["Furthermore, hospitalized patients are more likely to suffer from nosocomial pneumonia if they have periodontitis [61] .", [["pneumonia", "DISEASE", 77, 86], ["periodontitis", "DISEASE", 100, 113], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["nosocomial pneumonia", "PROBLEM", 66, 86], ["periodontitis", "PROBLEM", 100, 113], ["nosocomial", "OBSERVATION_MODIFIER", 66, 76], ["pneumonia", "OBSERVATION", 77, 86], ["periodontitis", "OBSERVATION", 100, 113]]], ["Previous studies suggest that providing oral care has a positive effect especially on the incidence of aspiration pneumonia [62] .", [["oral", "ANATOMY", 40, 44], ["aspiration pneumonia", "DISEASE", 103, 123], ["oral", "ORGANISM_SUBDIVISION", 40, 44], ["Previous studies", "TEST", 0, 16], ["oral care", "TREATMENT", 40, 49], ["aspiration pneumonia", "PROBLEM", 103, 123], ["aspiration", "OBSERVATION", 103, 113], ["pneumonia", "OBSERVATION", 114, 123]]], ["However, it should be noted that there are still barriers to access and effective oral care for these elderly individuals [62, 63] .Preventive oral health strategyMedical professionals providing treatment to COVID-19 risk group patients could benefit from using point-of-care diagnostics for screening in case of undiagnosed active periodontal disease [36, [45] [46] [47] [48] [49] [50] [51] [52] .", [["oral", "ANATOMY", 82, 86], ["oral", "ANATOMY", 143, 147], ["periodontal", "ANATOMY", 332, 343], ["periodontal disease", "DISEASE", 332, 351], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["oral", "ORGANISM_SUBDIVISION", 143, 147], ["patients", "ORGANISM", 228, 236], ["periodontal", "ORGAN", 332, 343], ["[45] [46] [47] [48] [49] [50] [51", "SIMPLE_CHEMICAL", 357, 390], ["patients", "SPECIES", 228, 236], ["effective oral care", "TREATMENT", 72, 91], ["Preventive oral health strategy", "TREATMENT", 132, 163], ["treatment", "TREATMENT", 195, 204], ["screening", "TEST", 292, 301], ["undiagnosed active periodontal disease", "PROBLEM", 313, 351], ["periodontal", "ANATOMY", 332, 343]]], ["If the point-of-care test is positive indicating a risk of active periodontal disease, patients should be referred to a dentist for periodontal examination and evaluation.", [["periodontal", "ANATOMY", 66, 77], ["periodontal", "ANATOMY", 132, 143], ["periodontal disease", "DISEASE", 66, 85], ["periodontal", "ORGAN", 66, 77], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["care test", "TEST", 16, 25], ["active periodontal disease", "PROBLEM", 59, 85], ["periodontal examination", "TEST", 132, 155], ["evaluation", "TEST", 160, 170], ["active", "OBSERVATION_MODIFIER", 59, 65], ["periodontal disease", "OBSERVATION", 66, 85]]], ["Systemic inflammation links periodontitis to several other chronic inflammatory diseases, such as diabetes, CVD and Alzheimer's disease, and can alter their course [4] [5] [6] [7] [8] [9] [10] 64] .", [["inflammation", "DISEASE", 9, 21], ["periodontitis", "DISEASE", 28, 41], ["diabetes", "DISEASE", 98, 106], ["CVD", "DISEASE", 108, 111], ["Alzheimer's disease", "DISEASE", 116, 135], ["[4] [5] [6] [7] [8] [9] [10] 64", "SIMPLE_CHEMICAL", 164, 195], ["Systemic inflammation links periodontitis", "PROBLEM", 0, 41], ["several other chronic inflammatory diseases", "PROBLEM", 45, 88], ["diabetes", "PROBLEM", 98, 106], ["CVD", "PROBLEM", 108, 111], ["Alzheimer's disease", "PROBLEM", 116, 135], ["inflammation", "OBSERVATION", 9, 21], ["periodontitis", "OBSERVATION", 28, 41], ["several", "OBSERVATION_MODIFIER", 45, 52], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["inflammatory", "OBSERVATION", 67, 79]]], ["Previous studies also indicate the positive effect of periodontal therapy on systemic markers of inflammation [65] .", [["periodontal", "ANATOMY", 54, 65], ["inflammation", "DISEASE", 97, 109], ["Previous studies", "TEST", 0, 16], ["periodontal therapy", "TREATMENT", 54, 73], ["inflammation", "PROBLEM", 97, 109], ["positive effect", "OBSERVATION_MODIFIER", 35, 50], ["periodontal therapy", "OBSERVATION", 54, 73], ["inflammation", "OBSERVATION", 97, 109]]], ["For example, recent consensus reports recommend regular oral examination, monitoring and maintenance for patients with a diagnosis of CVD and diabetes [5, 6] .", [["oral", "ANATOMY", 56, 60], ["CVD", "DISEASE", 134, 137], ["diabetes", "DISEASE", 142, 150], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["regular oral examination", "TEST", 48, 72], ["CVD", "PROBLEM", 134, 137], ["diabetes", "PROBLEM", 142, 150], ["diabetes", "OBSERVATION", 142, 150]]], ["Finally, although not a COVID-19 9 risk group, evidence suggest that maternal periodontal disease is associated with pregnancy complications such as gestational diabetes with elevated aMMP-8 levels in oral fluids [66, 67] .", [["periodontal", "ANATOMY", 78, 89], ["oral fluids", "ANATOMY", 201, 212], ["periodontal disease", "DISEASE", 78, 97], ["gestational diabetes", "DISEASE", 149, 169], ["aMMP-8", "CHEMICAL", 184, 190], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 184, 190], ["oral", "ORGANISM_SUBDIVISION", 201, 205], ["aMMP", "PROTEIN", 184, 188], ["a COVID", "TEST", 22, 29], ["maternal periodontal disease", "PROBLEM", 69, 97], ["pregnancy complications", "PROBLEM", 117, 140], ["gestational diabetes", "PROBLEM", 149, 169], ["elevated aMMP", "PROBLEM", 175, 188], ["oral fluids", "TEST", 201, 212], ["periodontal disease", "OBSERVATION", 78, 97], ["associated with", "UNCERTAINTY", 101, 116]]], ["In this regard, identifying patients at risk for periodontitis early enough by using an aMMP-8 point-of-care test could be beneficial also at maternity outpatient clinics for referring risk patients to targeted oral health promotion [66] .ConclusionIn conclusion, currently available oral fluid point-of-care tests could be useful for interdisciplinary screening and identification of individuals with severe periodontitis and active periodontal breakdown.", [["oral", "ANATOMY", 211, 215], ["oral", "ANATOMY", 284, 288], ["periodontal", "ANATOMY", 434, 445], ["periodontitis", "DISEASE", 49, 62], ["periodontitis", "DISEASE", 409, 422], ["periodontal breakdown", "DISEASE", 434, 455], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 190, 198], ["oral", "ORGANISM_SUBDIVISION", 211, 215], ["oral", "ORGANISM_SUBDIVISION", 284, 288], ["periodontal", "ORGAN", 434, 445], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 190, 198], ["periodontitis", "PROBLEM", 49, 62], ["an aMMP", "TEST", 85, 92], ["oral fluid point", "TEST", 284, 300], ["care tests", "TEST", 304, 314], ["interdisciplinary screening", "TEST", 335, 362], ["individuals", "PROBLEM", 385, 396], ["severe periodontitis", "PROBLEM", 402, 422], ["active periodontal breakdown", "PROBLEM", 427, 455], ["periodontitis", "OBSERVATION", 49, 62], ["severe", "OBSERVATION_MODIFIER", 402, 408], ["periodontitis", "OBSERVATION", 409, 422], ["active", "OBSERVATION_MODIFIER", 427, 433], ["periodontal breakdown", "OBSERVATION", 434, 455]]], ["They could extend periodontal disease diagnostics to situations and places where professional oral health care and resources are limited or unavailable, such as distant and rural areas or nursing homes and care homes.", [["periodontal", "ANATOMY", 18, 29], ["oral", "ANATOMY", 94, 98], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["periodontal", "ANATOMY", 18, 29], ["disease", "OBSERVATION", 30, 37]]], ["This could help to identify individuals at potential risk for undiagnosed periodontitis and be an important step towards helping patients initiate access to oral care for early intervention.", [["oral", "ANATOMY", 157, 161], ["periodontitis", "DISEASE", 74, 87], ["patients", "ORGANISM", 129, 137], ["oral", "ORGANISM_SUBDIVISION", 157, 161], ["patients", "SPECIES", 129, 137], ["undiagnosed periodontitis", "PROBLEM", 62, 87], ["oral care", "TREATMENT", 157, 166], ["early intervention", "TREATMENT", 171, 189], ["periodontitis", "OBSERVATION", 74, 87]]], ["After all, periodontitis is one of the most prevalent diseases globally which underscores the need for new approaches to identify patients at risk to enhance secondary prevention for periodontitis.", [["periodontitis", "DISEASE", 11, 24], ["periodontitis", "DISEASE", 183, 196], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["periodontitis", "PROBLEM", 11, 24], ["new approaches", "TREATMENT", 103, 117], ["periodontitis", "PROBLEM", 183, 196], ["periodontitis", "OBSERVATION", 11, 24], ["most prevalent", "OBSERVATION_MODIFIER", 39, 53], ["diseases", "OBSERVATION", 54, 62], ["periodontitis", "OBSERVATION", 183, 196]]], ["This study presented a rapid oral fluid point-of-care technology based on aMMP-8 that has had successful results in periodontal disease diagnostics.", [["oral", "ANATOMY", 29, 33], ["periodontal", "ANATOMY", 116, 127], ["aMMP-8", "CHEMICAL", 74, 80], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["This study", "TEST", 0, 10], ["a rapid oral fluid point", "TREATMENT", 21, 45], ["aMMP", "TEST", 74, 78], ["periodontal disease diagnostics", "PROBLEM", 116, 147], ["periodontal", "ANATOMY", 116, 127], ["disease", "OBSERVATION", 128, 135]]], ["There is enough data to warrant further research to determine the benefits of using the aMMP-8 point-of-care testing also outside the dentist's office, for example, in the hands of medical professionals in relation to chronic systemic diseases, such as diabetes and CVD.", [["systemic diseases", "DISEASE", 226, 243], ["diabetes", "DISEASE", 253, 261], ["CVD", "DISEASE", 266, 269], ["the aMMP", "TEST", 84, 92], ["chronic systemic diseases", "PROBLEM", 218, 243], ["diabetes", "PROBLEM", 253, 261], ["CVD", "PROBLEM", 266, 269], ["chronic", "OBSERVATION_MODIFIER", 218, 225], ["systemic", "OBSERVATION_MODIFIER", 226, 234], ["diseases", "OBSERVATION", 235, 243]]], ["Finally, if there is a causality between periodontal disease and severe COVID-19 infections, aMMP-8 oral fluid analytics could help to assess the risk of deterioration.ConclusionTherefore, further research on the association between aMMP-8 levels in oral fluids and severity of COVID-19 seems important.", [["periodontal", "ANATOMY", 41, 52], ["oral", "ANATOMY", 100, 104], ["oral fluids", "ANATOMY", 250, 261], ["periodontal disease", "DISEASE", 41, 60], ["COVID", "DISEASE", 72, 77], ["infections", "DISEASE", 81, 91], ["aMMP-8", "CHEMICAL", 93, 99], ["aMMP-8", "CHEMICAL", 233, 239], ["COVID-19", "CHEMICAL", 278, 286], ["COVID-19", "CHEMICAL", 278, 286], ["aMMP-8", "GENE_OR_GENE_PRODUCT", 233, 239], ["oral", "ORGANISM_SUBDIVISION", 250, 254], ["aMMP-8", "PROTEIN", 233, 239], ["periodontal disease", "PROBLEM", 41, 60], ["severe COVID-19 infections", "PROBLEM", 65, 91], ["aMMP", "TEST", 93, 97], ["oral fluid analytics", "TEST", 100, 120], ["deterioration", "PROBLEM", 154, 167], ["aMMP", "TEST", 233, 237], ["oral fluids", "TREATMENT", 250, 261], ["COVID", "TEST", 278, 283], ["periodontal", "ANATOMY", 41, 52], ["severe", "OBSERVATION_MODIFIER", 65, 71]]], ["Timo Sorsa is an inventor of US-patent 10488415B2, and a Japanese patent 2016-554676.", [["US", "TEST", 29, 31], ["patent", "OBSERVATION", 32, 38], ["patent", "OBSERVATION", 66, 72]]], ["Other authors report no conflicts of interest related to this study.", [["this study", "TEST", 57, 67]]], ["The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.", [["the study", "TEST", 41, 50]]]], "PMC7087267": [["Toll-like receptors ::: IntroductionThe first TLR, identified in an insect (Drosophila), was a molecule with a critical role in antifungal responses.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLR", "GENE_OR_GENE_PRODUCT", 46, 49], ["Drosophila", "ORGANISM", 76, 86], ["antifungal", "CANCER", 128, 138], ["Toll-like receptors", "PROTEIN", 0, 19], ["TLR", "PROTEIN", 46, 49], ["Drosophila", "SPECIES", 76, 86], ["Drosophila", "SPECIES", 76, 86], ["antifungal responses", "OBSERVATION", 128, 148]]], ["Subsequently, 13 types of TLRs (TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 and TLR13) have been identified in mammals.", [["TLRs", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLR1", "GENE_OR_GENE_PRODUCT", 32, 36], ["TLR2", "GENE_OR_GENE_PRODUCT", 38, 42], ["TLR3", "GENE_OR_GENE_PRODUCT", 44, 48], ["TLR4", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLR5", "GENE_OR_GENE_PRODUCT", 56, 60], ["TLR6", "GENE_OR_GENE_PRODUCT", 62, 66], ["TLR7", "GENE_OR_GENE_PRODUCT", 68, 72], ["TLR8", "GENE_OR_GENE_PRODUCT", 74, 78], ["TLR9", "GENE_OR_GENE_PRODUCT", 80, 84], ["TLR10", "GENE_OR_GENE_PRODUCT", 86, 91], ["TLR11", "GENE_OR_GENE_PRODUCT", 93, 98], ["TLR12", "GENE_OR_GENE_PRODUCT", 100, 105], ["TLR13", "GENE_OR_GENE_PRODUCT", 110, 115], ["TLRs", "PROTEIN", 26, 30], ["TLR1", "PROTEIN", 32, 36], ["TLR2", "PROTEIN", 38, 42], ["TLR3", "PROTEIN", 44, 48], ["TLR4", "PROTEIN", 50, 54], ["TLR5", "PROTEIN", 56, 60], ["TLR6", "PROTEIN", 62, 66], ["TLR7", "PROTEIN", 68, 72], ["TLR8", "PROTEIN", 74, 78], ["TLR9", "PROTEIN", 80, 84], ["TLR10", "PROTEIN", 86, 91], ["TLR11", "PROTEIN", 93, 98], ["TLR12", "PROTEIN", 100, 105], ["TLR13", "PROTEIN", 110, 115], ["TLRs (", "TREATMENT", 26, 32], ["TLR1", "TEST", 32, 36], ["TLR2", "TEST", 38, 42], ["TLR3", "TEST", 44, 48], ["TLR4", "TEST", 50, 54], ["TLR5", "TEST", 56, 60], ["TLR6", "TEST", 62, 66], ["TLR7", "TEST", 68, 72], ["TLR8", "TEST", 74, 78], ["TLR9", "TEST", 80, 84], ["TLR10", "TEST", 86, 91], ["TLR11", "TEST", 93, 98], ["TLR12", "TEST", 100, 105]]], ["It is noteworthy that TLR1-9 are present in both humans and mice, whereas TLR11, TLR12 and TLR13 are present only in mice (Fig. 1) [117].", [["TLR1-9", "GENE_OR_GENE_PRODUCT", 22, 28], ["humans", "ORGANISM", 49, 55], ["mice", "ORGANISM", 60, 64], ["TLR11", "GENE_OR_GENE_PRODUCT", 74, 79], ["TLR12", "GENE_OR_GENE_PRODUCT", 81, 86], ["TLR13", "GENE_OR_GENE_PRODUCT", 91, 96], ["mice", "ORGANISM", 117, 121], ["TLR1", "PROTEIN", 22, 26], ["TLR11", "PROTEIN", 74, 79], ["TLR12", "PROTEIN", 81, 86], ["TLR13", "PROTEIN", 91, 96], ["humans", "SPECIES", 49, 55], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 117, 121], ["humans", "SPECIES", 49, 55], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 117, 121], ["TLR1", "TEST", 22, 26], ["TLR11", "TEST", 74, 79], ["TLR1", "OBSERVATION", 22, 26]]], ["Finally, TLR10 was identified in humans; mice have a TLR10 gene, but it is interrupted and nonfunctional [42].", [["TLR10", "GENE_OR_GENE_PRODUCT", 9, 14], ["humans", "ORGANISM", 33, 39], ["mice", "ORGANISM", 41, 45], ["TLR10", "GENE_OR_GENE_PRODUCT", 53, 58], ["TLR10", "PROTEIN", 9, 14], ["TLR10 gene", "DNA", 53, 63], ["humans", "SPECIES", 33, 39], ["mice", "SPECIES", 41, 45], ["humans", "SPECIES", 33, 39], ["mice", "SPECIES", 41, 45], ["TLR10", "TREATMENT", 9, 14], ["a TLR10 gene", "TREATMENT", 51, 63]]], ["In birds, TLR2a, TLR2b, TLR4, TLR5 and TLR7 are comparable to their counterparts in humans and mice, whereas TLR1La, TLR1Lb and TLR15 are exclusive to birds [17].", [["birds", "ORGANISM", 3, 8], ["TLR2a", "GENE_OR_GENE_PRODUCT", 10, 15], ["TLR2b", "GENE_OR_GENE_PRODUCT", 17, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 24, 28], ["TLR5", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR7", "GENE_OR_GENE_PRODUCT", 39, 43], ["humans", "ORGANISM", 84, 90], ["mice", "ORGANISM", 95, 99], ["TLR1La", "GENE_OR_GENE_PRODUCT", 109, 115], ["TLR1Lb", "GENE_OR_GENE_PRODUCT", 117, 123], ["TLR15", "GENE_OR_GENE_PRODUCT", 128, 133], ["TLR2a", "PROTEIN", 10, 15], ["TLR2b", "PROTEIN", 17, 22], ["TLR4", "PROTEIN", 24, 28], ["TLR5", "PROTEIN", 30, 34], ["TLR7", "PROTEIN", 39, 43], ["TLR1La", "PROTEIN", 109, 115], ["TLR1Lb", "PROTEIN", 117, 123], ["TLR15", "PROTEIN", 128, 133], ["humans", "SPECIES", 84, 90], ["mice", "SPECIES", 95, 99], ["humans", "SPECIES", 84, 90], ["mice", "SPECIES", 95, 99], ["TLR5", "TREATMENT", 30, 34], ["TLR7", "TREATMENT", 39, 43], ["TLR15", "TREATMENT", 128, 133]]], ["Furthermore, in birds, the TLR8 gene is apparently nonfunctional [106] and the TLR9 gene is missing [136, 148].", [["birds", "ORGANISM", 16, 21], ["TLR8", "GENE_OR_GENE_PRODUCT", 27, 31], ["TLR9", "GENE_OR_GENE_PRODUCT", 79, 83], ["TLR8 gene", "DNA", 27, 36], ["TLR9 gene", "DNA", 79, 88], ["the TLR9 gene", "TEST", 75, 88], ["TLR8", "ANATOMY", 27, 31]]], ["That notwithstanding, TLR21, which is unique in birds and fish, has functions similar to those of TLR9 in mammals [16].", [["TLR21", "GENE_OR_GENE_PRODUCT", 22, 27], ["fish", "ORGANISM_SUBDIVISION", 58, 62], ["TLR9", "GENE_OR_GENE_PRODUCT", 98, 102], ["TLR21", "PROTEIN", 22, 27], ["TLR9", "PROTEIN", 98, 102]]]], "d9be5e947819328ac6bc7b228034624f5a63b300": [["In the COVIDpos patients, diarrhea is significantly amplified in the week preceding PCR testing ( Table 1 ; 2.2-fold; p-value = 3.9E-16).", [["diarrhea", "DISEASE", 26, 34], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["diarrhea", "PROBLEM", 26, 34], ["PCR testing", "TEST", 84, 95], ["p-value", "TEST", 118, 125], ["diarrhea", "OBSERVATION", 26, 34]]], ["Some of these undiagnosed COVID-19 patients that experience diarrhea may be unintentionally shedding SARS-CoV-2 fecally 7 .", [["diarrhea", "DISEASE", 60, 68], ["SARS", "DISEASE", 101, 105], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["these undiagnosed COVID", "PROBLEM", 8, 31], ["diarrhea", "PROBLEM", 60, 68], ["unintentionally shedding SARS", "PROBLEM", 76, 105], ["CoV", "TEST", 106, 109]]], ["Incidentally, epidemiological surveillance by waste water monitoring conducted recently in the state of Massachusetts observed copious SARS-CoV-2 RNA 8 .", [["SARS-CoV-2 RNA 8", "DNA", 135, 151], ["epidemiological surveillance", "TEST", 14, 42], ["waste water monitoring", "TEST", 46, 68], ["copious SARS", "PROBLEM", 127, 139]]], ["The amplification of diarrhea in COVIDpos over COVIDneg patients in the week preceding PCR testing highlights the importance and necessity for washing hands often.", [["diarrhea", "DISEASE", 21, 29], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["diarrhea", "PROBLEM", 21, 29], ["PCR testing", "TEST", 87, 98], ["diarrhea", "OBSERVATION", 21, 29]]]], "PMC7149785": [["Epstein\u2013Barr Virus", [["Epstein\u2013Barr Virus", "ORGANISM", 0, 18], ["Epstein\u2013Barr Virus", "SPECIES", 0, 18], ["Epstein\u2013Barr Virus", "PROBLEM", 0, 18], ["Barr Virus", "OBSERVATION", 8, 18]]]], "ab35e4d3c00a2bb71134c64b0671722fa525d1ac": [["BackgroundOn December 2019, the district of Wuhan in central China announced detection of a previously undescribed virus that led to clusters of pneumonia.", [["pneumonia", "DISEASE", 145, 154], ["a previously undescribed virus", "PROBLEM", 90, 120], ["pneumonia", "PROBLEM", 145, 154], ["virus", "OBSERVATION", 115, 120], ["pneumonia", "OBSERVATION", 145, 154]]], ["The disease caused by this novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was subsequently named coronavirus disease 2019, the COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["coronavirus disease", "DISEASE", 117, 136], ["SARS-CoV-2", "ORGANISM", 82, 92], ["coronavirus", "ORGANISM", 117, 128], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["The disease", "PROBLEM", 0, 11], ["this novel severe acute respiratory syndrome coronavirus", "PROBLEM", 22, 78], ["SARS-CoV", "TEST", 82, 90], ["coronavirus disease", "PROBLEM", 117, 136], ["the COVID", "TEST", 143, 152], ["disease", "OBSERVATION", 4, 11], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66], ["coronavirus disease", "OBSERVATION", 117, 136]]], ["The SARS-CoV-2 outbreak was declared as a public health emergency of international concern by the World Health Organization (WHO) on 30 January and a pandemic on 11 March [1] .", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8]]], ["Despite lessons learnt from previous outbreaks, the preparedness and awareness for such a transmittable virus was inadequate to stop its spread of COVID-19 to over 4,700,000 patients with crude mortality of 6.6% as of May 19 2020 [2] .", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["a transmittable virus", "PROBLEM", 88, 109], ["COVID", "TEST", 147, 152], ["crude mortality", "TEST", 188, 203]]], ["The mortality in mechanically ventilated COVID-19 patients remains high, and it is unclear if some of these patients may be rescued with ECMO.BackgroundThere have been several viral outbreaks in recent memory, including severe acute respiratory syndrome (SARS), pandemic H1N1 influenza and the Middle East respiratory syndrome (MERS) (Fig. 1) .", [["acute respiratory syndrome", "DISEASE", 227, 253], ["SARS", "DISEASE", 255, 259], ["H1N1 influenza", "DISEASE", 271, 285], ["Middle East respiratory syndrome", "DISEASE", 294, 326], ["MERS", "DISEASE", 328, 332], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 108, 116], ["pandemic H1N1 influenza", "SPECIES", 262, 285], ["Middle East respiratory syndrome (MERS)", "SPECIES", 294, 333], ["mechanically ventilated COVID", "TREATMENT", 17, 46], ["ECMO", "TREATMENT", 137, 141], ["several viral outbreaks", "PROBLEM", 168, 191], ["severe acute respiratory syndrome", "PROBLEM", 220, 253], ["SARS", "PROBLEM", 255, 259], ["pandemic H1N1 influenza", "PROBLEM", 262, 285], ["the Middle East respiratory syndrome", "PROBLEM", 290, 326], ["mechanically", "OBSERVATION_MODIFIER", 17, 29], ["ventilated", "OBSERVATION", 30, 40], ["high", "OBSERVATION", 67, 71], ["several", "OBSERVATION_MODIFIER", 168, 175], ["viral", "OBSERVATION_MODIFIER", 176, 181], ["outbreaks", "OBSERVATION_MODIFIER", 182, 191], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["respiratory syndrome", "OBSERVATION", 233, 253], ["H1N1 influenza", "OBSERVATION", 271, 285], ["Middle", "ANATOMY_MODIFIER", 294, 300], ["respiratory syndrome", "OBSERVATION", 306, 326]]], ["Whilst the SARS outbreak in China in 2002 [3] caused an outbreak of severe acute respiratory syndrome through coronavirus (SARS-CoV) [4] [5] [6] [7] [8] , there is minimal reported data on the use of ECMO.", [["SARS", "DISEASE", 11, 15], ["acute respiratory syndrome", "DISEASE", 75, 101], ["SARS-CoV) [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 123, 152], ["severe acute respiratory syndrome", "PROBLEM", 68, 101], ["coronavirus", "PROBLEM", 110, 121], ["ECMO", "TREATMENT", 200, 204], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome", "OBSERVATION", 81, 101]]], ["This was because ECMO was not commonly used at that time, even in those critically ill patients who did not respond favourably to conventional mechanical ventilation and other adjuncts [9] .", [["critically ill", "DISEASE", 72, 86], ["ECMO", "CHEMICAL", 17, 21], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["ECMO", "TREATMENT", 17, 21], ["conventional mechanical ventilation", "TREATMENT", 130, 165]]], ["There is some data on use of ECMO in MERS [10] [11] [12] [13] [14] [15] .", [["ECMO", "CHEMICAL", 29, 33], ["MERS [10] [11] [12] [13] [14] [15]", "CHEMICAL", 37, 71], ["MERS [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 37, 71], ["ECMO", "TREATMENT", 29, 33]]], ["The 2009 H1N1 pandemic witnessed the rise of ECMO, and this in part can be attributed to the significant \"age shift\" with younger patients (< 65 years of age) getting more affected by the virus.", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["ECMO", "TREATMENT", 45, 49], ["the virus", "PROBLEM", 184, 193]]], ["Improvements in technology over time have certainly played a significant role too.BackgroundSince the 2009 H1N1 pandemic, more evidence has emerged support venovenous (V-V) ECMO use in ARDS [16] [17] [18] [19] [20] .", [["H1N1 pandemic", "DISEASE", 107, 120], ["ARDS", "DISEASE", 185, 189], ["[16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 190, 214], ["ARDS", "PROBLEM", 185, 189]]], ["The use of venoarterial (V-A) ECMO for cardiac support is an evolving area and certainly needs further evidence.", [["venoarterial", "ANATOMY", 11, 23], ["cardiac", "ANATOMY", 39, 46], ["venoarterial", "MULTI-TISSUE_STRUCTURE", 11, 23], ["cardiac", "ORGAN", 39, 46], ["venoarterial (V-A) ECMO", "TREATMENT", 11, 34], ["cardiac support", "TREATMENT", 39, 54], ["venoarterial", "ANATOMY", 11, 23], ["cardiac", "ANATOMY", 39, 46]]], ["Although ECMO has a role in selected patients in context of the current pandemic, the criteria for patient selection and timing of ECMO initiation are yet to be defined.", [["patients", "ORGANISM", 37, 45], ["patient", "ORGANISM", 99, 106], ["patients", "SPECIES", 37, 45], ["patient", "SPECIES", 99, 106], ["ECMO", "TREATMENT", 9, 13], ["patient selection", "TREATMENT", 99, 116], ["ECMO initiation", "TREATMENT", 131, 146]]], ["In this narrative review, the focus will be on the use of ECMO during previous viral outbreak as well as in COVID-19 to learn lessons regarding guidance of treatment that will benefit all of healthcare workers and patients.Cardiopulmonary complications in viral outbreaksWhilst significant pulmonary pathology is the hallmark of recent viral outbreaks which was respiratory, the incidence of significant injuries to cardiovascular system has also been reported.Cardiopulmonary complications in viral outbreaksBoth H1N1 and MERS were associated with significant cardiopulmonary involvement.", [["pulmonary", "ANATOMY", 290, 299], ["cardiovascular system", "ANATOMY", 416, 437], ["injuries", "DISEASE", 404, 412], ["patients", "ORGANISM", 214, 222], ["pulmonary", "ORGAN", 290, 299], ["patients", "SPECIES", 214, 222], ["ECMO", "TREATMENT", 58, 62], ["treatment", "TREATMENT", 156, 165], ["Cardiopulmonary complications", "PROBLEM", 223, 252], ["viral outbreaks", "PROBLEM", 256, 271], ["significant pulmonary pathology", "PROBLEM", 278, 309], ["recent viral outbreaks", "PROBLEM", 329, 351], ["significant injuries to cardiovascular system", "PROBLEM", 392, 437], ["Cardiopulmonary complications", "PROBLEM", 461, 490], ["viral outbreaks", "PROBLEM", 494, 509], ["H1N1", "PROBLEM", 514, 518], ["MERS", "PROBLEM", 523, 527], ["significant cardiopulmonary involvement", "PROBLEM", 549, 588], ["complications", "OBSERVATION", 239, 252], ["viral outbreaks", "OBSERVATION", 256, 271], ["significant", "OBSERVATION_MODIFIER", 278, 289], ["pulmonary", "ANATOMY", 290, 299], ["pathology", "OBSERVATION", 300, 309], ["hallmark", "OBSERVATION_MODIFIER", 317, 325], ["viral", "OBSERVATION_MODIFIER", 336, 341], ["outbreaks", "OBSERVATION", 342, 351], ["significant", "OBSERVATION_MODIFIER", 392, 403], ["injuries", "OBSERVATION", 404, 412], ["cardiovascular system", "ANATOMY", 416, 437], ["complications", "OBSERVATION", 477, 490], ["viral", "OBSERVATION_MODIFIER", 494, 499], ["H1N1", "OBSERVATION", 514, 518], ["significant", "OBSERVATION_MODIFIER", 549, 560], ["cardiopulmonary", "ANATOMY", 561, 576], ["involvement", "OBSERVATION", 577, 588]]], ["Although severe pneumonia and ARDS were mostly commonly seen complications, Dawood et al. conducted calculations of crude respiratory and cardiovascular mortality rates from H1N1, estimating the total attributable deaths at 200,000 and 80,000, respectively [22] .", [["cardiovascular", "ANATOMY", 138, 152], ["pneumonia", "DISEASE", 16, 25], ["ARDS", "DISEASE", 30, 34], ["deaths", "DISEASE", 214, 220], ["severe pneumonia", "PROBLEM", 9, 25], ["ARDS", "PROBLEM", 30, 34], ["complications", "PROBLEM", 61, 74], ["crude respiratory and cardiovascular mortality rates", "PROBLEM", 116, 168], ["H1N1", "PROBLEM", 174, 178], ["the total attributable deaths", "PROBLEM", 191, 220], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["pneumonia", "OBSERVATION", 16, 25], ["ARDS", "OBSERVATION", 30, 34]]], ["Fulminant myocarditis was reported during the H1N1 pandemic [23] ; acute myocarditis, acute myocardial infarction, acute heart failure, pericarditis and shock were also reported in patients with MERS [13, [24] [25] [26] .Cardiopulmonary complications in viral outbreaksIn COVID-19, whilst most commonly reported pulmonary complications in critically ill patients were also pneumonia and ARDS [27] [28] [29] [30] , there are substantial concerns regarding micro-and macro-vascular complications, perhaps relating to intravascular thromboses or endothelial dysfunctions [31, 32] .", [["myocardial", "ANATOMY", 92, 102], ["heart", "ANATOMY", 121, 126], ["Cardiopulmonary", "ANATOMY", 221, 236], ["pulmonary", "ANATOMY", 312, 321], ["macro-vascular", "ANATOMY", 465, 479], ["intravascular", "ANATOMY", 515, 528], ["endothelial", "ANATOMY", 543, 554], ["myocarditis", "DISEASE", 10, 21], ["pandemic", "DISEASE", 51, 59], ["myocarditis", "DISEASE", 73, 84], ["acute myocardial infarction", "DISEASE", 86, 113], ["heart failure", "DISEASE", 121, 134], ["pericarditis", "DISEASE", 136, 148], ["shock", "DISEASE", 153, 158], ["pulmonary complications", "DISEASE", 312, 335], ["critically ill", "DISEASE", 339, 353], ["pneumonia", "DISEASE", 373, 382], ["ARDS", "DISEASE", 387, 391], ["intravascular thromboses", "DISEASE", 515, 539], ["endothelial dysfunctions", "DISEASE", 543, 567], ["myocardial", "MULTI-TISSUE_STRUCTURE", 92, 102], ["heart", "ORGAN", 121, 126], ["patients", "ORGANISM", 181, 189], ["pulmonary", "ORGAN", 312, 321], ["patients", "ORGANISM", 354, 362], ["macro-vascular", "MULTI-TISSUE_STRUCTURE", 465, 479], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 515, 528], ["endothelial", "CELL", 543, 554], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 354, 362], ["Fulminant myocarditis", "PROBLEM", 0, 21], ["acute myocarditis", "PROBLEM", 67, 84], ["acute myocardial infarction", "PROBLEM", 86, 113], ["acute heart failure", "PROBLEM", 115, 134], ["pericarditis", "PROBLEM", 136, 148], ["shock", "PROBLEM", 153, 158], ["Cardiopulmonary complications", "PROBLEM", 221, 250], ["viral outbreaksIn COVID", "TREATMENT", 254, 277], ["pulmonary complications", "PROBLEM", 312, 335], ["pneumonia", "PROBLEM", 373, 382], ["ARDS", "PROBLEM", 387, 391], ["micro-and macro-vascular complications", "PROBLEM", 455, 493], ["intravascular thromboses", "PROBLEM", 515, 539], ["endothelial dysfunctions", "PROBLEM", 543, 567], ["myocarditis", "OBSERVATION", 10, 21], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["myocarditis", "OBSERVATION", 73, 84], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["myocardial", "ANATOMY", 92, 102], ["infarction", "OBSERVATION", 103, 113], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["heart", "ANATOMY", 121, 126], ["failure", "OBSERVATION", 127, 134], ["pericarditis", "OBSERVATION", 136, 148], ["shock", "OBSERVATION", 153, 158], ["complications", "OBSERVATION", 237, 250], ["pulmonary", "ANATOMY", 312, 321], ["complications", "OBSERVATION", 322, 335], ["pneumonia", "OBSERVATION", 373, 382], ["complications", "OBSERVATION", 480, 493], ["intravascular", "ANATOMY", 515, 528], ["thromboses", "OBSERVATION", 529, 539], ["endothelial dysfunctions", "OBSERVATION", 543, 567]]], ["Regarding cardiovascular complications, acute cardiac injury (7~17%), shock (8-7%), septic shock (20%), arrhythmia (16.7%) and heart failure (23%) were reported in hospitalised patients [27] [28] [29] [30] .", [["cardiovascular", "ANATOMY", 10, 24], ["cardiac", "ANATOMY", 46, 53], ["heart", "ANATOMY", 127, 132], ["cardiovascular complications", "DISEASE", 10, 38], ["acute cardiac injury", "DISEASE", 40, 60], ["shock", "DISEASE", 70, 75], ["septic shock", "DISEASE", 84, 96], ["arrhythmia", "DISEASE", 104, 114], ["heart failure", "DISEASE", 127, 140], ["cardiovascular", "ANATOMICAL_SYSTEM", 10, 24], ["cardiac", "ORGAN", 46, 53], ["heart", "ORGAN", 127, 132], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["cardiovascular complications", "PROBLEM", 10, 38], ["acute cardiac injury", "PROBLEM", 40, 60], ["shock", "PROBLEM", 70, 75], ["septic shock", "PROBLEM", 84, 96], ["arrhythmia", "PROBLEM", 104, 114], ["heart failure", "PROBLEM", 127, 140], ["cardiovascular", "ANATOMY", 10, 24], ["complications", "OBSERVATION", 25, 38], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["cardiac", "ANATOMY", 46, 53], ["injury", "OBSERVATION", 54, 60], ["septic shock", "OBSERVATION", 84, 96], ["heart", "ANATOMY", 127, 132], ["failure", "OBSERVATION", 133, 140]]], ["There are few case reports of myopericarditis with cardiac tamponade and pericardial effusion [33, 34] .", [["cardiac", "ANATOMY", 51, 58], ["pericardial", "ANATOMY", 73, 84], ["myopericarditis", "DISEASE", 30, 45], ["cardiac tamponade", "DISEASE", 51, 68], ["pericardial effusion", "DISEASE", 73, 93], ["myopericarditis", "CANCER", 30, 45], ["cardiac", "ORGAN", 51, 58], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 73, 93], ["myopericarditis", "PROBLEM", 30, 45], ["cardiac tamponade", "PROBLEM", 51, 68], ["pericardial effusion", "PROBLEM", 73, 93], ["few", "OBSERVATION_MODIFIER", 10, 13], ["myopericarditis", "OBSERVATION", 30, 45], ["cardiac", "ANATOMY", 51, 58], ["tamponade", "OBSERVATION", 59, 68], ["pericardial", "ANATOMY", 73, 84], ["effusion", "OBSERVATION", 85, 93]]], ["Ruan et al. reported up to 7% of patients die of fulminant myocarditis and this may be a contributing factor in up to 33% of deaths [35] .Cardiopulmonary complications in viral outbreaksThus, the respiratory viral outbreaks may lead to significant cardiopulmonary failure that is refractory to conventional medical management.", [["myocarditis", "DISEASE", 59, 70], ["deaths", "DISEASE", 125, 131], ["respiratory viral outbreaks", "DISEASE", 196, 223], ["cardiopulmonary failure", "DISEASE", 248, 271], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["fulminant myocarditis", "PROBLEM", 49, 70], ["Cardiopulmonary complications", "PROBLEM", 138, 167], ["viral outbreaks", "PROBLEM", 171, 186], ["the respiratory viral outbreaks", "PROBLEM", 192, 223], ["significant cardiopulmonary failure", "PROBLEM", 236, 271], ["conventional medical management", "TREATMENT", 294, 325], ["fulminant", "OBSERVATION_MODIFIER", 49, 58], ["myocarditis", "OBSERVATION", 59, 70], ["complications", "OBSERVATION", 154, 167], ["viral outbreaks", "OBSERVATION", 171, 186], ["significant", "OBSERVATION_MODIFIER", 236, 247], ["cardiopulmonary", "ANATOMY", 248, 263], ["failure", "OBSERVATION", 264, 271]]], ["During a pandemic, carefully selected patients may be rescued with ECMO, as it warrants excess amounts of limited assetspersonnel.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["ECMO", "TREATMENT", 67, 71]]], ["Recently published Extracorporeal Life Support Organization (ELSO) COVID-19 guidelines provide recommendations for ECMO use in this setting [36] .", [["Extracorporeal", "OBSERVATION_MODIFIER", 19, 33]]], ["The reported complications in COVID-19 are described in Table 1 .H1N1The spring of 2009 in Mexico saw the nascence of the first pandemic of the twenty-first century, the influenza A, H1N1 [37] .", [["influenza", "DISEASE", 170, 179], ["H1N1", "DISEASE", 183, 187], ["H1N1", "ORGANISM", 65, 69], ["COVID-19", "DNA", 30, 38], ["The reported complications in COVID", "PROBLEM", 0, 35], ["H1N1", "PROBLEM", 65, 69], ["the influenza A", "PROBLEM", 166, 181], ["H1N1", "PROBLEM", 183, 187], ["complications", "OBSERVATION", 13, 26]]], ["This H1N1 virus initially spread through North America, but eventually caused a global pandemic that lasted beyond the usual influenza season in the Northern Hemisphere [38, 39] .H1N1Eight studies that reported ECMO use during H1N1 are summarised in Table 2 .", [["H1N1 virus", "ORGANISM", 5, 15], ["H1N1 virus", "SPECIES", 5, 15], ["H1N1 virus", "SPECIES", 5, 15], ["This H1N1 virus", "PROBLEM", 0, 15], ["a global pandemic", "PROBLEM", 78, 95], ["H1N1Eight studies", "TEST", 179, 196], ["global", "OBSERVATION_MODIFIER", 80, 86], ["pandemic", "OBSERVATION", 87, 95]]], ["H1N1-induced ARDS in 2009 resulted in the rapid uptake of ECMO use, and ECMO played an evolving role in critically ill patients [40, 48] .", [["H1N1", "DISEASE", 0, 4], ["ARDS", "DISEASE", 13, 17], ["critically ill", "DISEASE", 104, 118], ["H1N1", "ORGANISM", 0, 4], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["H1N1", "PROBLEM", 0, 4], ["ARDS", "PROBLEM", 13, 17], ["ECMO", "TREATMENT", 72, 76], ["ARDS", "OBSERVATION", 13, 17]]], ["Pham et al. have reported factors associated with death in 123 ECMO treated patients for H1N1induced ARDS [45] .", [["death", "DISEASE", 50, 55], ["ARDS", "DISEASE", 101, 105], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["death", "PROBLEM", 50, 55], ["ECMO", "TREATMENT", 63, 67], ["H1N1induced ARDS", "PROBLEM", 89, 105]]], ["They concluded that ECMO initiation facilitated the use of ultra-protective ventilation [40] .", [["ECMO", "CHEMICAL", 20, 24], ["ECMO initiation", "TREATMENT", 20, 35], ["ultra-protective ventilation", "TREATMENT", 59, 87], ["ECMO", "OBSERVATION", 20, 24]]], ["Although a systematic review to inform decisions concerning the use of ECMO in acute respiratory failure during H1N1 pandemic was published, there was insufficient evidence to strongly recommend use of ECMO for patients with H1N1-induced acute respiratory failure [48] .", [["respiratory", "ANATOMY", 85, 96], ["respiratory", "ANATOMY", 244, 255], ["acute respiratory failure", "DISEASE", 79, 104], ["H1N1", "DISEASE", 225, 229], ["acute respiratory failure", "DISEASE", 238, 263], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["ECMO", "TREATMENT", 71, 75], ["acute respiratory failure", "PROBLEM", 79, 104], ["H1N1 pandemic", "TREATMENT", 112, 125], ["ECMO", "TREATMENT", 202, 206], ["H1N1", "PROBLEM", 225, 229], ["acute respiratory failure", "PROBLEM", 238, 263], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory failure", "OBSERVATION", 85, 104], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["respiratory failure", "OBSERVATION", 244, 263]]], ["However, it highlighted that in selected patients, ECMO was associated with improved outcome.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["ECMO", "TREATMENT", 51, 55]]], ["Similar to H1N1-induced ARDS, patients with MERS received lung-protective mechanical ventilation and application of early prone positioning with neuromuscular blockade for patients with moderate to severe ARDS (PaO2:FiO2 < 150 mmHg) [52] .", [["lung", "ANATOMY", 58, 62], ["neuromuscular", "ANATOMY", 145, 158], ["H1N1", "DISEASE", 11, 15], ["ARDS", "DISEASE", 24, 28], ["neuromuscular blockade", "DISEASE", 145, 167], ["ARDS", "DISEASE", 205, 209], ["patients", "ORGANISM", 30, 38], ["lung", "ORGAN", 58, 62], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 172, 180], ["H1N1", "PROBLEM", 11, 15], ["ARDS", "PROBLEM", 24, 28], ["lung-protective mechanical ventilation", "TREATMENT", 58, 96], ["early prone positioning", "TREATMENT", 116, 139], ["neuromuscular blockade", "TREATMENT", 145, 167], ["moderate to severe ARDS", "PROBLEM", 186, 209], ["PaO2", "TEST", 211, 215], ["FiO2", "TEST", 216, 220], ["H1N1", "OBSERVATION", 11, 15], ["ARDS", "OBSERVATION", 24, 28], ["lung", "ANATOMY", 58, 62], ["mechanical ventilation", "OBSERVATION", 74, 96], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["ARDS", "OBSERVATION", 205, 209]]], ["Approximately 6% of patients were reported to receive ECMO support as they were unresponsive to conventional treatment [13] .", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["ECMO support", "TREATMENT", 54, 66], ["conventional treatment", "TREATMENT", 96, 118]]], ["Alshahrani et al. conducted a retrospective chart review on 35 MERS-CoV patients with refractory respiratory failure [14] .", [["respiratory", "ANATOMY", 97, 108], ["respiratory failure", "DISEASE", 97, 116], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 63, 71], ["refractory respiratory failure", "PROBLEM", 86, 116], ["refractory", "OBSERVATION_MODIFIER", 86, 96], ["respiratory failure", "OBSERVATION", 97, 116]]], ["Of these, 17 received ECMO and had a lower in-hospital mortality rate than those who received conventional oxygen therapy.", [["oxygen", "CHEMICAL", 107, 113], ["oxygen", "CHEMICAL", 107, 113], ["oxygen", "SIMPLE_CHEMICAL", 107, 113], ["ECMO", "TREATMENT", 22, 26], ["conventional oxygen therapy", "TREATMENT", 94, 121], ["oxygen therapy", "OBSERVATION", 107, 121]]], ["We have summarised 6 studies regarding study populations during MERS and ECMO data in Table 3 , although we found limited data regarding ECMO use details during MERS outbreak.ECMO use in ongoing viral outbreak: COVID-19ECMO may be considered in patients who develop severe cardiopulmonary failure due to COVID-19 which is refractory to optimal mechanical ventilation and other medical therapies [21] .", [["COVID-19ECMO", "CHEMICAL", 211, 223], ["cardiopulmonary failure", "DISEASE", 273, 296], ["COVID-19", "CHEMICAL", 304, 312], ["COVID-19ECMO", "CHEMICAL", 211, 223], ["COVID-19", "CHEMICAL", 304, 312], ["COVID-19ECMO", "SIMPLE_CHEMICAL", 211, 223], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["study populations", "TEST", 39, 56], ["ECMO data", "TEST", 73, 82], ["ECMO", "TREATMENT", 175, 179], ["severe cardiopulmonary failure", "PROBLEM", 266, 296], ["COVID", "TEST", 304, 309], ["optimal mechanical ventilation", "TREATMENT", 336, 366], ["other medical therapies", "TREATMENT", 371, 394], ["severe", "OBSERVATION_MODIFIER", 266, 272], ["cardiopulmonary", "ANATOMY", 273, 288], ["failure", "OBSERVATION", 289, 296], ["mechanical ventilation", "OBSERVATION", 344, 366]]], ["We have summarised data from recently published clinical reports, ELSO registry report and EuroELSO weekly survey in Table 4 to highlight ECMO use during the COVID-19 pandemic.ECMO use in ongoing viral outbreak: COVID-19During the early outbreak of COVID-19 in China, ECMO was employed for those unresponsive to conventional treatment.", [["COVID-19During", "CHEMICAL", 212, 226], ["COVID-19", "CHEMICAL", 249, 257], ["the COVID", "TEST", 154, 163], ["pandemic", "PROBLEM", 167, 175], ["ECMO", "TREATMENT", 176, 180], ["COVID", "TREATMENT", 249, 254], ["ECMO", "TREATMENT", 268, 272], ["conventional treatment", "TREATMENT", 312, 334]]], ["Initial reports suggested that ECMO has been used in approximately 3% of severe cases with restoration of adequate oxygenation [28] .", [["ECMO", "CHEMICAL", 31, 35], ["ECMO", "TREATMENT", 31, 35], ["ECMO", "OBSERVATION", 31, 35]]], ["Wang and colleagues described clinical characteristics of 138 hospitalised patients during very early stage of outbreak in Wuhan, China [28] and reported 36 intensive care unit (ICU) admitted patients.", [["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 192, 200]]], ["Among these, 17 (47%) required mechanical ventilation and 4 (11.1%) required Additionally, ELSO registry dashboard [57] provides live updates of ECMO use for COVID-19 cases on ECMO ( Table 4 ).", [["mechanical ventilation", "TREATMENT", 31, 53], ["COVID", "TEST", 158, 163], ["ECMO", "TREATMENT", 176, 180]]], ["Whilst 288 patients (59%) are still on ECMO, among 90 patients who discharged, 36 patients (40%) survived to discharge.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 82, 90], ["ECMO", "TREATMENT", 39, 43]]], ["ECMO support type was mostly respiratory (95%), and ECMO mode was mostly V-V (91%).", [["V-V", "GENE_OR_GENE_PRODUCT", 73, 76], ["ECMO support", "TREATMENT", 0, 12], ["ECMO mode", "TEST", 52, 61]]], ["Furthermore, in 4% of patients, ECMO was provided via V-A mode for cardiac and extracorporeal cardiopulmonary resuscitation and 3% had conversion.", [["cardiac", "ANATOMY", 67, 74], ["extracorporeal", "ANATOMY", 79, 93], ["patients", "ORGANISM", 22, 30], ["cardiac", "ORGAN", 67, 74], ["patients", "SPECIES", 22, 30], ["ECMO", "TREATMENT", 32, 36], ["cardiac and extracorporeal cardiopulmonary resuscitation", "TREATMENT", 67, 123], ["cardiac", "ANATOMY", 67, 74], ["extracorporeal cardiopulmonary", "ANATOMY", 79, 109]]], ["The EuroELSO survey [58] has now reported ECMO use in over 800 patients as of April 18.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["Whilst V-V ECMO being the predominant modality used, 423 patients are still on ECMO, 217 patients were weaned from ECMO and 189 ECMO were discontinued due to patients' death.", [["death", "DISEASE", 168, 173], ["V-V", "GENE_OR_GENE_PRODUCT", 7, 10], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 158, 166], ["ECMO", "TREATMENT", 79, 83], ["ECMO", "TREATMENT", 115, 119], ["ECMO", "TREATMENT", 128, 132], ["patients' death", "PROBLEM", 158, 173]]], ["Further data on patient demography, clinical management aspects and outcomes are awaited.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["patient demography", "TEST", 16, 34]]], ["Organisations such as the International ECMO Network (www.internationalecmonet.org) will play a significant role in delivering high-quality research in ECMO.ECMO use in ongoing viral outbreak: COVID-19As the COVID-19 pandemic grows, it is essential that we characterise the pathophysiology in those critically ill patients to guide management and optimise outcome.", [["COVID-19As", "CHEMICAL", 193, 203], ["critically ill", "DISEASE", 299, 313], ["COVID-19", "ORGANISM", 208, 216], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 314, 322], ["ECMO", "TREATMENT", 152, 156], ["ECMO", "TREATMENT", 157, 161], ["COVID", "TEST", 193, 198], ["the COVID", "TEST", 204, 213]]], ["To assist in obtaining as much clinical data as possible from all ICU patients admitted with COVID-19, the COVID-19 Critical Care Consortium Registry was formed in mid-January 2020 to facilitate data collection, decision support mechanisms through artificial intelligence and a vehicle for future studies regarding ventilation and treatments (ref, unpublished data).", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["COVID", "TEST", 93, 98], ["future studies", "TEST", 290, 304], ["ventilation", "TREATMENT", 315, 326], ["treatments", "TREATMENT", 331, 341]]], ["Since its initiation to end of March, more than 300 hospitals from 6 continents are participating to characterise critically ill patients and ultimately to reduce their global burden of this disease.ConclusionsThe experience from previous pandemics has provided preliminary guidance for ECMO use in the current pandemic.", [["critically ill", "DISEASE", 114, 128], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["this disease", "PROBLEM", 186, 198], ["ECMO", "TREATMENT", 287, 291], ["disease", "OBSERVATION", 191, 198]]], ["The COVID-19 pandemic is unfolding at a time where the better systems for ECMO provision are developed.", [["The COVID", "TEST", 0, 9], ["ECMO provision", "TREATMENT", 74, 88], ["ECMO", "OBSERVATION", 74, 78]]], ["ECMO is now a well-organised service in many parts of the world; however, inequality remains in terms of access to ECMO.", [["ECMO", "TREATMENT", 0, 4], ["ECMO", "TREATMENT", 115, 119]]], ["ECMO may not be a therapy that can be extensively used in such pandemic given the resource constraints and availability issues; a responsible use in selected patients is recommended.", [["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["ECMO", "TREATMENT", 0, 4], ["a therapy", "TREATMENT", 16, 25]]], ["Although ECMO has a role in critically ill patients, there is currently inadequate data to determine the efficacy, optimal patient selection and management on ECMO.", [["critically ill", "DISEASE", 28, 42], ["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 123, 130], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 123, 130], ["ECMO", "TREATMENT", 9, 13], ["management", "TREATMENT", 145, 155], ["ECMO", "TREATMENT", 159, 163]]], ["It is essential that we learn and understand throughout the current pandemic, in order determine the risk-benefit ratio of ECMO in COVID-19.", [["ECMO", "TREATMENT", 123, 127], ["COVID", "TEST", 131, 136]]]], "PMC7454065": [["Countries\u2019 responses to the coronavirus disease (COVID-19) emergency have been determined by their geopolitical, societal, and healthcare system characteristics.", [["coronavirus disease", "DISEASE", 28, 47], ["coronavirus", "ORGANISM", 28, 39], ["coronavirus", "SPECIES", 28, 39], ["the coronavirus disease", "PROBLEM", 24, 47]]], ["A successful response results from early identification of effective interventions tailored for these specific characteristics.", [["effective interventions", "TREATMENT", 59, 82]]], ["At the outset of the COVID-19 outbreak response, Israel\u2019s healthcare system faced a chronic shortage of healthcare resources; however, as Israel shifted from containment to mitigation, structural characteristics were leveraged to enhance the response.", [["chronic", "OBSERVATION_MODIFIER", 84, 91]]]]}